Science.gov

Sample records for epics pv gateway

  1. Experience with the EPICS PV Gateway at the APS.

    SciTech Connect

    Evans, K. Jr.; Smith, M.; Accelerator Systems Division

    2006-01-01

    The EPICS Process Variable Gateway has become a stable, high-performance application that provides access to process variables while minimizing the impact on critical Input-Output Controllers (IOCs) and implementing additional access security. The additional access security typically prevents write access but is highly configurable. The Advanced Photon Source (APS) currently uses 40 Gateways running on 11 workstations to provide access to the machine subnet from the offices and for the individual experimental teams. These include reverse Gateways that allow administration of all 40 APS Gateways from a single MEDM screen, even though the Gateways are running on separate networks. This administration includes starting, stopping, making and viewing reports, and viewing and editing access security files. There is one Gateway that provides process variable renaming. This paper provides an overview of the Gateways at the APS and describes the procedures that have been set up to use and administer them.

  2. The EPICS process variable gateway -- Version 2.

    SciTech Connect

    Evans, K.; Accelerator Systems Division

    2005-01-01

    The EPICS Process Variable Gateway is both a Channel Access Server and Channel Access Client that provides a means for many clients, typically on different subnets, to access a process variable while making only one connection to the server that owns the process variable. It also provides additional access security beyond that implemented on the server. It thus protects critical servers while providing suitably restricted access to needed process variables. The original version of the Gateway worked with EPICS Base 3.13 but required a special version, since the changes necessary for its operation were never incorporated into EPICS Base. Version 2 works with any standard EPICS Base 3.14.6 or later and has many improvements in both performance and features over the older version. The Gateway is now used at many institutions and has become a stable, high-performance application. It is capable of handling tens of thousands of process variables with hundreds of thousands of events per second. It has run for over three months in a production environment without having to be restarted. It has many internal process variables that can be used to monitor its state using standard EPICS client tools, such as MEDM and StripTool. Other internal process variables can be used to stop the Gateway, make several kinds of reports, or change the access security without stopping the Gateway. It can even be started on remote workstations from MEDM by using a Secure Shell script. This paper will describe the new Gateway and how it is used. The Gateway is both a server (like an EPICS Input/Output Controller (IOC)) and a client (like the EPICS Motif Editor and Display Manager (MEDM), StripTool, and others). Clients connect to the server side, and the client side connects to IOCs and other servers, possibly other Gateways. See Fig. 1. There are perhaps three principal reasons for using the Gateway: (1) it allows many clients to access a process variable while making only one connection to

  3. Enhancement of real-time EPICS IOC PV management for the data archiving system

    NASA Astrophysics Data System (ADS)

    Kim, Jae-Ha

    2015-10-01

    The operation of a 100-MeV linear proton accelerator, the major driving values and experimental data need to be archived. According to the experimental conditions, different data are required. Functions that can add new data and delete data in real time need to be implemented. In an experimental physics and industrial control system (EPICS) input output controller (IOC), the value of process variables (PVs) are matched with the driving values and data. The PV values are archived in text file format by using the channel archiver. There is no need to create a database (DB) server, just a need for large hard disk. Through the web, the archived data can be loaded, and new PV values can be archived without stopping the archive engine. The details of the implementation of a data archiving system with channel archiver are presented, and some preliminary results are reported.

  4. Photovoltaic Performance and Reliability Database: A Gateway to Experimental Data Monitoring Projects for PV at the Florida Solar Energy Center

    DOE Data Explorer

    This site is the gateway to experimental data monitoring projects for photovoltaic (PV) at the Florida Solar Energy Center. The website and the database were designed to facilitate and standardize the processes for archiving, analyzing and accessing data collected from dozens of operational PV systems and test facilities monitored by FSEC's Photovoltaics and Distributed Generation Division. [copied from http://www.fsec.ucf.edu/en/research/photovoltaics/data_monitoring/index.htm

  5. EPICS overview

    SciTech Connect

    1996-02-01

    This overview describes basic attributes, hardware, IOC software platforms, database access and scanning, record support, database monitors, channel access, client services, search server, connection management, OPI tools, and core software of the EPICS system.

  6. EPICS performance evaluation

    SciTech Connect

    Botlo, M.; Jagielski, M.; Romero, A.

    1993-09-01

    The authors report on the software architecture, some CPU and memory issues, and the performance of the Experimental Physics and Industrial Control System (EPICS). Specifically, they subject each EPICS software layer to a series of tests and extract quantitative results that should be useful to system architects planning to use EPICS for control applications.

  7. Teaching the Epic.

    ERIC Educational Resources Information Center

    Fleming, Margaret, Ed.

    Assembled to aid high school literature teachers in exploring the epic with their students, materials in this book approach the epic as a product of a specific culture which presents vivid pictures of earlier societies. Following the introduction and the opening essay, "The Role of the Supernatural in the Epic," chapters are grouped under the…

  8. TOAD Gateway

    NASA Technical Reports Server (NTRS)

    Bingel, Bradford D.

    1994-01-01

    TOAD Gateway is interactive software tool for converting data files to and from variety of file formats. Currently reads and writes following file formats: TOAD; Standard Interface File (SIF); Program to Optimize Simulated Trajectories (POST) input; Comma Separated Value and Tab Separated Value, common in PC and Macintosh spreadsheet and database packages; and general free format. Additional modules for accommodating other formats easily developed and installed. Companion program, TOAD Editor (LAR-14423), manipulates contents of TOAD files and extracts selected subsets of data. TOAD Gateway written in FORTRAN 77.

  9. EPIC Computer Upgrade

    NASA Video Gallery

    Expedition 30 Commander Dan Burbank and Flight Engineer Don Pettit work on installing hardware for the Enhanced Processor and Integrated Communications (EPIC) upgrade of the International Space Sta...

  10. EPICS V4 Evaluation for SNS Neutron Data

    SciTech Connect

    Kasemir, Kay; Pearson, Matthew R; Guyotte, Greg S

    2015-01-01

    Version 4 of the Experimental Physics and Industrial Control System (EPICS) toolkit allows defining application-specific structured data types (pvData) and offers a network protocol for their efficient exchange (pvAccess). We evaluated V4 for the transport of neutron events from the detectors of the Spallation Neutron Source (SNS) to data acquisition and experiment monitoring systems. This includes the comparison of possible data structures, performance tests, and experience using V4 in production on a beam line.

  11. American Epic: Then and Now.

    ERIC Educational Resources Information Center

    Glazer, Nathan

    1998-01-01

    Argues that the epic of America as frontier and vast land of freedom has been replaced by an epic that emphasizes racial and ethnic diversity in America, whether in an optimistic or pessimistic mood. The old epic was connected with an available frontier, but the new epic is city-centered in the stories of minorities. (SLD)

  12. EPICS: Experimental Physics and Industrial Control System

    NASA Astrophysics Data System (ADS)

    Epics Development Team

    2013-02-01

    EPICS is a set of software tools and applications developed collaboratively and used to create distributed soft real-time control systems for scientific instruments such as particle accelerators and telescopes. Such distributed control systems typically comprise tens or even hundreds of computers, networked together to allow communication between them and to provide control and feedback of the various parts of the device from a central control room, or even remotely over the internet. EPICS uses Client/Server and Publish/Subscribe techniques to communicate between the various computers. A Channel Access Gateway allows engineers and physicists elsewhere in the building to examine the current state of the IOCs, but prevents them from making unauthorized adjustments to the running system. In many cases the engineers can make a secure internet connection from home to diagnose and fix faults without having to travel to the site. EPICS is used by many facilities worldwide, including the Advanced Photon Source at Argonne National Laboratory, Fermilab, Keck Observatory, Laboratori Nazionali di Legnaro, Brazilian Synchrotron Light Source, Los Alamos National Laboratory, Australian Synchrotron, and Stanford Linear Accellerator Center.

  13. EPIC/JANUS user's guide

    SciTech Connect

    Not Available

    1986-07-30

    EPIC/JANUS, the Energy Information Administration's (EIA) Publication and Interactive Composition System, is a software system the allows text, tables, halftones, and graphics to be combined interactively in a single document. In essence, it automates the entire process of composition and production of camera-ready copy. EPIC is a machine-independent document management and translation system developed by EIA. JANUS is an interactive document composition system which formats and typesets a document. This User's Guide provides complete information on how to use the EPIC/JANUS system. Included in the discussion are sections on getting started, the EPIC system and EIA Standard Text Codes, EPIC interactive commands, graphics in EPIC/JANUS, tables in EPIC/JANUS, EPIC Error messages, MVS and VM listings from EPIC/JANUS, using JANUS interactively, mathematical formula, and producing EPIC/JANUS publications through a displaywriter. Appendices contain a quick reference guide to text codes and text code examples. (DWL)

  14. EPICS system: an overview

    SciTech Connect

    Bartlett, J.F.; Bobbitt, J.S.; Kramper, B.J.; Lahey, T.E.; MacKinnon, B.A.; West, R.E.

    1984-02-01

    This paper presents an overview of the EPICS control system at FERMILAB. EPICS is a distributed, multi-user, interactive system for the control and monitoring of particle beamlines at a high-energy experimental physics laboratory. The overview discusses the operating environment of the control system, the requirements which determined the design decisions, the hardware and software configurations, and plans for the future growth and enhancement of the present system. This paper is the first of three related papers on the EPICS system. The other two cover (1) the system structure and user interface and (2) RSX implementation issues.

  15. Perspectives on Epic Physics

    SciTech Connect

    Brodsky, Stanley J.

    1999-07-14

    An electron-proton/ion polarized beam collider (EPIC) with high luminosity and center of mass energy square root s = 25 GeV would be a valuable facility for fundamental studies of proton and nuclear structure and tests of quantum chromodynamics, I review a sample of prospective EPIC topics, particularly semi-exclusive reactions, studies of the proton fragmentation region, heavy quark electroproduction, and a new probe of odderon/pomeron interference.

  16. EPICS-DDS

    SciTech Connect

    Malitsky,N.; Shah, J.; Hasabnis, N.

    2009-05-04

    This paper presents a new extension to EPICS, approaching the Data Distributed Service (DDS) interface based on the Channel Access protocol. DDS is the next generation of middleware industrial standards, bringing a data-centric publish-subscribe paradigm to distributed control systems. In comparison with existing middleware technologies, the data-centric approach is able to provide a consistent consolidated model supporting difference data dissemination scenarios and integrating many important issues, such as quality of service, user-specific data structures, and others. The paper considers different features of the EPICS-DDS layer in the context of the high-level accelerator environment.

  17. EPIC'S PRODUCTS AND SERVICES

    EPA Science Inventory

    EPIC completes approximately 150 site characterizations annually using current and historical aerial photographs. This work is done in support of EPA Regional and Program
    offices. Site characterization provides detailed information about a site and its history, often going ba...

  18. EPICS and WANs: Tradeoffs between Isolation, Security, Robustness, and Transparency

    SciTech Connect

    J. Hill; K. Furukawa; S. Hunt; A. Johnson; R. Lange; J. Sage; E. Williams

    2003-10-01

    The Experimental Physics and Industrial Control System (EPICS)[1] was originally designed for use in local area networks (LANs). Today, the system is routinely deployed into complex wide area networks (WANs) using specialized configuration options and proxy gateways. There are advantages to the current approach including robustness and control over isolation and security. However, some important features are missing including WAN transparent configuration, resource location monitoring, detection of name space collisions during installation, and wildcard queries into the resource attribute space. The paper discusses these issues in detail exploring the relative tradeoffs between different solutions and including our plans for future enhancements.

  19. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2003-09-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abetimus sodium, adefovir dipivoxil, AGI-1067, alefacept, alemtuzumab, ALVAC-p53, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, Anti-CTLA-4 Mab, AOD-9604, apafant, aprinocarsen sodium, arsenic trioxide; Balaglitazone, BIM-23190, bimatoprost, bortezomib, bosentan, BR-1; Canertinib dihydrochloride, CDP-850, cevimeline hydrochloride, cinacalcet hydrochloride, clenoliximab, clevudine, CN-787; D-003, darusentan, deferasirox, desloratadine dexanabinol, duloxetine hydrochloride; E-5564, edaravone, efaproxiral sodium, elvucitabine emfilermin, EN-101, enfuvirtide, entecavir, epithalon, eplerenone, erlotinib hydrochloride, escitalopram oxalate, esomeprazole magnesium, eszopiclone, etilefrine pivalate hydrochloride etoricoxib, everolimus, exenatide; Fidarestat, fondaparinux sodium; Ganstigmine hydrochloride; Homoharringtonine, HuMax-IL-15, hyperimmune IVIG; Imatinib mesylate, IMC-1C11, Inhaled insulin, irofulven, iseganan hydrochloride, ISIS-14803, ISIS-5132, ivabradine hydrochloride; Keratinocyte growth factor; Lafutidine, lanthanum carbonate, LAS-34475, levocetirizine, liraglutide, LY-307161 SR; Magnesium sulfate, maribavir, melatonin, mycobacterium cell wall complex; NN-414, NO-aspirin, nociceptin, nolomirole hydrochloride; Olmesartan medoxomil oral insulin, ospemifene; PDX, perillyl alcohol, pimecrolimus, pitavastatin calcium, pramlintide acetate, prasterone, pregabalin, PRO-542, PV-701, pyrazoloacridine; R-744, ranelic acid distrontium salt, rasburicase, rDNA insulin, resiniferatoxin, reslizumab, ridogrel, riplizumab ropivacaine, rosuvastatin calcium, roxifiban acetate, ruboxistaurin mesilate

  20. The Owens Valley Epics

    ERIC Educational Resources Information Center

    Bahr, Donald

    2007-01-01

    One of the best-studied, least-discussed texts of Native American oral literature is a long Mojave "epic" taken down from a man named Inyo-kutavere by Alfred Kroeber in 1902 and published in 1951. The text was published in twenty-nine pages along with forty-eight pages of commentary and twenty-five pages of notes. In 1999, Arthur Hatto, an…

  1. Gateway to the Future

    ERIC Educational Resources Information Center

    DiJulio, Betsy

    2012-01-01

    "Gateway to the Future" pairs a painting of a gateway constructed from children's building blocks with an ink drawing of a personal symbol on a collaged background. The main objective of this lesson is to create a metaphoric artwork about moving from the present through a symbolic portal to the future. So, space--foreground, middle ground, and…

  2. Overview of EPIC2001

    NASA Astrophysics Data System (ADS)

    Raymond, D. J.

    2002-12-01

    The tropical eastern Pacific is a region in which coupled ocean-atmosphere climate models do a particularly poor job. In particular, the seasonal cycle is inadequately simulated in most cases. This is probably because certain physical processes are not properly represented in such models. The purpose of EPIC2001 is to develop a better understanding of key physical processes in this region with an eye to improving the associated model parameterizations. In this overview the aspects of the east Pacific which potentially can give climate models problems are outlined in the context of idealized theories of the behavior of the ocean-atmosphere system in the region. These aspects have been identified to be \\begin{itemize} the factors controlling the location and variability of east Pacific deep atmospheric convection; airmass transformations in the low-level cross-equatorial flow driven by the latitudinal sea surface temperature gradient; the effect of air-sea coupling on ocean mixed layer dynamics and SST in the east Pacific warm pool; the processes in the upper ocean that affect the structure and evolution of the shallow thermocline in this region; and dynamical, radiative, and microphysical factors affecting the energy balance in the widespread region of stratus-covered ocean south of the equator. This talk will give an overview of how the various aspects of the EPIC2001 field program are designed to address these problems and will serve as background for subsequent more specialized talks.

  3. EPICS system: RSX implementation issues

    SciTech Connect

    Lahey, T.E.; Bartlett, J.F.; Bobbitt, J.S.; Kramper, B.J.; MacKinnon, B.A.; West, R.E.

    1984-02-01

    This paper presents implementation details of the Experimental Physics Interactive Control System (EPICS). EPICS is used to control accelerated particle beams for high-energy physics experiments at the Fermi National Accelerator Laboratory. The topics discussed are: interprocessor communication, support of beamline terminals and devices, resource management, mapping, various problems, some solutions to the problems, performance measurement, and modifications and extensions to RSX-11M. This paper is the third of three related papers on the EPICS system. The other two cover (1) the system overview and (2) the system structure and user interface.

  4. Structuring an EPICS System to Optimize Reliability, Performance and Cost

    SciTech Connect

    Bickley, Matthew; White, Karen S

    2005-10-10

    Thomas Jefferson National Accelerator Facility (Jefferson Lab) uses EPICS as the basis for its control system, effectively operating a number of plants at the laboratory, including the Continuous Electron Beam Accelerator (CEBA), a Free Electron Laser (FEL), Central Helium Liquefier, and several ancillary systems. We now use over 200 distributed computers running over a complex segmented network with 350,000 EPICS records and 50,000 control points to support operation of two machines for three experimental halls, along with the supporting infrastructure. During the 10 years that EPICS has been in use we have made a number of design and implementation choices in the interest of optimizing control system reliability, performance, security and cost. At the highest level, the control system is divided into a number of distinct segments, each controlling a separate operational plant. This supports operational independence, and therefore reliability, and provides a more flexible environment for maintenance and support. The control system is relatively open, allowing any of the 300 account holders to look at data from any segment. However security and operational needs mandate restricted write access to the various control points based on each user's job function and the operational mode of the facility. Additionally, the large number of simultaneous users, coupled with the amount of available data, necessitates the use of throttling mechanisms such as a Nameserver, which effectively reduces broadcast traffic and improves application initialization performance. Our segmented approach provides natural boundaries for managing data flow and restricting access, using tools such as the EPICS Gateway and Channel Access Security. This architecture enables cost optimizations by allowing expensive resources, such as Oracle, to be effectively shared throughout the control system, while minimizing the impact of a failure in any single area. This paper discusses the various design

  5. From gateway to multisite gateway in one recombination event

    Technology Transfer Automated Retrieval System (TEKTRAN)

    We created a construct, pDONR-R4-R3, to easily convert any available Gateway destination vector to a MultiSite Gateway vector in a single recombination reaction. In addition, we designed pDONR-R4-R3 so that DNA fragments already cloned upstream or downstream of the Gateway cassette in the original d...

  6. Gateway to the Arts.

    ERIC Educational Resources Information Center

    Brooks, Katherine; Smith, Merilyn J.

    1990-01-01

    The development of the GATEWAY (Gifted And Talented Education With Artistic Youth) program is described. The Aiken County, South Carolina, summer program offers enrichment activities for students from grades 3-12 in music, drama, visual arts, and dance. Described are the student selection process and program activities. (JDD)

  7. DSCOVR_EPIC_L1A

    Atmospheric Science Data Center

    2015-09-29

    DSCOVR_EPIC_L1A Full sun-light Earth images calibrated with ... 680NM 688NM 551NM LAGRANGE L1B IMAGERY EPIC DSCOVR 325NM Order Data:  ASDC Order Tool: Order Data Readme Files:  EPIC Data Format Control Book Read Software Files :  ...

  8. EPICS system: system structure and user interface

    SciTech Connect

    West, R.E.; Bartlett, J.F.; Bobbitt, J.S.; Lahey, T.E.; Kramper, B.J.; MacKinnon, B.A.

    1984-02-01

    This paper present the user's view of and the general organization of the EPICS control system at Fermilab. Various subsystems of the EPICS control system are discussed. These include the user command language, software protection, the device database, remote computer interfaces, and several application utilities. This paper is related to two other papers on EPICS: an overview paper and a detailed implementation paper.

  9. Remote Asynchronous Message Service Gateway

    NASA Technical Reports Server (NTRS)

    Wang, Shin-Ywan; Burleigh, Scott C.

    2011-01-01

    The Remote Asynchronous Message Service (RAMS) gateway is a special-purpose AMS application node that enables exchange of AMS messages between nodes residing in different AMS "continua," notionally in different geographical locations. JPL s implementation of RAMS gateway functionality is integrated with the ION (Interplanetary Overlay Network) implementation of the DTN (Delay-Tolerant Networking) bundle protocol, and with JPL s implementation of AMS itself. RAMS protocol data units are encapsulated in ION bundles and are forwarded to the neighboring RAMS gateways identified in the source gateway s AMS management information base. Each RAMS gateway has interfaces in two communication environments: the AMS message space it serves, and the RAMS network - the grid or tree of mutually aware RAMS gateways - that enables AMS messages produced in one message space to be forwarded to other message spaces of the same venture. Each gateway opens persistent, private RAMS network communication channels to the RAMS gateways of other message spaces for the same venture, in other continua. The interconnected RAMS gateways use these communication channels to forward message petition assertions and cancellations among themselves. Each RAMS gateway subscribes locally to all subjects that are of interest in any of the linked message spaces. On receiving its copy of a message on any of these subjects, the RAMS gateway node uses the RAMS network to forward the message to every other RAMS gateway whose message space contains at least one node that has subscribed to messages on that subject. On receiving a message via the RAMS network from some other RAMS gateway, the RAMS gateway node forwards the message to all subscribers in its own message space.

  10. Extrasolar Planetary Imaging Coronagraph (EPIC)

    NASA Technical Reports Server (NTRS)

    Clampin, Mark

    2009-01-01

    EPIC is a NASA mission being studied to detect and characterize Jovian and superEarth planets, and, the dust/debris disks surrounding the parent star. It will be launched into a heliocentric Earth trailing orbit and operate for 5 years. EPIC would operate over the wavelength range of 480 - 960 nm with spectral resolutions of R < 50 and employs a visible nulling coronagraph (VNC) to suppress the starlight, yielding contrast ratios of greater than 9 orders of magnitude. We will discuss the science mission, and its role in the search for habitable planets.

  11. Industrial partnerships yield EPIC results

    SciTech Connect

    Moore, T.

    1996-08-01

    With a new era of competition approaching in the electricity supply industry, utilities are getting closer than ever to their industrial customers, in many cases making direct alliances as partners to help customers become more efficient, productive, and competitive. The EPRI Partnership for Industrial Competitiveness (EPIC) program aims to help industrial customers address critical priorities in environmental impact, efficiency, and productivity with the ultimate goals of long-term profitability and job retention. By offering in-plant consultant evaluations of systems and processes, EPIC helps industrial customers develop strategic insights into their operations and leverage technology and productivity solutions for competitive business advantage.

  12. The EPIC Brief: A Description of the EPIC Evaluation Center.

    ERIC Educational Resources Information Center

    EPIC Evaluation Center, Tucson, AZ.

    This initial issue describes the development, organization, staff, and facilities of the EPIC (Evaluative Programs for Innovative Curriculums) Evaluation Center, a cooperative effort of the U.S. Office of Education (under Title III of the Elementary and Secondary Education Act), the University of Arizona (College of Education), and the public and…

  13. Translating the concepts behind gateways.

    PubMed

    Kabachinski, Jeff

    2006-01-01

    The intention of this installment of IT World is to bring the various aspects of gateways into view. You can see how loosely the gateway term is used and how the meaning of the term has changed over time. Keep concepts of gateways in order by considering their main function. The main function for gateways is to convert from one set of communication protocols to some other set of communication protocols-thus allowing access to otherwise incompatible networks. These functions include: Protocol Conversion--When a message is prepared for transmission, each layer adds control information unique to the protocol used at that layer (see Figure 1). The gateway must be able to convert control information to the format the receiving network expects. Services affected may include message segmentation and reassembly, data flow control, and error detection and recovery. Protocol converters connect networks that use different communication protocols. Address Translation--Different networks may employ different network addressing schemes, mechanisms, and network address structures. The gateway must be able to interpret network addresses in one network and convert them into appropriate network addresses for the other network while holding the validity of the address resolution. Examples that include both protocol conversion and address translation are when a gateway converts a TCP/IP packet to a NetWare IPX packet and vice versa or from AppleTalk to DECnet, and so on. Message Format Conversion--Different networks can employ different message formats, maximum message sizes, or character codes. The gateway must be able to convert messages to an appropriate format, size, and coding for the receiving network. Examples are CGI and an email gateway (which is a layer 7-application layer-gateway). Keep these main concepts in mind while surfing the web trying to find out more information about what your gateways are up to! PMID:16796324

  14. Industrial partnerships yield EPIC results

    SciTech Connect

    Moore, T.

    1996-01-01

    With a new era of competition approaching in the electricity supply industry, utilities are getting closer than ever to their industrial customers, in many cases making direct alliances as partners to help customers become more efficient, productive, and competitive. The EPRI Partnership for Industrial Competitiveness-EPIC-program aims to help industrial customers address critical priorities in environmental impact, efficiency and productivity with the ultimate goals of long-term profitability and job retention. By offering in-plant consultant evaluations of systems and processes, EPIC helps industrial customers develop strategic insights into their operations and leverage technology and productivity solutions for competitive business advantage. This paper describes these strategies, areas of focus, investments and benefits.

  15. The federal health record gateway.

    PubMed

    Porter, Dennis

    2010-01-01

    The federal government can make federally held health data available to every American through a single, secure, recurring instance based portal on the emerging Nationwide Health Information Network (NHIN). The Federal Health Record Gateway (FHR Gateway) supports the President's initiatives for patient-centered health by enhancing transparency of government-held clinical and health claims data. PMID:20397336

  16. NASA gateway requirements analysis

    NASA Technical Reports Server (NTRS)

    Duncan, Denise R.; Doby, John S.; Shockley, Cynthia W.

    1991-01-01

    NASA devotes approximately 40 percent of its budget to R&D. Twelve NASA Research Centers and their contractors conduct this R&D, which ranges across many disciplines and is fueled by information about previous endeavors. Locating the right information is crucial. While NASA researchers use peer contacts as their primary source of scientific and technical information (STI), on-line bibliographic data bases - both Government-owned and commercial - are also frequently consulted. Once identified, the STI must be delivered in a usable format. This report assesses the appropriateness of developing an intelligent gateway interface for the NASA R&D community as a means of obtaining improved access to relevant STI resources outside of NASA's Remote Console (RECON) on-line bibliographic database. A study was conducted to determine (1) the information requirements of the R&D community, (2) the information sources to meet those requirements, and (3) ways of facilitating access to those information sources. Findings indicate that NASA researchers need more comprehensive STI coverage of disciplines not now represented in the RECON database. This augmented subject coverage should preferably be provided by both domestic and foreign STI sources. It was also found that NASA researchers frequently request rapid delivery of STI, in its original format. Finally, it was found that researchers need a better system for alerting them to recent developments in their areas of interest. A gateway that provides access to domestic and international information sources can also solve several shortcomings in the present STI delivery system. NASA should further test the practicality of a gateway as a mechanism for improved STI access.

  17. Extrasolar Planetary Imaging Coronagraph (EPIC)

    NASA Astrophysics Data System (ADS)

    Clampin, Mark

    2009-01-01

    The Extrasolar Planetary Imaging Coronagraph (EPIC) is a proposed NASA Exoplanet Probe mission to image and characterize extrasolar giant planets. EPIC will provide insights into the physical nature and architecture of a variety of planets in other solar systems. Initially, it will detect and characterize the atmospheres of planets identified by radial velocity surveys, determine orbital inclinations and masses and characterize the atmospheres around A and F type stars which cannot be found with RV techniques. It will also observe the inner spatial structure of exozodiacal disks. EPIC has a heliocentric Earth trailing drift-away orbit, with a 5 year mission lifetime. The robust mission design is simple and flexible ensuring mission success while minimizing cost and risk. The science payload consists of a heritage optical telescope assembly (OTA), and visible nulling coronagraph (VNC) instrument. The instrument achieves a contrast ratio of 10^9 over a 5 arcsecond field-of-view with an unprecedented inner working angle of 0.13 arcseconds over the spectral range of 440-880 nm. The telescope is a 1.65 meter off-axis Cassegrain with an OTA wavefront error of lambda/9, which when coupled to the VNC greatly reduces the requirements on the large scale optics.

  18. EPICS release 3.11 specific documentation -- EPICS release notes for 3.11

    SciTech Connect

    1994-01-19

    EPICS release 3.11 is now ready for user testing. A person who wants to set up a simplified application environment to boot an IOC and create databases using R3.11 should follow the directions in Appendix B, page 27, of the EPICS Source/Release Control Manual, Sept. 20, 1993. The R3.11 EPICS path at ANL/APS is /net/phebos/epics/R3.11 so the command to get the new release is /net/phebos/epics/R3.11/Unix/share/bin/getrel /net/phebos/epics/R3.11. An existing R3.8 short form report can be copied to this new directory and used to create a database. ANL/APS is currently testing an Application Developers Source/Release control system. It is not yet ready for general distribution. Attached are the EPICS R3.11 release notes.

  19. EPIC: E-field Parallel Imaging Correlator

    NASA Astrophysics Data System (ADS)

    Thyagarajan, Nithyanandan; Beardsley, Adam P.; Bowman, Judd D.; Morales, Miguel F.

    2015-11-01

    E-field Parallel Imaging Correlator (EPIC), a highly parallelized Object Oriented Python package, implements the Modular Optimal Frequency Fourier (MOFF) imaging technique. It also includes visibility-based imaging using the software holography technique and a simulator for generating electric fields from a sky model. EPIC can accept dual-polarization inputs and produce images of all four instrumental cross-polarizations.

  20. Extrasolar Planetary Imaging Coronagraph (EPIC)

    NASA Astrophysics Data System (ADS)

    Clampin, Mark; Melnick, Gary; Lyon, Richard; Kenyon, Scott; Sasselov, Dimitar; Tolls, Volker; Ford, Holland; Golimowski, David; Petro, Larry; Hartig, George; Sparks, William; Illingworth, Garth; Lin, Doug; Seager, Sara; Weinberger, Alycia; Harwit, Martin; Marley, Mark; Schneider, Jean; Shao, Michael; Levine, Marty; Ge, Jian; Woodruff, Robert

    2006-06-01

    The Extrasolar Planetary Imaging Coronagraph (EPIC) is a proposed NASA Discovery mission to image and characterize extrasolar giant planets in orbits with semi-major axes between 2 and 10 AU. EPIC will provide insights into the physical nature of a variety of planets in other solar systems complimenting radial velocity (RV) and astrometric planet searches. It will detect and characterize the atmospheres of planets identified by radial velocity surveys, determine orbital inclinations and masses, characterize the atmospheres around A and F type stars which cannot be found with RV techniques, and observe the inner spatial structure and colors of debris disks. EPIC has a proposed launch date of 2012 to heliocentric Earth trailing drift-away orbit, with a 3 year mission lifetime (5 year goal), and will revisit planets at least three times at intervals of 9 months. The robust mission design is simple and flexible ensuring mission success while minimizing cost and risk. The science payload consists of a heritage optical telescope assembly (OTA), and visible nulling coronagraph (VNC) instrument. The instrument achieves a contrast ratio of 109 over a 4.84 arcsecond field-of-view with an unprecedented inner working angle of 0.14 arcseconds over the spectral range of 440-880 nm, with spectral resolutions from 10 - 150. The telescope is a 1.5 meter offaxis Cassegrain with an OTA wavefront error of λ/9, which when coupled to the VNC greatly reduces the requirements on the large scale optics, compressing them to stability requirements within the relatively compact VNC optical chain. The VNC features two integrated modular nullers, a spatial filter array (SFA), and an E2V-L3 photon counting CCD. Direct null control is accomplished from the science focal mitigating against complex wavefront and amplitude sensing and control strategies.

  1. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2005-11-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (Z)-4-Hydroxytamoxifen, [18F]-FPS; Adalimumab, alefacept, alemtuzumab, alfimeprase, aprepitant, aripiprazole, atomoxetine hydrochloride; Belatacept, bortezomib; C340, caspofungin acetate, clazosentan sodium, Cypher; Darbepoetin alfa, DB-289, decitabine, dronedarone hydrochloride, duloxetine hydrochloride; Eletriptan, entecavir, ertapenem sodium, escitalopram oxalate, eszopiclone, etoricoxib; Gaboxadol, gadofosveset sodium, galiximab, gemifloxacin mesilate, glutamine; Human insulin; I-131 ch-TNT-1/B, indiplon, inhaled insulin, isatoribine; L-Arginine hydrochloride, liposomal doxorubicin, lopinavir/ritonavir, lumiracoxib; Magnesium sulfate; Natalizumab; Olmesartan medoxomil, omapatrilat, OncoVEX (GM-CSF); rDNA insulin, rupatadine fumarate; Sorafenib; Tadalafil, teduglutide, temsirolimus, tenofovir disoproxil fumarate, tiotropium bromide; Valdecoxib, vardenafil hydrochloride hydrate. PMID:16357953

  2. TDRS Ku band gateway

    NASA Technical Reports Server (NTRS)

    Collins, Cynthia; Lecha, Javier; Principe, Caleb M.; Ross, Douglas

    1987-01-01

    The Wideband Transport Frame Formatter (WTFF) is the tracking and data relay satellite (TDRS) ku-band return link gateway. The WTFF system is a multiplexing device developed to process and downlink the high rate data generated by a wide variety of users. The WTFF is designed to frame and format high data rate user channels into transport frames and multiplex according to a predefined schedule into two bit streams that are compatible with TDRS Ku I and Q band service. The combined data rate will be 300 Mbps. The WTFF will service up to eight input channels generating data in the range of 10 to 150 Mbps. In addition to these input channels, audio data will be accepted by the WTFF system and inserted in the downlink. A second function of the WTFF is to provide telecommunication coding as assigned to each virtual channel to ensure a given quality of service.

  3. Experience using EPICS on PC platforms

    SciTech Connect

    Hill, J.O.; Kasemire, K.U.

    1998-03-01

    The Experimental Physics and Industrial Control System (EPICS) has been widely adopted in the accelerator community. Although EPICS is available on many platforms, the majority of implementations have used UNIX workstations as clients, and VME- or VXI-based processors for distributed input output controllers. Recently, a significant portion of EPICS has been ported to personal computer (PC) hardware platforms running Microsoft`s operating systems, and also Wind River System`s real time vxWorks operating system. This development should significantly reduce the cost of deploying EPICS systems, and the prospect of using EPICS together with the many high quality commercial components available for PC platforms is also encouraging. A hybrid system using both PC and traditional platforms is currently being implemented at LANL for LEDA, the low energy demonstration accelerator under construction as part of the Accelerator Production of Tritium (APT) project. To illustrate these developments the authors compare their recent experience deploying a PC-based EPICS system with experience deploying similar systems based on traditional (UNIX-hosted) EPICS hardware and software platforms.

  4. Integrating commercial and legacy systems with EPICS

    SciTech Connect

    Hill, J.O.; Kasemir, K.U.; Kowalkowski, J.B.

    1997-09-01

    The Experimental Physics and Industrial Control System (EPICS) is a software toolkit, developed by a worldwide collaboration, which significantly reduces the level of effort required to implement a new control system. Recent developments now also significantly reduce the level of effort required to integrate commercial, legacy and/or site-authored control systems with EPICS. This paper will illustrate with an example both the level and type of effort required to use EPICS with other control system components as well as the benefits that may arise.

  5. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2002-05-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables can be retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abacavir sulfate, abarelix, abciximab, acarbose, alefacept, alteplase, amisulpride, amoxicillin trihydrate, apomorphine hydrochloride, aprepitant, argatroban monohydrate, aspirin, atenolol; Betamethasone dipropionate, betamethasone valerate, bicalutamide, bleomycin sulfate; Calcium carbonate, candesartan cilexetil, celecoxib, cetirizine hydrochloride, cisplatin, clarithromycin, clavulanate potassium, clomethiazole edisilate, clopidogrel hydrogensulfate, cyclophosphamide, chorionic gonadotropin (human); Dalteparin sodium, desloratadine, dexamethasone, doxorubicin, DPC-083; Efalizumab, efavirenz, enoxaparin sodium, eprosartan mesilate, etanercept, etoposide, ezetimibe; Faropenem daloxate, fenofibrate, fluocinolone acetonide, flutamide, fluvastatin sodium, follitropin beta, fondaparinux sodium; Gabapentin, glibenclamide, goserelin, granisetron hydrochloride; Haloperidol, hydrochlorothiazide; Imiquimod, interferon beta-1a, irbesartan, iseganan hydrochloride; L-758298, lamivudine, lanoteplase, leflunomide, leuprorelin acetate, loratadine, losartan potassium; Melagatran, metformin hydrochloride, methotrexate, metronidazole, micafungin sodium, mitoxantrone hydrochloride; Nelfinavir mesilate, neutral insulin injection, nizatidine; Olopatadine hydrochloride, omeprazole, ondansetron hydrochloride; Pamidronate sodium, paracetamol, paroxetine hydrochloride, perindopril, pimecrolimus, pioglitazone hydrochloride, piroxicam, pleconaril, pralmorelin, pravastatin sodium, prednisolone, prednisone, propofol; Raloxifene hydrochloride, ranpirnase, remifentanil hydrochloride, risedronate sodium, risperidone, rofecoxib, ropinirole

  6. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2005-09-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in the current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: AAV-NGFbeta, aprepitant, aripiprazole, atomoxetine hydrochloride; beta-Methyl-6-chloromelatonin, BMS-214662, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, CEA-TRICOM, cetuximab, ciclesonide, clofarabine, Cypher; Dalbavancin, darbepoetin alfa, darifenacin hydrobromide, desloratadine, Dexamet, drospirenone, drospirenone/ethinylestradiol, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecogramostim, efalizumab, ertapenem sodium, escitalopram oxalate, eszopiclone; Fenretinide; Gefitinib, gestodene, ghrelin (human); hMaxi-K, human papillomavirus vaccine; Imatinib mesylate, indiplon, iodine (i131) tositumomab, irofulven, ISS-1018; Lasofoxifene tartrate, levodopa/carbidopa/entacapone, liposomal doxorubicin; Nemifitide ditriflutate, nesiritide; Omalizumab; Pegfilgrastim, peginterferon alfa-2a, peginterferon alfa-2b, phVEGF-A165, pimecrolimus, pramlintide acetate; Rasburicase, rimonabant hydrochloride; Satraplatin, St. John's Wort extract, sunitinib malate; Tadalafil, tanaproget, Taxus, tiotropium bromide, treprostinil sodium; Valdecoxib, vardenafil hydrochloride hydrate; Ximelagatran; Zileuton. PMID:16258596

  7. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2005-03-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 3-AP, 667-coumate, 9-aminocamptothecin; Ad5CMV-p53, AES-14, alefacept, anecortave acetate, APC-8024, APD-356, asoprisnil; Bevacizumab, bimakalim, bimatoprost, BLP-25, BR-1; Caspofungin acetate, cetuximab, cypher; Darbepoetin alfa, dexanabinol, dextromethorphan/quinidine sulfate, DNA.HIVA; Efaproxiral sodium, ertapenem sodium; Frovatriptan; HuMax-EGFr, HYB-2055, gamma-hydroxybutyrate sodium, Id-KLH vaccine, imatinib mesylate; Lapatinib, lonafarnib, Motexafin lutetium, MVA.HIVA, mycophenolic acid sodium salt; Nesiritide, NS-2330; Olmesartan medoxomil; Peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pemetrexed disodium, perifosine, pimecrolimus, pregabalin; QbG-10; Ralfinamide, rasburicase, rFGF-2, Ro-31-7453; Sitaxsentan sodium, sorafenib; Tadalafil, TC-1734, telmisartan/hydrochlorothiazide, tenofovir disoproxil fumarate, thymus nuclear protein, tipifarnib; Vandetanib, vibriolysin, vildagliptin, voriconazole. PMID:15834466

  8. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2004-12-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abetimus sodium, ademetionine, agalsidase alfa, agalsidase beta, alemtuzumab, alfimeprase, AMG-162, androgel, anidulafungin, antigastrin therapeutic vaccine, aripiprazole, atomoxetine hydrochloride; Bazedoxifene acetate, bevacizumab, bosentan; Caldaret hydrate, canfosfamide hydrochloride, choriogonadotropin alfa, ciclesonide, combretastatin A-4 phosphate, CY-2301; Darbepoetin alfa, darifenacin hydrobromide, decitabine, degarelix acetate, duloxetine hydrochloride; ED-71, enclomiphene citrate, eplerenone, epratuzumab, escitalopram oxalate, eszopiclone, ezetimibe; Fingolimod hydrochloride, FP-1096; HMR-3339A, HSV-TK/GCV gene therapy, human insulin, HuOKT3gamma1(Ala234-Ala235); Idursulfase, imatinib mesylate, indiplon, InnoVax C insulin glargine, insulin glulisine, irofulven; Labetuzumab, lacosamide, lanthanum carbonate, LyphoDerm, Lyprinol; Magnesium sulfate, metelimumab, methylphenidate hydrochloride; Natalizumab, NO-aspirin; OROS(R); PC-515, pegaptanib sodium, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pemetrexed disodium, peptide YY3-36, posaconazole, pregabalin, PT-141, pyridoxamine; R-744, ramelteon, ranelic acid distrontium salt, rebimastat, repinotan hydrochloride, rhC1, rhGAD65, rosiglitazone maleate/metformin hydrochloride; Sardomozide, solifenacin succinate; Tadalafil, taxus, telavancin, telithromycin, tenofovir disoproxil fumarate, teriparatide, testosterone transdermal patch, tetomilast, tirapazamine, torcetrapib; Valspodar, vardenafil hydrochloride hydrate, vildagliptin; Yttrium Y90 epratuzumab; Ziprasidone hydrochloride. PMID:15672123

  9. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2002-12-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abacavir sulfate, adalimumab, AERx morphine sulphate, alefacept, alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, almotriptan, amprenavir, aripiprazole, atenolol, atorvastatin calcium; BSYX-A110; Cantuzumab mertansine, capravirine, CDP-571, CDP-870, celecoxib; Delavirdine mesilate, docetaxel, dofetilide, donepezil hydrochloride, duloxetine hydrochloride, dutasteride, dydrogesterone; Efavirenz, emtricitabine, enjuvia, enteryx, epristeride, erlotinib hydrochloride, escitalopram oxalate, etanercept, etonogestrel, etoricoxib; Fesoterodine, finasteride, flt3ligand; Galantamine hydrobromide, gemtuzumab ozogamicin, genistein, gepirone hydrochloride; Indinavir sulfate, infliximab; Lamivudine, lamivudine/zidovudine/abacavir sulfate, leteprinim potassium, levetiracetam, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, losartan potassium; MCC-465, MRA; Nebivolol, nesiritide, nevirapine; Olanzapine, OROS(R)-Methylphenidate hydrochloride; Peginterferon alfa-2a, peginterferon alfa-2b, Pimecrolimus, polyethylene glycol 3350, pramlintide acetate, pregabalin, PRO-2000; Risedronate sodium, risperidone, ritonavir, rituximab, rivastigmine tartrate, rofecoxib, rosuvastatin calcium; Saquinavir mesilate, Stavudine; Tacrolimus, tadalafil, tamsulosin hydrochloride, telmisartan, tomoxetine hydrochloride, treprostinil sodium, trimegestone, trimetrexate; Valdecoxib, venlafaxine hydrochloride; Zoledronic acid monohydrate. PMID:12616965

  10. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2003-12-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abetimus sodium, adalimumab, alefacept, alemtuzumab, almotriptan, AMGN-0007, anakinra, anti-CTLA-4 Mab, L-arginine hydrochloride, arzoxifene hydrochloride, astemizole, atazanavir sulfate, atlizumab; Belimumab, BG-9928, binodenoson, bosentan, botulinum toxin type B, bovine lactoferrin, BufferGel; Caspofungin acetate, ciclesonide,cilomilast, ciluprevir, clofarabine, CVT-3146; Darbepoetin alfa, desloratadine, diflomotecan, doripenem, dronedarone hydrochloride, drotrecogin alfa (activated), DT388-GM-CSF, duloxetine hydrochloride, E-5564, efalizumab, enfuvirtide, esomeprazole magnesium, estradiol acetate, ETC-642, exenatide, exisulind, ezetimib; Febuxostat; Gallium maltolate, ganirelix acetate, garenoxacin mesilate, gefitinib; H11, HuMax; IL-15, IDD-1, IGIV-C, imatinib mesylate, ISIS-14803, ITF-1697, ivabradine hydrochloride; KRN-5500; L-365260, levetiracetam, levosimendan, licofelone, linezolid, LJP-1082, lopinavir lumiracoxib; MCC-478, melatonin, morphine hydrochloride, morphine-6-glucuronide, moxidectin; N-Acetylcarnosine, natalizumab, NM-702, NNC-05-1869, NSC-703940; Ocinaplon OM-89, omalizumab, omeprazole/ sodium bicarbonate, OPC-28326, ospemifene; PEG-filgrastim peginterferon alfa-2a, pegsunercept, pirfenidone, pralmorelin, pregabalin; Recombinant glucagon-like peptide-1 (7-36) amide, repifermin, RSD-1235; S-8184, selodenoson, sodium dichloroacetate, suberanilohydroxamic acid; TAS-102, terfenadine, teriparatide, tipranavir troxacitabine; Ximelagatran; YM-337. PMID:14735233

  11. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2003-04-01

    Gateways to clinical trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 5A8; Agomelatine, alefacept, almotriptan, anakinra, APC-8015, atazanavir, atomoxetine hydrochloride, azimilide hydrochloride; Bicifadine; Cannabidiol, caspofungin acetate, CAT-213, CGP-51901, ciclesonide, cipamfylline; Darbepoetin alfa, desloratadine, dibotermin alfa, DX-9065a; Ecogramostim, efalizumab, eletriptan, eniluracil, EPI-KAL2, erlosamide, ertapenem sodium, etilevodopa, etoricoxib, ezetimibe; Fosamprenavir calcium, fosamprenavir sodium, fumagillin; Gadofosveset sodium, gefitinib, gemtuzumab ozogamicin; HSPPC-96, human papillomavirus vaccine; Icatibant Id-KLH, imatinib mesylate, INS-37217, iodine (I131) tositumomab; LAS-34475, levobupivacaine hydrochloride, levocetirizine, linezolid, 131I-lipiodol, lonafarnib, lopinavir, LY-450108; Magnetites, MBI-594AN, melagatran, melatonin, mepolizumab, mycophenolic acid sodium salt; NC-100100; 1-Octanol, omalizumab, omapatrilat, onercept; PEG-filgrastim, (PE)HRG21, peginterferon alfa-2a, peginterferon alfa-2b, pleconaril, pneumococcal 7-valent conjugate vaccine, prasterone; Ranelic acid distrontium salt, rasagiline mesilate, reslizumab, rFGF-2, rhOP-1, rosuvastatin calcium, roxifiban acetate; Sitaxsentan sodium, sodium lauryl sulfate; Tadalafil, telithromycin, tenofovir disoproxil fumarate, tipranavir, TMC-114, tucaresol; Valdecoxib, voriconazole; Ximelagatran; Zofenopril calcium, zosuquidar trihydrochloride. PMID:12743628

  12. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2002-11-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abacavir sulfate, abarelix, adalimumab, adefovir dipivoxil, AdGVVEGF121.10, anastrozole, anecortave acetate, aripiprazole, asulacrine isethionate, atazanavir, ATL-962, 16-Aza-epothilone B; Bevacizumab, bicalutamide, blonanserin, BMS-188667, bosentan; Celecoxib, celmoleukin, cetuximab, cilomilast, cinacalcet hydrochloride, CNTF(Ax15), colesevelam hydrochloride; Daclizumab, delavirdine mesilate, desogestrel, desoxyepothilone B, dexmethylphenidate hydrochloride, duloxetine hydrochloride; Ecogramostim, emtricitabine, epalrestat, escitalopram oxalate, examorelin, exendin-4, ezetimibe; Fidarestat, frovatriptan; HIV-1 Immunogen; Iloperidone, insulin detemir, insulin lispro, irinotecan hydrochloride; Keratinocyte growth factor; Lasofoxifene tartrate, levetiracetam, levormeloxifene, levosimendan, lumiracoxib, LY-307161 SR; Memantine hydrochloride, MEN-10755, metformin hydrochloride, metreleptin, motexafin gadolinium; Naratriptan hydrochloride, natalizumab, nesiritide, nicotine, NN-2211, NN-414; Olanzapine, omalizumab; Pegaptanib sodium, peginterferon alfa-2a, peginterferon alfa-2b, pegvisomant, pimecrolimus, pirfenidone, pramlintide acetate prasterone, pregabalin; Quetiapine fumarate; Rabeprazole sodium, raloxifene hydrochloride, raltitrexed, rDNA insulin, rFGF-2, risedronate sodium, rofecoxib, roflumilast, rosiglitazone maleate; SN-22995; Tacrolimus, tadalafil, tegaserod maleate, tiotropium bromide, tomoxetine hydrochloride, trastuzumab, trimegestone; Voglibose, Voriconazole; Ziprasidone hydrochloride. PMID:12616707

  13. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2006-06-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 131-I-chlorotoxin; Ad5CMV-p53, adalimumab, albumin interferon alfa, alemtuzumab, aliskiren fumarate, aminolevulinic acid methyl ester, anakinra, AR-C126532, atomoxetine hydrochloride; Bevacizumab, bosentan, botulinum toxin type B, brimonidine tartrate/timolol maleate; Calcipotriol/betamethasone dipropionate, cangrelor tetrasodium, cetuximab, ciclesonide, cinacalcet hydrochloride, collagen-PVP, Cypher; Darbepoetin alfa, darusentan, dasatinib, denosumab, desloratadine, dexosome vaccine (lung cancer), dexrazoxane, dextromethorphan/quinidine sulfate, duloxetine hydrochloride; ED-71, eel calcitonin, efalizumab, entecavir, etoricoxib; Falciparum merozoite protein-1/AS02A, fenretinide, fondaparinux sodium; gamma-Hydroxybutyrate sodium, gefitinib, ghrelin (human); hLM609; Icatibant acetate, imatinib mesylate, ipsapirone, irofulven; LBH-589, LE-AON, levocetirizine, LY-450139; Malaria vaccine, mapatumumab, motexafin gadolinium, muraglitazar, mycophenolic acid sodium salt; nab-paclitaxel, nelarabine; O6-Benzylguanine, olmesartan medoxomil, orbofiban acetate; Panitumumab, peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed disodium, peptide YY3-36, pleconaril, prasterone, pregabalin; Ranolazine, rebimastat, recombinant malaria vaccine, rosuvastatin calcium; SQN-400; Taxus, tegaserod maleate, tenofovir disoproxil fumarate, teriparatide, troxacitabine; Valganciclovir hydrochloride, Val-Tyr sardine peptidase, VNP-40101M, vorinostat. PMID:16845450

  14. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2002-01-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses, which has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the world's first drug discovery and development portal, providing information on study design, treatments, conclusions and references. This issue focuses on the following selection of drugs: Abacavir sulfate; abciximab; abetimus sodium; adalimumab; aldesleukin; almotriptan; alteplase; amisulpride; amitriptyline hydrochloride; amoxicillin trihydrate; atenolol; atorvastatin calcium; atrasentan; Beclometasone dipropionate; bosentan; Captopril; ceftriaxone sodium; cerivastatin sodium; cetirizine hydrochloride; cisplatin; citalopram hydrobromide; Dalteparin sodium; darusentan; desirudin; digoxin; Efalizumab; enoxaparin sodium; ertapenem sodium; esomeprazole magnesium; estradiol; ezetimibe; Famotidine; farglitazar; fluorouracil; fluticasone propionate; fosamprenavir sodium; Glibenclamide; glucosamine sulfate; Heparin sodium; HSPPC-96; hydrochlorothiazide; Imatinib mesilate; implitapide; Lamivudine; lansoprazole; lisinopril; losartan potassium; l-Propionylcarnitine; Melagatran; metformin hydrochloride; methotrexate; methylsulfinylwarfarin; Nateglinide; norethisterone; Olmesartan medoxomil; omalizumab; omapatrilat; omeprazole; oseltamivir phosphate; oxatomide; Pantoprazole; piperacillin sodium; pravastatin sodium; Quetiapine hydrochloride; Rabeprazole sodium; raloxifene hydrochloride; ramosetron hydrochloride; ranolazine; rasburicase; reboxetine mesilate; recombinant somatropin; repaglinide; reteplase; rosiglitazone; rosiglitazone maleate; rosuvastatin calcium; Sertraline; simvastatin; sumatriptan succinate; Tazobactam sodium; tenecteplase; tibolone; tinidazole; tolterodine tartrate; troglitazone; Uniprost; Warfarin sodium; Ximelagatran. PMID:11980386

  15. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2005-12-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity. prous.com. This issue focuses on the following selection of drugs: 131I-chTNT; Abatacept, adalimumab, alemtuzumab, APC-8015, aprepitant, atazanavir sulfate, atomoxetine hydrochloride, azimilide hydrochloride; Bevacizumab, bortezomib, bosentan, buserelin; Caspofungin acetate, CC-4047, ChAGCD3, ciclesonide, clopidogrel, curcumin, Cypher; Dabigatran etexilate, dapoxetine hydrochloride, darbepoetin alfa, darusentan, denosumab, DMXB-Anabaseine, drospirenone, drospirenone/estradiol, duloxetine hydrochloride, dutasteride; Edodekin alfa, efaproxiral sodium, elaidic acid-cytarabine, erlotinib hydrochloride, ertapenem sodium, escitalopram oxalate, eszopiclone, etonogestrel/testosterone decanoate, exenatide; Fulvestrant; Gefitinib, glycine, GVS-111; Homoharringtonine; ICC-1132, imatinib mesylate, iodine (I131) tositumomab, i.v. gamma-globulin; Levetiracetam, levocetirizine, lintuzumab, liposomal nystatin, lumiracoxib, lurtotecan; Manitimus, mapatumumab, melatonin, micafungin sodium, mycophenolic acid sodium salt; Oblimersen sodium, OGX-011, olmesartan medoxomil, omalizumab, omapatrilat, oral insulin; Parathyroid hormone (human recombinant), pasireotide, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, phVEGF-A165, pimecrolimus, pitavastatin calcium, plerixafor hydrochloride, posaconazole, pramlintide acetate, prasterone, pregabalin, PT-141; Quercetin; Ranolazine, rosuvastatin calcium, rubitecan, rupatadine fumarate; Sardomozide, sunitinib malate; Tadalafil, talactoferrin alfa, tegaserod maleate, telithromycin, testosterone transdermal patch, TH-9507, tigecycline, tiotropium bromide, tipifarnib, tocilizumab, treprostinil sodium; Valdecoxib, vandetanib

  16. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2003-10-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 3,4-DAP; Adefovir dipivoxil, ADL-10-0101, alefacept, alemtuzumab, alosetron hydrochloride, ALT-711, aprepitant, atazanavir sulfate, atlizumab, atvogen; Bortezomib; CETP vaccine, clevudine, crofelemer; DAC:GLP-1, darbepoetin alfa, decitabine, drotrecogin alfa (activated), DX-9065a; E-7010, edodekin alfa, emivirine, emtricitabine, entecavir, erlosamide, erlotinib hydrochloride, everolimus, exenatide; Fondaparinux sodium, frovatriptan, fulvestrant; Gemtuzumab ozogamicin, gestodene; Homoharringtonine, human insulin; Imatinib mesylate, indiplon, indium 111 (111In) ibritumomab tiuxetan, inhaled insulin, insulin detemir, insulin glargine, ivabradine hydrochloride; Lanthanum carbonate, lapatinib, LAS-34475, levetiracetam, liraglutide, lumiracoxib; Maxacalcitol, melagatran, micafungin sodium; Natalizumab, NSC-640488; Oblimersen sodium; Parecoxib sodium, PEG-filgrastim, peginterferon alfa-2(a), peginterferon alfa-2b, pexelizumab, pimecrolimus, pleconaril, pramlintide acetate, pregabalin, prucalopride; rAHF-PFM, Ranelic acid distrontium salt, ranolazine, rDNA insulin, recombinant human soluble thrombomodulin, rhGM-CSF, roxifiban acetate, RSD-1235, rubitecan, ruboxistaurin mesilate hydrate; SC-51, squalamine; Tegaserod maleate, telbivudine, tesaglitazar, testosterone gel, tezosentan disodium, tipranavir; Vatalanib succinate; Ximelagatran; Yttrium 90 (90Y) ibritumomab tiuxetan; Zoledronic acid monohydrate. PMID:14671684

  17. Next generation epics interface to abstract data.

    SciTech Connect

    Hill, J. O.; Lange, R.

    2001-01-01

    The set of externally visible properties associated with process variables in the Experimental Physics and Industrial Control System (EPICS) is predefined in the EPICS base distribution and is therefore not extensible by plug-compatible applications. We believe that this approach, while practical for early versions of the system with a smaller user base, is now severely limiting expansion of the high-level application tool set for EPICS. To eliminate existing barriers, we propose a new C++ based interface to abstract containerized data. This paper describes the new interface, its application to message passing in distributed systems, its application to direct communication between tightly coupled programs co-resident in an address space, and its paramount position in an emerging role for EPICS -- the integration of dissimilar systems.

  18. The Experimental Projectile Impact Chamber (EPIC), Spain

    NASA Astrophysics Data System (ADS)

    Ormö, J.; Melero-Asensio, I.; Housen, K.; Wünnemann, K.; Elbeshausen, D.; Collins, G.

    2015-09-01

    We show that EPIC dry sand experiments are consistent with previous experimental work within the pi-group scaling framework, and use the craters as ground truth for the validation of numerical impact models, before moving forward with wet targets.

  19. EPIC View of Moon Transiting the Earth

    NASA Video Gallery

    This animation features actual satellite images of the far side of the moon, illuminated by the sun, as it crosses between the DSCOVR spacecraft's Earth Polychromatic Imaging Camera (EPIC) and tele...

  20. Supported PV module assembly

    SciTech Connect

    Mascolo, Gianluigi; Taggart, David F.; Botkin, Jonathan D.; Edgett, Christopher S.

    2013-10-15

    A supported PV assembly may include a PV module comprising a PV panel and PV module supports including module supports having a support surface supporting the module, a module registration member engaging the PV module to properly position the PV module on the module support, and a mounting element. In some embodiments the PV module registration members engage only the external surfaces of the PV modules at the corners. In some embodiments the assembly includes a wind deflector with ballast secured to a least one of the PV module supports and the wind deflector. An array of the assemblies can be secured to one another at their corners to prevent horizontal separation of the adjacent corners while permitting the PV modules to flex relative to one another so to permit the array of PV modules to follow a contour of the support surface.

  1. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2008-10-01

    Gateways to clinical trials is a guide to the most recent trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (+)-Dapoxetine hydrochloride, (S)-Tenatoprazole sodium salt monohydrate 19-28z, Acotiamide hydrochloride hydrate, ADV-TK, AE-37, Aflibercept, Albinterferon alfa-2b, Aliskiren fumarate, Asenapine maleate, Axitinib; Bavituximab, Becatecarin, beta-1,3/1,6-Glucan, Bevacizumab, Bremelanotide; Calcipotriol/betamethasone dipropionate, Casopitant mesylate, Catumaxomab, CDX-110, Cediranib, CMD-193, Cositecan; Darinaparsin, Denosumab, DP-b99, Duloxetine hydrochloride; E75, Ecogramostim, Elacytarabine, EMD-273063, EndoTAG-1, Enzastaurin hydrochloride, Eplerenone, Eribulin mesilate, Esomeprazole magnesium, Etravirine, Everolimus, Ezetimibe; Faropenem daloxate, Febuxostat, Fenretinide; Ghrelin (human); I-131 ch-TNT-1/B, I-131-3F8, Iclaprim, Iguratimod, Iloperidone, Imatinib mesylate, Inalimarev/Falimarev, Indacaterol, Ipilimumab, Iratumumab, Ispinesib mesylate, Ixabepilone; Lapatinib ditosylate, Laquinimod sodium, Larotaxel dehydrate, Linezolid, LOR-2040; Mapatumumab, MKC-1, Motesanib diphosphate, Mycophenolic acid sodium salt; NK-012; Olanzapine pamoate, Oncolytic HSV, Ortataxel; Paclitaxel nanoparticles, Paclitaxel poliglumex, Paliperidone palmitate, Panitumumab, Patupilone, PCV-9, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pertuzumab, Picoplatin, Pimavanserin tartrate, Pimecrolimus, Plerixafor hydrochloride, PM-02734, Poly I:CLC, PR1, Prasugrel, Pregabalin, Progesterone caproate, Prucalopride, Pumosetrag hydrochloride; RAV-12, RB-006, RB-007, Recombinant human erythropoietin alfa, Rimonabant, Romidepsin; SAR-109659, Satraplatin, Sodium butyrate; Tadalafil, Talampanel, Tanespimycin, Tarenflurbil, Tariquidar

  2. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2004-06-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 101M; Adalimumab, adefovir dipivoxil, adenosine triphosphate, albumin interferon alfa, alefacept, alemtuzumab, aminolevulinic acid hexyl ester, autologous renal tumor vaccine, azimilide hydrochloride; Bortezomib, bosentan, BR-1; C340, cantuzumab mertansine, caspofungin acetate, CGP-36742, CHAMPION everolimus-eluting coronary stent, cypher; Dalbavancin, darbepoetin alfa, desloratadine, duloxetine hydrochloride, dutasteride; Efalizumab, emtricitabine, enfuvirtide, erlosamide, ertapenem sodium, everolimus, ezetimibe; Flesinoxan hydrochloride, fosamprenavir calcium, FR-901228, frovatriptan; Gadofosveset sodium, gadomer-17, galiximab, gamma-hydroxybutyrate sodium, gefitinib; HuOKT3gamma1(Ala234-Ala235); IDN-6556, imatinib mesylate, iodine (I131) tositumomab, iseganan hydrochloride, ixabepilone; Keratinocyte growth factor; LB-80380, levocetirizine, liposomal doxorubicin, LMB-9, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Mecasermin, midostaurin, morphine hydrochloride; Natalizumab, nelfinavir, nesiritide, niacin/lovastatin; Olcegepant, omalizumab, oregovomab; Parecoxib sodium, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ ribavirin, perospirone hydrochloride, pexelizumab, pimecrolimus, prinomastat; Resiquimod, rhIGFBP-3, rhIGF-I/rhIGFBP-3, ritanserin, ro-31-7453, rosuvastatin calcium; SCIO-469, SDZ-SID-791, SU-11248, suberanilohydroxamic acid; Tadalafil, taxus, telithromycin, tenofovir disoproxil fumarate, TER-286, tezosentan disodium, TH-9507, tipifarnib, tipranavir, tolvaptan, tramadol hydrochloride/acetaminophen, travoprost, treprostinil sodium, tucaresol

  3. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2006-05-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com/. This issue focuses on the following selection of drugs: Adalimumab, adenosine triphosphate, alemtuzumab, alendronate sodium/cholecalciferol, aliskiren fumarate, AMGN-0007, aminolevulinic acid methyl ester, anakinra, anidulafungin, aripiprazole, atomoxetine hydrochloride; Bevacizumab, bosentan; Calcipotriol/beta methasone dipropionate, caldaret hydrate, caspofungin acetate, cetuximab, cinacalcet hydrochloride, clopidogrel, cocaine-BSA conjugate, conivaptan hydrochloride, Cypher; Darbepoetin alfa, delmitide, desloratadine, desmoteplase, desoxyepothilone B, disufenton sodium, DU-176b, duloxetine hydrochloride, dutasteride; EBV-specific CTLs, ecogramostim, edodekin alfa, efalizumab, eletriptan, emtricitabine, entecavir, erlotinib hydrochloride, ertapenem sodium, escitalopram oxalate, etoricoxib, everolimus, ezetimibe; Fanapanel, fondaparinux sodium; Gefitinib, GTI-2040, GW-501516; Her2 E75-peptide vaccine, human insulin; Ibogaine, icatibant acetate, Id-KLH vaccine, imatinib mesylate, immune globulin subcutaneous [human], indacaterol, inolimomab, ipilimumab, i.v. gamma-globulin, ivabradine hydrochloride, ixabepilone; Lacosamide, lanthanum carbonate, lenalidomide, levocetirizine, levodopa methyl ester hydrochloride/carbidopa, levodopa/carbidopa/entacapone, lidocaine/prilocaine; Maraviroc, mecasermin, melevodopa hydrochloride, mepolizumab, mitumomab; Nesiritide; Omalizumab, oral insulin; Parathyroid hormone (human recombinant), patupilone, pegaptanib sodium, PEG-filgrastim, pemetrexed disodium, photochlor, pimecrolimus, posaconazole, prasterone, prasugrel, pregabalin, prilocaine, PRX-00023; QS-21; Ranibizumab, ranirestat, rhodamine 123, rotigaptide; Sarcosine, sirolimus

  4. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2004-03-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Activated protein C concentrate, Ad-CD154, Adeno-Interferon gamma, alemtuzumab, APC-8024, 9-aminocamptothecin, aprepitant, l-arginine hydrochloride, aripiprazole, arsenic trioxide, asimadoline; O6-Benzylguanine, bevacizumab, Bi-20, binodenoson, biphasic insulin aspart, bivatuzumab, 186Re-bivatuzumab, BMS-181176, bosentan, botulinum toxin type B, BQ-123, bryostatin 1; Carboxy- amidotriazole, caspofungin acetate, CB-1954, CC-4047, CDP-860, cerivastatin sodium, clevidipine, CTL-102; 3,4-DAP, darbepoetin alfa, decitabine, desloratadine, DHA-paclitaxel, duloxetine hydrochloride; Efalizumab, EGF vaccine, eletriptan, eniluracil, ENMD-0997, eplerenone, eplivanserin, erlosamide, ertapenem sodium, escitalopram oxalate, esomeprazole magnesium, eszopiclone, everolimus, exatecan mesilate, exenatide, ezetimibe; Fondaparinux sodium, FR-901228, FTY-720; Gefitinib, gemtuzumab ozogamicin, gepirone hydrochloride; Hexyl insulin M2, human insulin; Imatinib mesylate, insulin detemir, insulin glargine, iodine (I131) tositumomab, ISV-205, ivabradine hydrochloride, ixabepilone; Levetiracetam, levocetirizine, linezolid, liposomal NDDP, lonafarnib, lopinavir, LY-156735; Mafosfamide cyclohexylamine salt, magnesium sulfate, maxacalcitol, meclinertant, melagatran, melatonin, MENT, mepolizumab, micafungin sodium, midostaurin, motexafin gadolinium; Nesiritide, NS-1209, NSC-601316, NSC-683864; Osanetant; Palonosetron hydrochloride, parecoxib sodium, pegaptanib sodium, peginterferon alfa-2a, peginterferon alfa-2b, pegylated OB protein, pemetrexed disodium, perillyl alcohol, picoplatin, pimecrolimus, pixantrone maleate, plevitrexed

  5. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2006-01-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: ABT-510, adalimumab, alefacept, ambrisentan, aminolevulinic acid methyl ester, armodafinil, aselizumab, asenapine maleate, azelnidipine; Bevacizumab, bexarotene, bimosiamose, biphasic insulin aspart, bortezomib, bosentan, BQ-123; C340, cannabidiol, caspofungin acetate, CC-4047, certolizumab pegol, cetuximab, ciclesonide, cilansetron, Cypher; Dabigatran etexilate, darbepoetin alfa, darifenacin hydrobromide, desloratadine, dexosome vaccine (melanoma), dimethyl fumarate, dronabinol/cannabidiol, drospirenone, drospirenone/estradiol, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Efalizumab, eglumetad hydrate, emoxipin hydrochloride, eplerenone, erlotinib hydrochloride, escitalopram oxalate, etonogestrel/ethinylestradiol; Garenoxacin mesilate, gamma-hydroxybutyrate sodium, gefitinib; H5N1 pandemic influenza vaccine, human growth hormone-(177-191), human insulin; Indacaterol, INKP-100, INKP-102, insulin glargine, i.v. gamma-globulin; KLH; Lapatinib, L-arginine hydrochloride, lasofoxifene tartrate, levocetirizine, licochalcone A, LMI vaccine, lomefloxacin, lubiprostone, lumiracoxib; Miglustat, mycograb; Natalizumab, NCX-4016, nortopixantrone hydrochloride; Olmesartan medoxomil, omalizumab, oral insulin, OrM3; Parathyroid hormone (human recombinant), parecoxib sodium, PCK-3145, PEG-filgrastim, peginterferon alfa-2a, pemetrexed disodium, pexelizumab, photochlor, pimecrolimus, pneumococcal 7-valent conjugate vaccine, polyphenon E; R-126638, R-411, resveratrol, roflumilast, RS-86, ruboxistaurin mesilate hydrate, rupatadine fumarate; Sipuleucel-T, somatropin, St. John's Wort extract; Tadalafil, Taxus

  6. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2006-01-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs:(R)-Flurbiprofen, 90Yttrium-DOTA-huJ591; ABT-510, ACP-103, Ad5-FGF4, adalimumab, ademetionine, AG-7352, alemtuzumab, Amb a 1 ISS-DNA, anakinra, apaziquone, aprepitant, aripiprazole, atazanavir sulfate; BAL-8557, bevacizumab, BMS-188797, bortezomib, bosentan, brivudine; Calcipotriol/betamethasone dipropionate, cannabidiol, caspofungin acetate, catumaxomab, CERE-120, cetuximab, ciclesonide, cilomilast, cizolirtine citrate, Cypher, cystemustine; Dalbavancin, darifenacin hydrobromide, dasatinib, deferasirox, denosumab, desmoteplase, dihydrexidine, dimethyl fumarate, dutasteride, DW-166HC; Eculizumab, enfuvirtide, entecavir, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, eszopiclone, etoricoxib, everolimus; Fallypride, febuxostat, fenretinide, fesoterodine, fingolimod hydrochloride; Gabapentin enacarbil, gefitinib; hMaxi-K, human papillomavirus vaccine, HYAL-CT1101; Imatinib mesylate, indiplon, inolimomab, ISAtx-247; J591; Lacosamide, landiolol, lasofoxifene tartrate, lestaurtinib, lidocaine/prilocaine, linezolid, lixivaptan, lonafarnib, lopinavir, lopinavir/ritonavir, lumiracoxib; Natalizumab, nesiritide; OC-108, omalizumab, onercept, OSC; Palifermin, palonosetron hydrochloride, parathyroid hormone (human recombinant), parecoxib sodium, PD-MAGE-3 vaccine, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, pegsunercept, pelitinib, pitavastatin calcium, plerixafor hydrochloride, posaconazole, prasterone sulfate, pregabalin; Ramelteon, ranelic acid distrontium salt, rasburicase, rosuvastatin calcium, rotigotine, RSD-1235, rufinamide, rupatadine fumarate; Sarizotan hydrochloride, SHL-749

  7. Gateways to clinical trials.

    PubMed

    Moral, M A; Tomillero, A

    2008-03-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 131-I-Chlorotoxin, 423557; Abatacept, Ad.Egr.TNF.11D, Adalimumab, AE-941, Ambrisentan, AMR-001, Anacetrapib, Anakinra, Aripiprazole, Atazanavir sulfate; BAY-639044, Bazedoxifene acetate, Belimumab, Bevacizumab, Bortezomib, Botulinum toxin type B, Brivaracetam, Bucindolol hydrochloride; Carfilzomib, Carisbamate, CCX-282, CD20Bi, Ceftobiprole, Certolizumab pegol, CF-101, Cinacalcet hydrochloride, Cypher; Darifenacin hydrobromide, Degarelix acetate, Denosumab, Desvenlafaxine succinate, Dexlansoprazole, Dexverapamil, Drotrecogin alfa (activated), Duloxetine hydrochloride, Dutasteride; Efalizumab, EPs-7630, Escitalopram oxalate, Etoricoxib; Fluticasone furoate, Fondaparinux sodium, Fospropofol disodium; Hexadecyloxypropyl-cidofovir, HIV gp120/NefTat/AS02A, HPV-6/11/16/18; INCB-18424, Incyclinide, Inhalable human insulin, Insulin detemir; KNS-760704, KW-0761; Lacosamide, Lenalidomide, Levetiracetam, Licofelone, Lidocaine/prilocaine; mAb 216, MEDI-528, Men ACWY, Meningococcal C-CRM197 vaccine, Methylnaltrexone bromide; Nemifitide ditriflutate, Nicotine conjugate vaccine, Nilotinib hydrochloride monohydrate; Octaparin; Parathyroid hormone (human recombinant), Pegaptanib octasodium, Pitrakinra, Prasterone, Pregabalin; Ranelic acid distrontium salt, Rasagiline mesilate, Retigabine, Rimonabant, RTS,S/AS02D; Sarcosine, Sitaxentan sodium, Solifenacin succinate, Sunitinib malate; Taranabant, Taxus, Teduglutide, Teriparatide, Ticagrelor, Travoprost, TRU-015; USlipristal acetate, Urocortin 2; Vardenafil hydrochloride hydrate; YM-155, Yttrium 90 (90Y) ibritumomab tiuxetan; Zanolimumab, Zoledronic acid monohydrate, Zotarolimus

  8. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2006-09-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com This issue focuses on the following selection of drugs: A-007, A6, adalimumab, adenosine triphosphate, alefacept, alemtuzumab, AllerVax Ragweed, amphora, anakinra, angiotensin-(1-7), anidulafungin, apomine, aripiprazole, atomoxetine hydrochloride, avanafil; BAL-8557, becatecarin, bevacizumab, biphasic insulin aspart, BMS-188797, bortezomib, bosentan, botulinum toxin type B, brivudine; Calcipotriol/betamethasone dipropionate, caspofungin acetate, catumaxomab, certolizumab pegol, cetuximab, CG-0070, ciclesonide, cinacalcet hydrochloride, clindamycin phosphate/benzoyl peroxide, cryptophycin 52, Cypher; Dabigatran etexilate, darapladib, darbepoetin alfa, decitabine, deferasirox, desloratadine, dexanabinol, dextromethorphan/quinidine sulfate, DMF, drotrecogin alfa (activated), duloxetine hydrochloride; E-7010, edaravone, efalizumab, emtricitabine, entecavir, eplerenone, erlotinib hydrochloride, escitalopram oxalate, estradiol valerate/dienogest, eszopiclone, exenatide, ezetimibe; Fondaparinux sodium, fulvestrant; Gefitinib, gestodene, GYKI-16084; Hyaluronic acid, hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, indiplon, insulin glargine; Juzen-taiho-to; Lamivudine/zidovudine/abacavir sulfate, L-arginine hydrochloride, lasofoxifene tartrate, L-BLP-25, lenalidomide, levocetirizine, levodopa/carbidopa/entacapone, lexatumumab, lidocaine/prilocaine, lubiprostone, lumiracoxib; MAb-14.18, mitoquidone; Natalizumab, neridronic acid, neuradiab; Olpadronic acid sodium salt, omalizumab; p53-DC vaccine, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed disodium, perifosine, pimecrolimus, prasterone, prasugrel, PRO-2000

  9. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2010-12-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Thomson Reuters Integrity(SM), the drug discovery and development portal, http://www.thomsonreutersintegrity.com. This issue focuses on the following selection of drugs: 17-Hydroxyprogesterone caproate; Abacavir sulfate/lamivudine, Aclidinium bromide, Adalimumab, Adefovir, Alemtuzumab, Alkaline phosphatase, Amlodipine, Apilimod mesylate, Aripiprazole, Axitinib, Azacitidine; Belotecan hydrochloride, Berberine iodide, Bevacizumab, Bortezomib, Bosentan, Bryostatin 1; Calcipotriol/hydrocortisone, Carglumic acid, Certolizumab pegol, Cetuximab, Cinacalcet hydrochloride, Cixutumumab, Coumarin, Custirsen sodium; Darbepoetin alfa, Darifenacin hydrobromide, Darunavir, Dasatinib, Denibulin hydrochloride, Denosumab, Diacetylmorphine, Dulanermin, Duloxetine hydrochloride; Ecogramostim, Enfuvirtide, Entecavir, Enzastaurin hydrochloride, Eplerenone, Escitalopram oxalate, Esomeprazole sodium, Etravirine, Everolimus, Ezetimibe; Fenofibrate/pravastatin sodium, Ferric carboxymaltose, Flavangenol, Fondaparinux sodium; Glutamine, GSK-1024850A; Hepatitis B hyperimmunoglobulin, Hib-MenC, HIV-LIPO-5; Immunoglobulin intravenous (human), Indacaterol maleate, Indibulin, Indium 111 (¹¹¹In) ibritumomab tiuxetan, Influenza A (H1N1) 2009 Monovalent vaccine, Inhalable human insulin, Insulin glulisine; Lapatinib ditosylate, Leucovorin/UFT; Maraviroc, Mecasermin, MMR-V, Morphine hydrochloride, Morphine sulfate/naltrexone hydrochloride, Mycophenolic acid sodium salt; Naproxen/esomeprazole magnesium, Natalizumab; Oncolytic HSV; Paliperidone, PAN-811, Paroxetine, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b/ribavirin, Pegvisomant, Pemetrexed disodium, Pimecrolimus, Posaconazole, Pregabalin; Raltegravir potassium, Ranelic acid distrontium salt, Rasburicase, Rilpivirine

  10. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2004-01-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Know- ledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: ABI-007, Ad.Egr.TNF.11D, adefovir dipivoxil, AdPEDF.11, AES-14, albumex, alefacept, alemtuzumab, aliskiren fumarate, alvimopan hydrate, aAminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anti-IL-12 MAb, aprepitant, atazanavir sulfate, atrasentan, avanafil; Banoxantrone, BG-12, bimatoprost, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, caspofungin acetate, CBT-1, ciclesonide, clofarabine, conivaptan hydrochloride, CpG-7909, C-Vax, Cypher; DA-8159, DAC:GLP-1, darbepoetin alfa, darifenacin, duloxetine hydrochloride; Eculizumab, efalizumab, efaproxiral sodium, EGF vaccine, eletriptan, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, ETC-642, etoricoxib, everolimus, exenatide; Gefitinib, IV gamma-globulin; Human insulin, gamma-hydroxybutyrate sodium; IDN-6556, iguratimod, imatinib mesylate, indiplon, ixabepilone; Laquinimod, LB-80380, lidocaine/prilocaineliraglutide, lopinavir, lopinavir/ritonavir, lucinactant; MAb-14.18, melatonin, MLN-591-DM1; NC-531, neridronic acid, nesiritide, neutrophil-inhibitory factor, niacin/lovastatin; Oblimersen sodium, olcegepant, oral Insulin, ORV-105; Palonosetron hydrochloride, PAmAb, pegaptanib sodium, peginterferon alfa-2a, pegvisomant, perifosine, pexelizumab, phenoxodiol, phenserine tartrate, pimecrolimus, pramlintide acetate, pregabalin, PRO-542, prostate cancer vaccine, PT-141; Ramelteon, rasagiline mesilate, rDNA insulin, reslizumab, rh-Lactoferrin, ribamidine hydrochloride, rosuvastatin calcium; S-8184l, SC-1, sorafenib, St. John's Wort extract, SU-11248; Taxus, telbivudine, tenofovir disoproxil fumarate, teriparatide

  11. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2004-01-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abetimus sodium, Ad5-FGF4, adeno-Interferon gamma, AE-941, AERx, alemtuzumab, alicaforsen sodium, almotriptan, alpharadin, anakinra, anatumomab mafenatox, ANG-453, anti-CTLA-4 Mab, AP-12009, aprepitant, aripiprazole, arsenic trioxide, astemizole, atlizumab, atomoxetine hydrochloride; Bevacizumab, BG-9928, BMS-188667, botulinum toxin type B, BufferGel; Caffeine, CDP-870, cetuximab, cilomilast, ciluprevir, clofarabine, continuous erythropoiesis receptor activator, CP-461; Darbepoetin alfa, deferasirox, desloratadine, desoxyepothilone B, diflomotecan, dolasetron, drotrecogin alfa (activated), duloxetine hydrochloride; ED-71, efalizumab, efaproxiral sodium, EKB-569, eletriptan, EMD-72000, enfuvirtide, erlotinib hydrochloride, escitalopram oxalate, etoricoxib; Fampridine, ferumoxytol, fondaparinux sodium; Gadofosveset sodium, gastrazole, gefitinib, gemtuzumab ozogamicin, gepirone hydrochloride glutamine; hLM609, HSPPC-96, human insulin; IDD-1, imatinib mesylate, indisulam, inhaled insulin, ixabepilone; Keratinocyte growth factor; Lapatinib, laquinimod, LDP-02, LE-SN38, levetiracetam, levosimendan, licofelone, liposomal doxorubicin, liposomal NDDP, lopinavir, lumiracoxib, LY-156735; Morphine hydrochloride, morphine-6-glucuronide, motexafin gadolinium, MS-27-275, MVA-5T4, MVA-Muc1-IL-2; Nemifitide ditriflutate, neridronic acid nitronaproxen, NSC-683864, NSC-703940, NVP-LAF-237; Oblimersen sodium, ocinaplon, oncomyc-NG, OPC-28326, ortataxel, ospemifene; Palonosetron hydrochloride, PEG-filgrastim peginterferon alfa-2(a), peginterferon alfa-2b, pegsunercept, pemetrexed disodium, pregabalin, prilocaine, pyridoxamine; RDP

  12. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2007-12-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Intergrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 249553, 2-Methoxyestradiol; Abatacept, Adalimumab, Adefovir dipivoxil, Agalsidase beta, Albinterferon alfa-2b, Aliskiren fumarate, Alovudine, Amdoxovir, Amlodipine besylate/atorvastatin calcium, Amrubicin hydrochloride, Anakinra, AQ-13, Aripiprazole, AS-1404, Asoprisnil, Atacicept, Atrasentan; Belimumab, Bevacizumab, Bortezomib, Bosentan, Botulinum toxin type B, Brivaracetam; Catumaxomab, Cediranib, Cetuximab, cG250, Ciclesonide, Cinacalcet hydrochloride, Curcumin, Cypher; Darbepoetin alfa, Denosumab, Dihydrexidine; Eicosapentaenoic acid/docosahexaenoic acid, Entecavir, Erlotinib hydrochloride, Escitalopram oxalate, Etoricoxib, Everolimus, Ezetimibe; Febuxostat, Fenspiride hydrochloride, Fondaparinux sodium; Gefitinib, Ghrelin (human), GSK-1562902A; HSV-tk/GCV; Iclaprim, Imatinib mesylate, Imexon, Indacaterol, Insulinotropin, ISIS-112989; L-Alanosine, Lapatinib ditosylate, Laropiprant; Methoxy polyethylene glycol-epoetin-beta, Mipomersen sodium, Motexafin gadolinium; Natalizumab, Nimotuzumab; OSC, Ozarelix; PACAP-38, Paclitaxel nanoparticles, Parathyroid Hormone-Related Protein-(1-36), Pasireotide, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pertuzumab, Picoplatin, Pimecrolimus, Pitavastatin calcium, Plitidepsin; Ranelic acid distrontium salt, Ranolazine, Recombinant human relaxin H2, Regadenoson, RFB4(dsFv)-PE38, RO-3300074, Rosuvastatin calcium; SIR-Spheres, Solifenacin succinate, Sorafenib, Sunitinib malate; Tadalafil, Talabostat, Taribavirin hydrochloride, Taxus, Temsirolimus, Teriparatide, Tiotropium bromide, Tipifarnib, Tirapazamine, Tocilizumab; UCN-01, Ularitide

  13. Gateways to Clinical Trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2002-04-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the world's first drug discovery and development portal, and provides information on study design, treatments, conclusions and references. This issue focuses on the following selection of drugs: Abiciximab, acetylcholine chloride, acetylcysteine, alefacept, alemtuzumab, alicaforsen, alteplase, aminopterin, amoxicillin sodium, amphotericin B, anastrozole, argatroban monohydrate, arsenic trioxide, aspirin, atazanavir, atorvastatin, augmerosen, azathioprine; Benzylpenicillin, BMS-284756, botulinum toxin type A, botulinum toxin type B, BQ-123, budesonide, BXT-51072; Calcium folinate, carbamazepine, carboplatin, carmustine, ceftriaxone sodium, cefuroxime axetil, chorionic gonadotropin (human), cimetidine, ciprofloxacin hydrochloride, cisplatin, citalopram hydrobromide, cladribine, clarithromycin, clavulanic acid, clofarabine, clopidogrel hydrogensulfate, clotrimazole, CNI-1493, colesevelam hydrochloride, cyclophosphamide, cytarabine; Dalteparin sodium, daptomycin, darbepoetin alfa, debrisoquine sulfate, dexrazoxane, diaziquone, didanosine, docetaxel, donezepil, doxorubicin hydrochloride liposome injection, DX-9065a; Eberconazole, ecogramostim, eletriptan, enoxaparin sodium, epoetin, epoprostenol sodium, erlizumab, ertapenem sodium, ezetimibe; Fampridine, fenofibrate, filgrastim, fluconazole, fludarabine phosphate, fluorouracil, 5-fluorouracil/epinephrine, fondaparinux sodium, formoterol fumarate; Gabapentin, gemcitabine, gemfibrozil, glatiramer; Heparin sodium, homoharringtonine; Ibuprofen, iloprost, imatinib mesilate, imiquimod, interferon alpha-2b, interferon alpha-2c, interferon-beta; KW-6002; Lamotrigine, lanoteplase, metoprolol tartrate, mitoxantrone hydrochloride; Naproxen sodium, naratriptan, Natalizumab, nelfinavir mesilate

  14. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2010-11-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Thomson Reuters Integrity(SM), the drug discovery and development portal, http://www.thomsonreutersintegrity.com. This issue focuses on the following selection of drugs: Abatacept, Adalimumab, AdCD40L, Adefovir, Aleglitazar, Aliskiren fumarate, AM-103, Aminolevulinic acid methyl ester, Amlodipine, Anakinra, Aprepitant, Aripiprazole, Atazanavir sulfate, Axitinib; Belimumab, Bevacizumab, Bimatoprost, Bortezomib, Bupropion/naltrexone; Calcipotriol/betamethasone dipropionate, Certolizumab pegol, Ciclesonide, CYT-997; Darbepoetin alfa, Darunavir, Dasatinib, Desvenlafaxine succinate, Dexmethylphenidate hydrochloride cogramostim; Eltrombopag olamine, Emtricitabine, Escitalopram oxalate, Eslicarbazepine acetate, Eszopiclone, Etravirine, Everolimus-eluting coronary stent, Exenatide, Ezetimibe; Fenretinide, Filibuvir, Fludarabine; Golimumab; Hepatitis B hyperimmunoglobulin, HEV-239, HP-802-247, HPV-16/18 AS04, HPV-6/11/16/18, Human albumin, Human gammaglobulin; Imatinib mesylate, Inotuzumab ozogamicin, Invaplex 50 vaccine; Lapatinib ditosylate, Lenalidomide, Liposomal doxorubicin, Lopinavir, Lumiliximab, LY-686017; Maraviroc, Mecasermin rinfabate; Narlaprevir; Ocrelizumab, Oral insulin, Oritavancin, Oxycodone hydrochloride/naloxone; Paclitaxel-eluting stent, Palonosetron hydrochloride, PAN-811, Paroxetine, Pazopanib hydrochloride, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pertuzumab, Pitavastatin calcium, Posaconazole, Pregabalin, Prucalopride succinate; Raltegravir potassium, Ranibizumab, RHAMM R3 peptide, Rosuvastatin calcium; Salclobuzic acid sodium salt, SCY-635, Selenate sodium, Semapimod hydrochloride, Silodosin, Siltuximab, Silybin, Sirolimus-eluting stent, SIR-Spheres, Sunitinib malate; Tapentadol hydrochloride, Tenofovir disoproxil

  15. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2004-04-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: ABI-007, adalimumab, adefovir dipivoxil, alefacept, alemtuzumab, 3-AP, AP-12009, APC-8015, L-Arginine hydrochloride, aripiprazole, arundic acid, avasimibe; Bevacizumab, bivatuzumab, BMS-181176, BMS-184476, BMS-188797, bortezomib, bosentan, botulinum toxin type B, BQ-123, BRL-55730, bryostatin 1; CEP-1347, cetuximab, cinacalcet hydrochloride, CP-461, CpG-7909; D-003, dabuzalgron hydrochloride, darbepoetin alfa, desloratadine, desoxyepothilone B, dexmethylphenidate hydrochloride, DHA-paclitaxel, diflomotecan, DN-101, DP-b99, drotrecogin alfa (activated), duloxetine hydrochloride, duramycin; Eculizumab, Efalizumab, EKB-569, elcometrine, enfuvirtide, eplerenone, erlotinib hydrochloride, ertapenem sodium, eszopiclone, everolimus, exatecan mesilate, ezetimibe; Fenretinide, fosamprenavir calcium, frovatriptan; GD2L-KLH conjugate vaccine, gefitinib, glufosfamide, GTI-2040; Hexyl insulin M2, human insulin, hydroquinone, gamma-Hydroxybutyrate sodium; IL-4(38-37)-PE38KDEL, imatinib mesylate, indisulam, inhaled insulin, ixabepilone; KRN-5500; LY-544344; MDX-210, melatonin, mepolizumab, motexafin gadolinium; Natalizumab, NSC-330507, NSC-683864; 1-Octanol, omalizumab, ortataxel; Pagoclone, peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed disodium, phenoxodiol, pimecrolimus, plevitrexed, polyphenon E, pramlintide acetate, prasterone, pregabalin, PX-12; QS-21; Ragaglitazar, ranelic acid distrontium salt, RDP-58, recombinant glucagon-like peptide-1 (7-36) amide, repinotan hydrochloride, rhEndostatin, rh-Lactoferrin, (R)-roscovitine; S-8184, semaxanib, sitafloxacin hydrate, sitaxsentan sodium, sorafenib, synthadotin

  16. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2003-01-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 81C6; Adefovir dipivoxil, Agalsidase alfa, AGM-1470, albumin interferon alfa, alefacept, alosetron hydrochloride, anakinra, anti-CTLA-4 Mab, aprepitant, aripiprazole, atazanavir; BAY-43-9006, BBR-3438, beta-L-Fd4C, bimatoprost, bortezomib, bosentanBR96-doxorubicin; Caspofungin acetate, ciclesonide, cilengitide, cilomilast, COL-1621, COL-3, CpG-7909, cyclosporine; DCVax-Brain, dexmethylphenidate hydrochloride, dexosome vaccine (melanoma), donepezil hydrochloride, drotrecogin alfa (activated), DTI-015, [99Tc]-DTPA-mannosyldextran, duloxetine hydrochloride; Emivirine, emtricitabine, entecavir, epothilone B, estradiol-MNP, etonogestrel/etonogestrel/ethinylestradiol, etoricoxib; Febuxostat, fondaparinux sodium, fosamprenavir calcium; Gefitinib, GVS-111; Heparinase I, HspE7, human alpha-glucosidase, human insulin; Imatinib mesylate, INGN-241, interferon alfa B/D hybrid, interferon alfa Biphasix, ISIS-14803; Lanicemine hydrochloride, 1311-lipiodol, liposome-encapsulated mitoxantrone, lixivaptan, lumiracoxib, lupus-AHP, LY-466700; Marimastat, MEN-10755, micafungin sodium; Nitronaproxen, NSC-683864 Omalizumab, oral insulin; Palonosetron hydrochloride, peginterferon alfa-2a, pimecrolimus, pralnacasan, pramlintide acetate, pregabalin, pyrazoloacridine; R-165335, ranolazine, risperidone, RPR-109881;, RSD-1235, Satraplatin, seocalcitol, sertindole, SMART anti-interferon gamma antibody, sulfasalazine; T-138067, TAK-013, tegaserod maleate, telithromycin, tenofovir disoproxil fumarate, teriparatide, tiotropium bromide, tipifarnib, TP-38; Valdecoxib, vatalanib succinate, voriconazole; ZD-9331. PMID:12690708

  17. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2004-09-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 101M, 166Ho-DOTMP, 3-AP; Abatacept, abetimus sodium, ACR-16, adefovir dipivoxil, alefacept, AMD-070, aminolevulinic acid hexyl ester, anatumomab mafenatox, anti-CTLA-4 MAb, antigastrin therapeutic vaccine, AP-12009, AP-23573, APC-8024, aripiprazole, ATL-962, atomoxetine hydrochloride; Bevacizumab, bimatoprost, bortezomib, bosentan, BR-1; Calcipotriol/betamethasone dipropionate, cinacalcet hydrochloride, clofazimine, colchicine, cold-adapted influenza vaccine trivalent, CRM197; Desloratadine, desoxyepothilone B, diethylhomospermine; Edodekin alfa, efalizumab, elcometrine, eletriptan, enfuvirtide, entecavir, EP-2101, eplerenone, erlotinib hydrochloride, etoricoxib, everolimus, exherin, ezetimibe; Febuxostat, fluorescein lisicol, fosamprenavir calcium, frovatriptan; Hemoglobin raffimer, HSPPC-96, human insulin; Imatinib mesylate, insulin detemir, insulin glargine, IRX-2, istradefylline, IV gamma-globulin, ixabepilone; Kahalalide F; L-759274, levodopa/carbidopa/entacapone, licofelone, lonafarnib, lopinavir, lurtotecan, LY-156735; MAb G250, mecasermin, melatonin, midostaurin, muraglitazar; Nesiritide, nitronaproxen; O6-Benzylguanine, olmesartan medoxomil, olmesartan medoxomil/hydrochlorothiazide, omapatrilat, oral insulin; Parecoxib sodium, PCK-3145, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ ribavirin, pemetrexed disodium, peptide YY3-36, PG-CPT, phenoxodiol, pimecrolimus, posaconazole; Rasagiline mesilate, rDNA insulin, RG228, rimonabant hydrochloride, rosuvastatin calcium, rotigotine hydrochloride; S-3304, safinamide mesilate, salcaprozic acid sodium salt, SDZ-SID-791, SGN-30, soblidotin

  18. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2009-09-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: AAV1/SERCA2a, Abacavir sulfate/lamivudine, Adalimumab, Aliskiren fumarate, Ambrisentan, Aripiprazole, AT-7519, Atazanavir sulfate, Atomoxetine hydrochloride, Azacitidine, Azelnidipine; Besifloxacin hydrochloride, Bevacizumab, Bioabsorbable everolimus-eluting coronary stent, Bortezomib, Bosentan, Budesonide/formoterol fumarate; CAIV-T, Carisbamate, Casopitant mesylate, Certolizumab pegol, Cetuximab, Ciclesonide, Ciprofloxacin/dexamethasone, CTCE-9908; Dalcetrapib, Darunavir, Deferasirox, Desloratadine, Disitertide, Drotrecogin alfa (activated), DTA-H19, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Efalizumab, Emtricitabine, Eribulin mesilate, Escitalopram oxalate, Eszopiclone, EUR-1008, Everolimus-eluting coronary stent, Exenatide; Fampridine, Fluticasone furoate, Formoterol fumarate/fluticasone propionate, Fosamprenavir calcium, Fulvestrant; Gabapentin enacarbil, GS-7904L; HPV-6/11/16/18, Human Secretin, Hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, Imexon, Inalimarev/Falimarev, Indacaterol, Indacaterol maleate, Inhalable human insulin, Insulin detemir, Insulin glargine, Ixabepilone; L-Alanosine, Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liraglutide, Lisdexamfetamine mesilate, Lopinavir, Loratadine/montelukast sodium, Lutropin alfa; MeNZB, Mepolizumab, Micafungin sodium, Morphine hydrochloride; Nabiximols, Nikkomycin Z; Olmesartan medoxomil, Omalizumab; Paclitaxel-eluting stent, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Perifosine, PF-489791, Plitidepsin, Posaconazole, Pregabalin; QAX-576; Raltegravir potassium, Ramelteon, Rasagiline

  19. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X

    2008-01-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prouse Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 101M, 3F8; Abatacept, ABT-263, Adalimumab, AG-7352, Agatolimod sodium, Alfimeprase, Aliskiren fumarate, Alvimopan hydrate, Aminolevulinic acid hexyl ester, Ammonium tetrathiomolybdate, Anakinra, Aripiprazole, AS-1404, AT-9283, Atomoxetine hydrochloride, AVE-1642, AVE-9633, Axitinib, AZD-0530; Becocalcidiol, Belotecan hydrochloride, Bevacizumab, BG-9928, BIBF-1120, BMS-275183, Bortezomib, Bosentan; Catumaxomab, Cetuximab, CHR-2797, Ciclesonide, Clevidipine, Cypher, Cytarabine/daunorubicin; Darifenacin hydrobromide, Darunavir, Denosumab, Desvenlafaxine succinate, Disufenton sodium, Duloxetine hydrochloride, Dutasteride; Eculizumab, Efalizumab, Eicosapentaenoic acid/docosahexaenoic acid, Eplerenone, Epratuzumab, Erlotinib hydrochloride, Escitalopram oxalate, Ethynylcytidine, Etravirine, Everolimus, Ezetimibe; Fulvestrant; Garenoxacin mesilate, Gefitinib, Gestodene; HI-164, Hydralazine hydrochloride/isosorbide dinitrate; Icatibant acetate, ICX-RHY, Idraparinux sodium, Indacaterol, Ispronicline, Ivabradine hydrochloride, Ixabepilone; KB-2115, KW-2449; L-791515, Lapatinib ditosylate, LGD-4665, Licofelone, Liposomal doxorubicin, Lisdexamfetamine mesilate, Lumiracoxib; Methoxy polyethylene glycol-epoetin-beta, Miglustat, Mipomersen sodium, Mitumprotimut-T, MK-0822A, MK-0974; Nelarabine; Obatoclax mesylate, Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide; Paliperidone, Palonosetron hydrochloride, Panitumumab, Pegfilgrastim, Peginterferon alfa-2a, Pemetrexed disodium, Perospirone hydrochloride, Pertuzumab, Pimecrolimus, Pitrakinra, Pixantrone maleate, Posaconazole, Pregabalin; Quercetin; RALGA, Raltegravir

  20. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2004-10-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abiraterone acetate, Ad5CMV-p53, adefovir dipivoxil, AE-941, ambrisentan, aripiprazole, atomoxetine hydrochloride, atrasentan; BCH-10618, bimatoprost, BMS-184476, BMS-275183, BMS-387032, botulinum toxin type B, BR-1, BR96-Doxorubicin; Capravirine, caspofungin acetate, cinacalcet hydrochloride; Darbepoetin alfa, desloratadine, dextrin sulfate, DJ-927, duloxetine hydrochloride; Elacridar, emtricitabine, eplerenone, ertapenem sodium, escitalopram oxalate, ESP-24217, etoricoxib, exenatide, ezetimibe; Ferumoxtran-10, fondaparinux sodium, fosamprenavir calcium; GS-7904L, GW-5634; HMN-214, human insulin; IC-14, imatinib mesylate, indiplon, insulin glargine, insulinotropin, iseganan hydrochloride; Lanthanum carbonate, L-Arginine hydrochloride, LEA29Y, lenalidomide, LE-SN38, lestaurtinib, L-MDAM, lometrexol, lopinavir, lopinavir/ritonavir; Magnesium sulfate, maraviroc, mepolizumab, metreleptin, milataxel, MNA-715, morphine hydrochloride; Nesiritide, neutrophil-inhibitory factor, NK-911; Olanzapine/fluoxetine hydrochloride, olmesartan medoxomil, omalizumab, ortataxel, oxycodone hydrochloride/ibuprofen; Panitumumab, patupilone, PC-515, PD-MAGE-3 Vaccine, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ ribavirin, pemetrexed disodium, pimecrolimus, prasugrel, pregabalin, PRO-2000; Rosuvastatin calcium, RPR-113090; sabarubicin hydrochloride, safinamide mesilate, SB-715992, sitaxsentan sodium, soblidotin, synthadotin; Tadalafil, taltobulin, temsirolimus, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate/emtricitabine, testosterone gel, tigecycline, tipranavir, tirapazamine, trabectedin

  1. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2005-10-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (-)-Epigallocatechin gallate, (Z)-4-hydroxytamoxifen; Ad.muIFN-beta AD-237, adalimumab, adefovir dipivoxil, agalsidase alfa, alemtuzumab, almotriptan, ALVAC vCP1452, alvimopan hydrate, ambrisentan, anakinra, anti-IFN-gamma MAb; Bimatoprost, BMS-188797, BMS-214662, bortezomib, bosentan, bovine lactoferrin; Caffeine, canertinib dihydrochloride, canfosfamide hydrochloride, cannabidiol, caspofungin acetate, cetuximab, cH36, ChimeriVax-JE, ciclesonide, cilansetron, cinacalcet hydrochloride, clopidogrel, CpG-7909, Cypher; Daptomycin, darbepoetin alfa, darifenacin hydrobromide, decitabine, denufosol tetrasodium, Dexamet, diindolemethane, drotrecogin alfa (activated), duloxetine hydrochloride, DX-9065a; E-7010, edaravone, efalizumab, eicosapentaenoic acid/docosahexaenoic acid, elacridar, eletriptan, emtricitabine, epratuzumab, erlotinib hydrochloride, ertapenem sodium, eszopiclone, everolimus, ezetimibe; Fludarabine, fondaparinux sodium; gamma-Hydroxybutyrate sodium, gavestinel sodium, gefitinib, granisetron-Biochronomer; Human Albumin, human insulin; Imatinib mesylate, indiplon, interleukin-2 XL, isatoribine, ISS-1018, i.v. gamma-globulin, ivabradine hydrochloride, ixabepilone; Lanthanum carbonate, L-arginine hydrochloride, liposomal doxorubicin, LY-450139; Magnesium sulfate, melatonin, motexafin gadolinium, mycophenolic acid sodium salt; Natalizumab, nesiritide, niacin/lovastatin; OGX-011, olmesartan medoxomil, omalizumab, ospemifene; PACAP38, panitumumab, parathyroid hormone (human recombinant), parecoxib sodium, patupilone, pegfilgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b

  2. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2005-04-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity. prous.com. This issue focuses on the following selection of drugs: ABX-IL-8, Acclaim, adalimumab, AGI-1067, alagebrium chloride, alemtuzumab, Alequel, Androgel, anti-IL-12 MAb, AOD-9604, aripiprazole, atomoxetine hydrochloride; Biphasic insulin aspart, bosentan, botulinum toxin type B, bovine lactoferrin, brivudine; Cantuzumab mertansine, CB-1954, CDB-4124, CEA-TRICOM, choriogonadotropin alfa, cilansetron, CpG-10101, CpG-7909, CTL-102, CTL-102/CB-1954; DAC:GRF, darbepoetin alfa, davanat-1, decitabine, del-1 Genemedicine, dexanabinol, dextofisopam, dnaJP1, dronedarone hydrochloride, dutasteride; Ecogramostim, eletriptan, emtricitabine, EPI-hNE-4, eplerenone, eplivanserin fumarate, erlotinib hydrochloride, ertapenem sodium, escitalopram oxalate, esomeprazole magnesium, etoricoxib, ezetimibe; Falecalcitriol, fingolimod hydrochloride; Gepirone hydrochloride; HBV-ISS, HSV-2 theracine, human insulin; Imatinib mesylate, Indiplon, insulin glargine, ISAtx-247; L612 HuMAb, levodopa/carbidopa/entacapone, lidocaine/prilocaine, LL-2113AD, lucinactant, LY-156735; Meclinertant, metelimumab, morphine hydrochloride, morphine-6-glucuronide; Natalizumab, nimotuzumab, NX-1207, NYVAC-HIV C; Omalizumab, onercept, osanetant; PABA, palosuran sulfate, parathyroid hormone (human recombinant), parecoxib sodium, PBI-1402, PCK-3145, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pemetrexed disodium, pimecrolimus, PINC, pregabalin; Ramelteon, rasagiline mesilate, rasburicase, rimonabant hydrochloride, RO-0098557, rofecoxib, rosiglitazone maleate/metformin hydrochloride; Safinamide mesilate, SHL-749, sitaxsentan sodium, sparfosic acid, SprayGel, squalamine, St. John's Wort

  3. International Collaboration on Internet Subject Gateways.

    ERIC Educational Resources Information Center

    Place, Emma

    A number of libraries in Europe are involved in the development of Internet subject gateways--services that aim to help users find high quality resources on the Internet. Subject gateways such as SOSIG (Social Science Information Gateway) have been available on the Internet for some years now, and they offer an alternative to Internet search…

  4. HOSC DTN Gateway Test Report

    NASA Technical Reports Server (NTRS)

    Pitts, Robert Lee

    2012-01-01

    Goals of this activity: Test the Huntsville Operations Support Center (HOSC) Delay/Disruption Tolerant Networking (DTN) Gateway for operational use Current activity includes: (1) Test the Implementation of a new DTN2 gateway at the HOSC (2) Confirm integration of DTN nodes into the S-band uplink and Ku-band downlink of the ISS for limited use (3) Implement Aggregate Custody Signal to ISS platforms (4) Verify operational support for Colorado University (CU) onboard components (5) Verify ability to support Multi-Purpose End-To- End Robotic Operation Network (METERON) OpsCon-2

  5. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2006-10-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issues focuses on the following selection of drugs: (-)-Epigallocatechin gallate, (-)-gossypol, 2-deoxyglucose, 3,4-DAP, 7-monohydroxyethylrutoside; Ad5CMV-p53, adalimumab, adefovir dipivoxil, ADH-1, alemtuzumab, aliskiren fumarate, alvocidib hydrochloride, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, amrubicin hydrochloride, AN-152, anakinra, anecortave acetate, antiasthma herbal medicine intervention, AP-12009, AP-23573, apaziquone, aprinocarsen sodium, AR-C126532, AR-H065522, aripiprazole, armodafinil, arzoxifene hydrochloride, atazanavir sulfate, atilmotin, atomoxetine hydrochloride, atorvastatin, avanafil, azimilide hydrochloride; Bevacizumab, biphasic insulin aspart, BMS-214662, BN-83495, bortezomib, bosentan, botulinum toxin type B; Caspofungin acetate, cetuximab, chrysin, ciclesonide, clevudine, clofarabine, clopidogrel, CNF-1010, CNTO-328, CP-751871, CX-717, Cypher; Dapoxetine hydrochloride, darifenacin hydrobromide, dasatinib, deferasirox, dextofisopam, dextromethorphan/quinidine sulfate, diclofenac, dronedarone hydrochloride, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Edaravone, efaproxiral sodium, emtricitabine, entecavir, eplerenone, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, etoricoxib, ezetimibe, ezetimibe/simvastatin; Finrozole, fipamezole hydrochloride, fondaparinux sodium, fulvestrant; Gabapentin enacarbil, gaboxadol, gefitinib, gestodene, ghrelin (human); Human insulin, human papillomavirus vaccine; Imatinib mesylate, immunoglobulin intravenous (human), indiplon, insulin detemir, insulin glargine, insulin glulisine, intranasal insulin, istradefylline, i.v. gamma

  6. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2006-03-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 131I-labetuzumab; Abacavir sulfate, abatacept, adalimumab, ademetionine, adjuvanted influenza vaccine, alefacept, alemtuzumab, amlodipine, amphotericin B, anakinra, aripiprazole, aspirin, axitinib; Betamethasone dipropionate, bevacizumab, biphasic insulin aspart, bortezomib, bosentan, botulinum toxin type B, BQ-123; Calcium folinate, canertinib dihydrochloride, carboplatin, carmustine, cetirizine hydrochloride, cetuximab, cholecalciferol, ciclesonide, ciclosporin, cinacalcet hydrochloride, cisplatin, clarithromycin, clofazimine, cold-adapted influenza vaccine trivalent, CpG-7909; Darbepoetin alfa, darifenacin hydrobromide, DB-289, desloratadine, Dexamet, dicycloverine hydrochloride, dimethyl fumarate, docetaxel, dolastatin 10, drospirenone, drospirenone/estradiol, duloxetine hydrochloride; Ecogramostim, edotecarin, efaproxiral sodium, enalapril maleate, epoetin beta, epoprostenol sodium, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, estradiol, etanercept; Fluconazole, fludarabine phosphate, fluorouracil; Gefitinib, gemcitabine, Ghrelin (human), glibenclamide, glimepiride, GTI-2040; Haloperidol, human insulin, hydrocortisone probutate; Imatinib mesylate, indisulam, influenza vaccine, inhaled insulin, insulin aspart, insulin glulisine, insulin lispro, irinotecan, ispronicline; Lamivudine, lamivudine/zidovudine/abacavir sulfate, lapatinib, letrozole, levocetirizine, lomustine, lonafarnib, lumiracoxib;Magnesium sulfate, MD-1100, melphalan, metformin hydrochloride, methotrexate, metoclopramide hydrochloride, mitiglinide calcium hydrate, monophosphoryl lipid A, montelukast sodium, motexafin gadolinium

  7. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2008-09-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com.This issue focuses on the following selection of drugs: ABT-263, AC-2307, Aclidinium bromide, Adefovir dipivoxil, ADH-1, Agatolimod sodium, Alefacept, Aliskiren fumarate, Aminolevulinic acid methyl ester, Anakinra, Apaziquone, Aprepitant, Aripiprazole, ASM-8, Atiprimod hydrochloride, AVE-0277, AVE-1642, AVE-8062, Axitinib, Azacitidine, AZD-0530; Bazedoxifene acetate, Bevacizumab, Bexarotene, BI-2536, Biphasic insulin aspart, BMS-387032, BMS-663513, Bortezomib, BQ-123, Brivanib alaninate, BSI-201; Caspofungin acetate, CDX-110, Cetuximab, Ciclesonide, CR-011, Cypher; Daptomycin, Darbepoetin alfa, Dasatinib, Decitabine, Deferasirox, Denosumab, Dexlansoprazole, Dexmethylphenidate hydrochloride, DNA-Hsp65 vaccine, Dovitinib, Drotrecogin alfa (activated), DTaP-HBV-IPV/Hibvaccine, DTaP-IPV-HB-PRP-T, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Elacytarabine, Emtricitabine, Endothelin, Entecavir, Eplivanserin fumarate, Escitalopram oxalate, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Farletuzumab, Fesoterodine fumarate, Fibrin sealant (human), Fulvestrant; Gefitinib, Gemtuzumab ozogamicin, Glufosfamide, GSK-1562902A; Hib-TT; Imatinib mesylate, IMC-11F8, Imidazoacridinone, IMP-321, INCB-18424, Indiplon, Indisulam, INNO-406, Irinotecan hydrochloride/Floxuridine, ITF-2357, Ixabepilone; KRN-951; Lasofoxifene tartrate; Lenalidomide, LGD-4665, Lonafarnib, Lubiprostone, Lumiliximab; MDX-1100, Melan-A/MART-1/gp100/IFN-alfa, Methyl-CDDO, Metreleptin, MLN-2704, Mycophenolic acid sodium salt; Na-ASP-2, Naproxcinod, Nilotinib hydrochloride monohydrate, NPI-2358; Oblimersen sodium, Odanacatib; Paclitaxel nanoparticles, PAN-811, Panobinostat, PBI-1402, PC-515, Peginterferon alfa

  8. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2005-01-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (-)-Epigallocatechin gallate; ACP-103, Ad.Egr.TNF.11 D, adalimumab, AF-IL 12, AIDSVAX gp120 B/B, alefacept, alemtuzumab, a-Galactosylceramide, ALVAC vCP 1452, alvimopan hydrate, alvocidib hydrochloride, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anidulafungin, antarelix, aprepitant, aripiprazole, arsenic sulfide, asoprisnil, atazanavir sulfate, atomoxetine hydrochloride; Bevacizumab, bimatoprost, BMS-184476, bortezomib, bosentan, botulinum toxin type B, BrachySil, brivudine; Caffeine, calcipotriol/betamethasone dipropionate, cannabidiol, capsaicin for injection, caspofungin acetate, CC-4047, cetuximab, CGP-36742, clofazimine, CpG-7909, Cypher; Darbepoetin alfa, dextromethorphan/quinidine sulfate, dimethylfumarate, dronabinol/cannabidiol, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecogramostim, efalizumab, eletriptan, emtricitabine, enfuvirtide, eplerenone, esomeprazole magnesium, estradiol acetate, eszopiclone, etoricoxib, exenatide, ezetimibe, ezetimibe/simvastatin; Fampridine, fondaparinux sodium, fosamprenavir calcium; Gefitinib, GPI-0100; hA 20, HTU-PA, human insulin, HuOKT 3 gamma 1(Ala 234-Ala 235), hyaluronic acid; Icatibant, imatinib mesylate, Indiplon, INKP-100, INKP-102, iodine (I131) tositumomab, istradefylline, IV gamma-globulin, ivabradine hydrochloride, ixabepilone; Lacosamide, landiolol, lanthanum carbonate, lasofoxifene tartrate, LB-80380, lenalidomide, lidocaine/tetracaine, linezolid, liposomal doxorubicin, liposomal vincristine sulfate, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Maribavir, morphine glucuronide, MVA-5 T

  9. THE REMOTE SENSING DATA GATEWAY

    EPA Science Inventory

    The EPA Remote Sensing Data Gateway (RSDG) is a pilot project in the National Exposure Research Laboratory (NERL) to develop a comprehensive data search, acquisition, delivery and archive mechanism for internal, national and international sources of remote sensing data for the co...

  10. Information Gateways: Collaboration on Content.

    ERIC Educational Resources Information Center

    Heery, Rachel

    2000-01-01

    This report, informed by discussion of content activities at the 1999 IMesh Workshop, considers implications for subject based gateways of co-operation regarding coverage policy, creation of metadata, and provision of searching and browsing across services. Other possibilities for co-operation include working more closely with information…

  11. UAS-NAS Live Virtual Constructive Distributed Environment (LVC): LVC Gateway, Gateway Toolbox, Gateway Data Logger (GDL), SaaProc Software Design Description

    NASA Technical Reports Server (NTRS)

    Jovic, Srboljub

    2015-01-01

    This document provides the software design description for the two core software components, the LVC Gateway, the LVC Gateway Toolbox, and two participants, the LVC Gateway Data Logger and the SAA Processor (SaaProc).

  12. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2005-06-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abiraterone acetate, acyline, adalimumab, adenosine triphosphate, AEE-788, AIDSVAX gp120 B/B, AK-602, alefacept, alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, alprazolam, amdoxovir, AMG-162, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, aminophylline hydrate, anakinra, anecortave acetate, anti-CTLA-4 MAb, APC-8015, aripiprazole, aspirin, atazanavir sulfate, atomoxetine hydrochloride, atorvastatin calcium, atrasentan, AVE-5883, AZD-2171; Betamethasone dipropionate, bevacizumab, bimatoprost, biphasic human insulin (prb), bortezomib, BR-A-657, BRL-55730, budesonide, busulfan; Calcipotriol, calcipotriol/betamethasone dipropionate, calcium folinate, capecitabine, capravirine, carmustine, caspofungin acetate, cefdinir, certolizumab pegol, CG-53135, chlorambucil, ciclesonide, ciclosporin, cisplatin, clofarabine, clopidogrel hydrogensulfate, clozapine, co-trimoxazole, CP-122721, creatine, CY-2301, cyclophosphamide, cypher, cytarabine, cytolin; D0401, darbepoetin alfa, darifenacin hydrobromide, DASB, desipramine hydrochloride, desloratadine, desvenlafaxine succinate, dexamethasone, didanosine, diquafosol tetrasodium, docetaxel, doxorubicin hydrochloride, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecallantide, efalizumab, efavirenz, eletriptan, emtricitabine, enfuvirtide, enoxaparin sodium, estramustine phosphate sodium, etanercept, ethinylestradiol, etonogestrel, etonogestrel/ethinylestradiol, etoposide, exenatide; Famciclovir, fampridine, febuxostat, filgrastim, fludarabine phosphate, fluocinolone acetonide, fluorouracil, fluticasone propionate

  13. The Electric Propulsion Interactions Code (EPIC)

    NASA Technical Reports Server (NTRS)

    Mikellides, I. G.; Mandell, M. J.; Kuharski, R. A.; Davis, V. A.; Gardner, B. M.; Minor, J.

    2004-01-01

    Science Applications International Corporation is currently developing the Electric Propulsion Interactions Code, EPIC, as part of a project sponsored by the Space Environments and Effects Program at the NASA Marshall Space Flight Center. Now in its second year of development, EPIC is an interactive computer tool that allows the construction of a 3-D spacecraft model, and the assessment of a variety of interactions between its subsystems and the plume from an electric thruster. These interactions may include erosion of surfaces due to sputtering and re-deposition of sputtered materials, surface heating, torque on the spacecraft, and changes in surface properties due to erosion and deposition. This paper describes the overall capability of EPIC and provides an outline of the physics and algorithms that comprise many of its computational modules.

  14. Epic Flooding in Georgia, 2009

    USGS Publications Warehouse

    Gotvald, Anthony J.; McCallum, Brian E.

    2010-01-01

    Metropolitan Atlanta-September 2009 Floods * The epic floods experienced in the Atlanta area in September 2009 were extremely rare. Eighteen streamgages in the Metropolitan Atlanta area had flood magnitudes much greater than the estimated 0.2-percent (500-year) annual exceedance probability. * The Federal Emergency Management Agency (FEMA) reported that 23 counties in Georgia were declared disaster areas due to this flood and that 16,981 homes and 3,482 businesses were affected by floodwaters. Ten lives were lost in the flood. The total estimated damages exceed $193 million (H.E. Longenecker, Federal Emergency Management Agency, written commun., November 2009). * On Sweetwater Creek near Austell, Ga., just north of Interstate 20, the peak stage was more than 6 feet higher than the estimated peak stage of the 0.2-percent (500-year) flood. Flood magnitudes in Cobb County on Sweetwater, Butler, and Powder Springs Creeks greatly exceeded the estimated 0.2-percent (500-year) floods for these streams. * In Douglas County, the Dog River at Ga. Highway 5 near Fairplay had a peak stage nearly 20 feet higher than the estimated peak stage of the 0.2-percent (500-year) flood. * On the Chattahoochee River, the U.S. Geological Survey (USGS) gage at Vinings reached the highest level recorded in the past 81 years. Gwinnett, De Kalb, Fulton, and Rockdale Counties also had record flooding. South Georgia March and April 2009 Floods * The March and April 2009 floods in South Georgia were smaller in magnitude than the September floods but still caused significant damage. * No lives were lost in this flood. Approximately $60 million in public infrastructure damage occurred to roads, culverts, bridges and a water treatment facility (Joseph T. McKinney, Federal Emergency Management Agency, written commun., July 2009). * Flow at the Satilla River near Waycross, exceeded the 0.5-percent (200-year) flood. Flows at seven other stations in South Georgia exceeded the 1-percent (100-year) flood.

  15. Centrally managed name resolution schemes for EPICS

    SciTech Connect

    Jun, D.; Bryan, D.; Watson, W.

    1997-12-01

    The Experimental Physics and Industrial Control System (EPICS) uses a broadcast method to locate resources and controls distributed across control servers. There are many advantages offered by using a centrally managed name resolution method, in which resources are located using a repository. The suitability of DCE Directory Service as a name resolution method is explored, and results from a study involving DCE are discussed. An alternative nameserver method developed and in use at the Thomas Jefferson national Accelerator Facility (Jefferson Lab) is described and results of integrating this new method with existing EPICS utilities presented. The various methods discussed in the paper are compared.

  16. Energy 101: Solar PV

    ScienceCinema

    None

    2013-05-29

    Solar photovoltaic (PV) systems can generate clean, cost-effective power anywhere the sun shines. This video shows how a PV panel converts the energy of the sun into renewable electricity to power homes and businesses.

  17. Energy 101: Solar PV

    SciTech Connect

    2011-01-01

    Solar photovoltaic (PV) systems can generate clean, cost-effective power anywhere the sun shines. This video shows how a PV panel converts the energy of the sun into renewable electricity to power homes and businesses.

  18. Ad Hoc Access Gateway Selection Algorithm

    NASA Astrophysics Data System (ADS)

    Jie, Liu

    With the continuous development of mobile communication technology, Ad Hoc access network has become a hot research, Ad Hoc access network nodes can be used to expand capacity of multi-hop communication range of mobile communication system, even business adjacent to the community, improve edge data rates. For mobile nodes in Ad Hoc network to internet, internet communications in the peer nodes must be achieved through the gateway. Therefore, the key Ad Hoc Access Networks will focus on the discovery gateway, as well as gateway selection in the case of multi-gateway and handover problems between different gateways. This paper considers the mobile node and the gateway, based on the average number of hops from an average access time and the stability of routes, improved gateway selection algorithm were proposed. An improved gateway selection algorithm, which mainly considers the algorithm can improve the access time of Ad Hoc nodes and the continuity of communication between the gateways, were proposed. This can improve the quality of communication across the network.

  19. A Science Data Gateway for Environmental Management

    SciTech Connect

    Agarwal, Deborah, A; Faybishenko, Boris; Freedman, Vicky, L; Krishnan, Harinarayan; Kushner, Gary; Lansing, Carina; Porter, Ellen; Romosan, Alexandru; Shoshani, Arie; Wainwright, Haruko; Weidmer, Arthur; Wu, Kesheng

    2015-10-12

    Science data gateways are effective in providing complex science data collections to the world-wide user communities. In this paper we describe a gateway for the Advanced Simulation Capability for Environmental Management (ASCEM) framework. Built on top of established web service technologies, the ASCEM data gateway is specifically designed for environmental modeling applications. Its key distinguishing features include: (1) handling of complex spatiotemporal data, (2) offering a variety of selective data access mechanisms, (3) providing state of the art plotting and visualization of spatiotemporal data records, and (4) integrating seamlessly with a distributed workflow system using a RESTful interface. ASCEM project scientists have been using this data gateway since 2011.

  20. Reflections on the Epic Challenge, 1989

    ERIC Educational Resources Information Center

    Meiers, Marion

    2013-01-01

    In this article, Marion Meiers reflects on the often-cited address "Literacy: The Epic Challenge Beyond Progressivism" by Garth Boomer at the 1989 joint National Conference of the Australian Reading Association (now the Australian Literacy Educator's Association) and the Australian Association for the Teaching of English at Darin…

  1. EPIC: Building a Structured Learning Environment.

    ERIC Educational Resources Information Center

    Westhead, Martin D.

    This paper outlines work in progress at the University of Edinburgh on the construction of a small World Wide Web-based interactive learning environment (EPIC) developed for the teaching of high performance computing. The paper begins by outlining work done in cognitive science on how people make use of structure in physical environments. Within…

  2. ET: EPICS TCL/TK interface

    SciTech Connect

    Daly, B.

    1995-02-01

    This document describes the tc1 command and command types which are used to communicate with EPICS database servers. The application libraries upon which et is built include tc1, tk, tc1-dp, and blt. The reader of this document is assumed to be familiar with tc1/tk.

  3. Education for Change: Epic Charter School

    ERIC Educational Resources Information Center

    EDUCAUSE, 2015

    2015-01-01

    The student-centered school model of Epic Charter School in Oakland, California, framed around a hero's journey empowers middle school students with sense of unity and purpose in life, where they can feel part of a culture with a shared experience and with more opportunities to experiences growth and accomplishment. Design and engineering is front…

  4. Stabilized PV system

    DOEpatents

    Dinwoodie, Thomas L.

    2002-12-17

    A stabilized PV system comprises an array of photovoltaic (PV) assemblies mounted to a support surface. Each PV assembly comprises a PV module and a support assembly securing the PV module to a position overlying the support surface. The array of modules is circumscribed by a continuous, belt-like perimeter assembly. Cross strapping, extending above, below or through the array, or some combination of above, below and through the array, secures a first position along the perimeter assembly to at least a second position along the perimeter assembly thereby stabilizing the array against wind uplift forces. The first and second positions may be on opposite sides on the array.

  5. Fire resistant PV shingle assembly

    DOEpatents

    Lenox, Carl J.

    2012-10-02

    A fire resistant PV shingle assembly includes a PV assembly, including PV body, a fire shield and a connection member connecting the fire shield below the PV body, and a support and inter-engagement assembly. The support and inter-engagement assembly is mounted to the PV assembly and comprises a vertical support element, supporting the PV assembly above a support surface, an upper interlock element, positioned towards the upper PV edge, and a lower interlock element, positioned towards the lower PV edge. The upper interlock element of one PV shingle assembly is inter-engageable with the lower interlock element of an adjacent PV shingle assembly. In some embodiments the PV shingle assembly may comprise a ventilation path below the PV body. The PV body may be slidably mounted to the connection member to facilitate removal of the PV body.

  6. Subject Gateway Sites and Search Engine Ranking.

    ERIC Educational Resources Information Center

    Thelwall, Mike

    2002-01-01

    Discusses subject gateway sites and commercial search engines for the Web and presents an explanation of Google's PageRank algorithm. The principle question addressed is the conditions under which a gateway site will increase the likelihood that a target page is found in search engines. (LRW)

  7. Looking Forward: Community Gateways at Victoria University

    ERIC Educational Resources Information Center

    Mountford, Christine

    2011-01-01

    The mission and values of Victoria University provide the underlying criteria for the development and implementation of the Community Gateways initiative, which aims to transform the lives of those living in the west of Melbourne through the power of further education. Community Gateways takes the university into the community by providing career…

  8. CORC: A System for Gateway Creation.

    ERIC Educational Resources Information Center

    Hickey, Thomas B.

    2000-01-01

    CORC (Cooperative Online Resource Catalog) is an OCLC (Online Computer Library Center) project developing tools and systems to enable libraries to provide enhanced access to Internet resources. A system for hosting and supporting subject gateways-than a gateway itself- relying on large-scale cooperation among libraries to maintain a centralized…

  9. Global Resource Sharing: A Gateway Model.

    ERIC Educational Resources Information Center

    Miller, Rush G.; Zhou, Peter X.

    1999-01-01

    Describes the Gateway Service Center of Chinese Journal Publications that was established at the University of Pittsburgh to deliver digital copies of Chinese journal articles. Discusses the gateway model for global resource sharing as one component of a global virtual library and considers copyright, access versus ownership, and future…

  10. Tgw: a webcast transcoding gateway

    NASA Astrophysics Data System (ADS)

    Fitz, Timothy

    2003-01-01

    Internet webcasting is gaining attention as the cost of communications and computer processing declines. The UC Berkeley Multimedia, Interfaces, and Graphics Seminar is webcast worldwide on the Internet using IETF standards on the Multicast Backbone (Mbone). Many potential viewers are unable to receive the webcast due to network problems and/or the lack of software supporting the Mbone protocols and codecs. The Transcoding Gateway, called tgw, simplifies the management of simulcasting several transmissions that use different transport protocols, media formats, and network bandwidth. Tgw incorporates transmission bandwidth allocation, transcoding to alternative formats, and redirection of streams to alternate addresses to manage transmission of a webcast.

  11. GATEWAY - COMMUNICATIONS GATEWAY SOFTWARE FOR NETEX, DECNET, AND TCP/IP

    NASA Technical Reports Server (NTRS)

    Keith, B.

    1994-01-01

    The Communications Gateway Software, GATEWAY, provides process-to-process communication between remote applications programs in different protocol domains. Communicating peer processes may be resident on any paired combination of NETEX, DECnet, or TCP/IP hosts. The gateway provides the necessary mapping from one protocol to another and will facilitate practical intermachine communications in a cost effective manner by eliminating the need to standardize on a single protocol or the need to implement multiple protocols in the host computers. The purpose of the gateway is to support data transfers between application programs on different host computers using different protocols. The gateway computer must be physically connected to both host computers and must contain the system software needed to use the communication protocols of both host computers. The communication process between application partners can be divided into three phases: session establishment, data transfer, and session termination. The communication protocols supported by GATEWAY (DECnet, NETEX, and TCP/IP) have addressing mechanisms that allow an application to identify itself and distinguish among other applications on the network. The exact form of the address varies depending on whether an application is passively offering (awaiting the receipt of a network connection from another network application) or actively connecting to another network. When the gateway is started, GATEWAY reads a file of address pairs. One of the address pairs is used by GATEWAY for passively offering on one network while the other address in the pair is used for actively connecting on the other network establishing the session. Now the two application partners can send and receive data in a manner appropriate to their home networks. GATEWAY accommodates full duplex transmissions. Thus, if the application partners are sophisticated enough, they can send and receive simultaneously. GATEWAY also keeps track of the number

  12. The success and the future of EPICS

    SciTech Connect

    M.E. Thuot; M. Clausen; L.R. Dalesio; T. Katoh; M.R. Kraimer; R. Mueller; H. Shoaee; W.A. Watson

    1996-08-01

    During the past five years, the control system software toolkit called EPICS (Experimental Physics and Industrial Control System), has developed from a comparatively small code co-development effort between Los Alamos National Laboratory and Argonne National Laboratory into an international collaboration on real-time distributed control systems. The wide application of this set of tools is the result of a combination of high performance, scaleable distributed control and well defined open interfaces between system layers that encourage users to add extensions. These extensions can subsequently be reused by others, adding to the utility of the tools. This paper will describe the architectural features that have supported these extensions, some of the new extensions produced by the 58 projects currently using EPICS and some of the new functions and interfaces we are planning to add to this control system toolkit.

  13. The success and the future of EPICS

    SciTech Connect

    Thuot, M.E., Dalesio, L.R.; Clausen, M.; Katoh, T.

    1996-09-01

    During the past 5 years, the control system software toolkit EPICS (Experimental Physics and Industrial Control System) has developed from a small code co-development effort between LANL and ANL into an international collaboration on real-time distributed control system (for an accelerator facility, etc.). The wide application of this set of tools is the result of a combination of high performance, scaleable distributed control, and well defined open interfaces between system layers that encourage users to add extensions. These extensions can subsequently be reused by others, adding to the utility of the tools. This paper describes the architectural features that have supported these extensions, some of the new extensions produced by the 58 projects currently using EPICS and some of the new functions and interfaces being planned to be added to this control system toolkit.

  14. 47 CFR 10.320 - Provider alert gateway requirements.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... protocols between the Federal alert gateway and the CMS provider gateway. (d) Geographic targeting. The CMS... provide profile information on the CMS provider for the Federal alert gateway to maintain at the Federal alert gateway. This profile information must be provided by an authorized CMS provider representative...

  15. 47 CFR 10.320 - Provider alert gateway requirements.

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... protocols between the Federal alert gateway and the CMS provider gateway. (d) Geographic targeting. The CMS... provide profile information on the CMS provider for the Federal alert gateway to maintain at the Federal alert gateway. This profile information must be provided by an authorized CMS provider representative...

  16. 47 CFR 10.320 - Provider alert gateway requirements.

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... protocols between the Federal alert gateway and the CMS provider gateway. (d) Geographic targeting. The CMS... provide profile information on the CMS provider for the Federal alert gateway to maintain at the Federal alert gateway. This profile information must be provided by an authorized CMS provider representative...

  17. 47 CFR 10.320 - Provider alert gateway requirements.

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... protocols between the Federal alert gateway and the CMS provider gateway. (d) Geographic targeting. The CMS... provide profile information on the CMS provider for the Federal alert gateway to maintain at the Federal alert gateway. This profile information must be provided by an authorized CMS provider representative...

  18. EPICS Version 4 - Implementing Complex Data Types

    SciTech Connect

    Marty Kraimer,; John dalesio

    2012-11-27

    Through phase 1 and phase 2 SBIR grants, s fully functional I/O Controller and communication protocol for version 4 of EPICS is completed. This new software architecture provides a flexible and extendible architecture. Version 4 is implemented fully in Java. The performance metrics look promising. The final portion of phase 2 is to optimize the communication mechanisms. Subsequent work on different aspects of this are required to provide a viable solutions in various areas. Version 3 of EPICS is able to provide a platform for implementing channel based control, because the channel and attributes for time stamping, alarm, display and control were narrow, well defined, and complete. To extend EPICS functionality beyond this, it is necessary to define attributes needed for archive data, array, image data, and directory services. The proper handling of several array types enables the development of middle layer servers such as orbit and bump control in accelerators. Phase 1 should produce a well defined, reviewed, and agreed upon definition of the metadata required for these services. A Phase 2 grant would provide tools that implemented archiving, general array, imaging, and directory applications.

  19. Gateway design specification for fiber optic local area networks

    NASA Technical Reports Server (NTRS)

    1985-01-01

    This is a Design Specification for a gateway to interconnect fiber optic local area networks (LAN's). The internetworking protocols for a gateway device that will interconnect multiple local area networks are defined. This specification serves as input for preparation of detailed design specifications for the hardware and software of a gateway device. General characteristics to be incorporated in the gateway such as node address mapping, packet fragmentation, and gateway routing features are described.

  20. PV_LIB Toolbox

    Energy Science and Technology Software Center (ESTSC)

    2012-09-11

    While an organized source of reference information on PV performance modeling is certainly valuable, there is nothing to match the availability of actual examples of modeling algorithms being used in practice. To meet this need, Sandia has developed a PV performance modeling toolbox (PV_LIB) for Matlab. It contains a set of well-documented, open source functions and example scripts showing the functions being used in practical examples. This toolbox is meant to help make the multi-stepmore » process of modeling a PV system more transparent and provide the means for model users to validate and understand the models they use and or develop. It is fully integrated into Matlab’s help and documentation utilities. The PV_LIB Toolbox provides more than 30 functions that are sorted into four categories« less

  1. PV_LIB Toolbox

    SciTech Connect

    2012-09-11

    While an organized source of reference information on PV performance modeling is certainly valuable, there is nothing to match the availability of actual examples of modeling algorithms being used in practice. To meet this need, Sandia has developed a PV performance modeling toolbox (PV_LIB) for Matlab. It contains a set of well-documented, open source functions and example scripts showing the functions being used in practical examples. This toolbox is meant to help make the multi-step process of modeling a PV system more transparent and provide the means for model users to validate and understand the models they use and or develop. It is fully integrated into Matlab’s help and documentation utilities. The PV_LIB Toolbox provides more than 30 functions that are sorted into four categories

  2. The BUG BITBUS Universal Gateway

    SciTech Connect

    Nawrocki, G.

    1996-02-01

    The BITBUS Universal Gateway (BUG) provides a unique, cost effective solution to many different computer interface problems. Each BUG node, utilizing ``on board`` intelligence, has the ability to provide a communication link between BITBUS protocol and other computer-signal interfaces. Among them, IEEE-488, RS232, and raw analog and binary signal 1/0. BITBUS is a multidrop, multinode link with the ability to communicate over great distances. By using this method of signal transfer, along with the communication conversion ability of the BUG, one could accomplish such things as the ability to run IEEE-488 instruments over great distances, extend a multidrop links to RS232 instruments, and provide a convenient interface point for remote analog and binary 1/0 signals, all on one homogeneous network. The BUG not only provides this through the wired ``twisted pair`` standard of BITBUS, but extends the ability to fiber optic communications for signal transfer over extreme distances and through electrically ``noisy`` environments.

  3. TeraGrid Gateways for Earth Science

    NASA Astrophysics Data System (ADS)

    Wilkins-Diehr, Nancy

    2010-05-01

    The increasingly digital component of science today poses exciting challenges and opportunities for researchers. Whether it's streaming data from sensors to computations, tagging video in the study of language patterns or the use of geographic information systems to anticipate the spread of disease, the challenges are enormous and continue to grow. The existence of advanced cyberinfrastructure (CI) tools or science gateways can significantly increase the productivity of researchers facing the most difficult challenges - in some cases making the impossible possible. The TeraGrid Science Gateways program works to incorporate high end resources through these community-designed interfaces. This talk will present an overview of TeraGrid's gateway program and highlight several gateways in atmospheric science, earth sciences and geography and regional science, geophysics, global atmospheric research, materials research and seismology.

  4. Reweaving the Fabric of Rural Vermont: The EPIC Project.

    ERIC Educational Resources Information Center

    Richardson, Jean

    1998-01-01

    A Vermont project, the Environmental Programs/Partnerships in Communities (EPIC) project provides a transferable model for rural development. The program is sensitive to people and environmental needs, and emphasizes long-term functioning of the entire community system, not just specific outcomes. EPIC has supported leadership training, local…

  5. Evaluation Report: The EPIC Leadership Development Model and Pilot Programs

    ERIC Educational Resources Information Center

    New Leaders (NJ1), 2011

    2011-01-01

    New Leaders created the Effective Practice Incentive Community (EPIC) initiative in 2006 to learn from educators driving achievement gains in high-need urban schools. EPIC identifies school leaders and teachers whose students are making significant achievement gains and financially rewards these educators in exchange for sharing and documenting…

  6. The EPIC Leadership Development Program Evaluation Report. Research Brief

    ERIC Educational Resources Information Center

    New Leaders for New Schools (NJ1), 2011

    2011-01-01

    New Leaders for New Schools created the Effective Practice Incentive Community (EPIC) initiative in 2006 to learn from educators driving achievement gains in high-need urban schools. EPIC identifies school leaders and teachers whose students are making significant achievement gains and financially rewards these educators in exchange for sharing…

  7. EPIC and APEX: Model use, calibration, and validation

    Technology Transfer Automated Retrieval System (TEKTRAN)

    The Environmental Policy Integrated Climate (EPIC) and Agricultural Policy/Environmental eXtender (APEX) models have been developed to assess a wide variety of agricultural water resource, water quality, and other environmental problems. The EPIC model is designed to be applied at a field-scale leve...

  8. EPIC: A Framework for Using Video Games in Ethics Education

    ERIC Educational Resources Information Center

    Schrier, Karen

    2015-01-01

    Ethics education can potentially be supplemented through the use of video games. This article proposes a novel framework (Ethics Practice and Implementation Categorization [EPIC] Framework), which helps educators choose games to be used for ethics education purposes. The EPIC Framework is derived from a number of classic moral development,…

  9. Modular Curriculum: English. Comparative Literature: The Epic Tradition.

    ERIC Educational Resources Information Center

    Watkins, Barbara; Wiley, Shirley

    This independent course of study is designed to be completed within a one-year period. The course centers on the epic tradition, analyzing several well-known epics and comparing them from a critic's point of view. It is emphasized that many aspects of the course involve questions for which there are no ready answers. The introductions following…

  10. Perfusion Electronic Record Documentation Using Epic Systems Software.

    PubMed

    Riley, Jeffrey B; Justison, George A

    2015-12-01

    The authors comment on Steffens and Gunser's article describing the University of Wisconsin adoption of the Epic anesthesia record to include perfusion information from the cardiopulmonary bypass patient experience. We highlight the current-day lessons and the valuable quality and safety principles the Wisconsin-Epic model anesthesia-perfusion record provides. PMID:26834289

  11. EPIC: Helping School Life and Family Support Each Other.

    ERIC Educational Resources Information Center

    Montgomery, David

    1992-01-01

    Born out of a 1981 murder, Buffalo (New York) Public Schools' EPIC (Effective Parenting Information for Children) program successfully combines parenting, effective teaching, and community programs to help family and school life support each other. Under EPIC, teachers are advised to help students acquire 23 skills involving self-esteem, rules,…

  12. AN OVERVIEW OF EPA ENVIRONMENTAL PHOTOGRAPHIC INTERPRETATION CENTER (EPIC)

    EPA Science Inventory



    The EPA Environmental Photographic Interpretation Center (EPIC) supports the EPA Regions and Program Offices with remote sensing based technical support and research and development products. Since 1972, EPIC has provided both imagery and imagery-derived products to the E...

  13. AN OVERVIEW OF THE EPA ENVIRONMENTAL PHOTOGRAPHIC INTERPRETATION CENTER (EPIC)

    EPA Science Inventory



    The EPA Environmental Photographic Interpretation Center (EPIC) supports the EPA Regions and Program Offices with remote sensing based technical support and research and development products. Since 1972, EPIC has provided both imagery and imagery-derived products to the E...

  14. GridPV Toolbox

    Energy Science and Technology Software Center (ESTSC)

    2014-07-15

    Matlab Toolbox for simulating the impact of solar energy on the distribution grid. The majority of the functions are useful for interfacing OpenDSS and MATLAB, and they are of generic use for commanding OpenDSS from MATLAB and retrieving GridPV Toolbox information from simulations. A set of functions is also included for modeling PV plant output and setting up the PV plant in the OpenDSS simulation. The toolbox contains functions for modeling the OpenDSS distribution feedermore » on satellite images with GPS coordinates. Finally, example simulations functions are included to show potential uses of the toolbox functions.« less

  15. GridPV Toolbox

    SciTech Connect

    Broderick, Robert; Quiroz, Jimmy; Grijalva, Santiago; Reno, Matthew; Coogan, Kyle

    2014-07-15

    Matlab Toolbox for simulating the impact of solar energy on the distribution grid. The majority of the functions are useful for interfacing OpenDSS and MATLAB, and they are of generic use for commanding OpenDSS from MATLAB and retrieving GridPV Toolbox information from simulations. A set of functions is also included for modeling PV plant output and setting up the PV plant in the OpenDSS simulation. The toolbox contains functions for modeling the OpenDSS distribution feeder on satellite images with GPS coordinates. Finally, example simulations functions are included to show potential uses of the toolbox functions.

  16. 77 FR 73655 - Epic Marketplace, Inc., and Epic Media Group, LLC; Analysis of Proposed Consent Order To Aid...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2012-12-11

    ... site for a fee (``publishers'') and advertisers who wish to have their advertisements placed on Web sites. Epic purchases advertising space on publishers' Web sites and contracts with advertisers to place... advertising space as the Epic Marketplace Network, which includes over 45,000 publishers. The...

  17. Grid integrated distributed PV (GridPV).

    SciTech Connect

    Reno, Matthew J.; Coogan, Kyle

    2013-08-01

    This manual provides the documentation of the MATLAB toolbox of functions for using OpenDSS to simulate the impact of solar energy on the distribution system. The majority of the functions are useful for interfacing OpenDSS and MATLAB, and they are of generic use for commanding OpenDSS from MATLAB and retrieving information from simulations. A set of functions is also included for modeling PV plant output and setting up the PV plant in the OpenDSS simulation. The toolbox contains functions for modeling the OpenDSS distribution feeder on satellite images with GPS coordinates. Finally, example simulations functions are included to show potential uses of the toolbox functions. Each function in the toolbox is documented with the function use syntax, full description, function input list, function output list, example use, and example output.

  18. A MySQL Based EPICS Archiver

    SciTech Connect

    Christopher Slominski

    2009-10-01

    Archiving a large fraction of the EPICS signals within the Jefferson Lab (JLAB) Accelerator control system is vital for postmortem and real-time analysis of the accelerator performance. This analysis is performed on a daily basis by scientists, operators, engineers, technicians, and software developers. Archiving poses unique challenges due to the magnitude of the control system. A MySQL Archiving system (Mya) was developed to scale to the needs of the control system; currently archiving 58,000 EPICS variables, updating at a rate of 11,000 events per second. In addition to the large collection rate, retrieval of the archived data must also be fast and robust. Archived data retrieval clients obtain data at a rate over 100,000 data points per second. Managing the data in a relational database provides a number of benefits. This paper describes an archiving solution that uses an open source database and standard off the shelf hardware to reach high performance archiving needs. Mya has been in production at Jefferson Lab since February of 2007.

  19. Earth Observing System Data Gateway

    NASA Technical Reports Server (NTRS)

    Pfister, Robin; McMahon, Joe; Amrhein, James; Sefert, Ed; Marsans, Lorena; Solomon, Mark; Nestler, Mark

    2006-01-01

    The Earth Observing System Data Gateway (EDG) software provides a "one-stop-shopping" standard interface for exploring and ordering Earth-science data stored at geographically distributed sites. EDG enables a user to do the following: 1) Search for data according to high-level criteria (e.g., geographic location, time, or satellite that acquired the data); 2) Browse the results of a search, viewing thumbnail sketches of data that satisfy the user s criteria; and 3) Order selected data for delivery to a specified address on a chosen medium (e.g., compact disk or magnetic tape). EDG consists of (1) a component that implements a high-level client/server protocol, and (2) a collection of C-language libraries that implement the passing of protocol messages between an EDG client and one or more EDG servers. EDG servers are located at sites usually called "Distributed Active Archive Centers" (DAACs). Each DAAC may allow access to many individual data items, called "granules" (e.g., single Landsat images). Related granules are grouped into collections called "data sets." EDG enables a user to send a search query to multiple DAACs simultaneously, inspect the resulting information, select browseable granules, and then order selected data from the different sites in a seamless fashion.

  20. Early westward flow across the Tasman Gateway

    NASA Astrophysics Data System (ADS)

    Sijp, W. P.; von der Heydt, A. S.; Bijl, P. K.

    2015-10-01

    The timing and role in ocean circulation and climate of the opening of Southern Ocean gateways is as yet elusive. Recent micropaleontological studies suggest the onset of throughflow of surface waters from the SW Pacific into the Australo-Antarctic Gulf through a southern shallow opening of the Tasman Gateway from 49-50 Ma onwards. Here, we present the first model results specific to the early-to-middle Eocene where, in agreement with the field evidence, southerly shallow opening of the Tasman Gateway indeed causes a westward flow across the Tasman Gateway. As a result, modelled estimates of dinoflagellate biogeography are in agreement with the recent findings. Crucially, in this situation where Australia is still situated far south and almost attached to Antarctica, the Drake Passage must be sufficiently restricted to allow the prevailing easterly wind pattern to set up this southerly restricted westward flow. In contrast, an open Drake Passage, to 517 m depth, leads to an eastward flow, even when the Tasman Gateway and the Australo-Antarctic gulf are entirely contained within the latitudes of easterly wind.

  1. Rear (northeast side) of gateway with building 9 on the ...

    Library of Congress Historic Buildings Survey, Historic Engineering Record, Historic Landscapes Survey

    Rear (northeast side) of gateway with building 9 on the left and building 10 on the right - Fitzsimons General Hospital, Entrance Gateway, East Colfax Avenue & Peoria Street, Northeast Corner, Aurora, Adams County, CO

  2. 47 CFR 10.310 - Federal alert gateway. [Reserved

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 47 Telecommunication 1 2010-10-01 2010-10-01 false Federal alert gateway. 10.310 Section 10.310 Telecommunication FEDERAL COMMUNICATIONS COMMISSION GENERAL COMMERCIAL MOBILE ALERT SYSTEM System Architecture § 10.310 Federal alert gateway....

  3. 47 CFR 10.310 - Federal alert gateway. [Reserved

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... 47 Telecommunication 1 2012-10-01 2012-10-01 false Federal alert gateway. 10.310 Section 10.310 Telecommunication FEDERAL COMMUNICATIONS COMMISSION GENERAL COMMERCIAL MOBILE ALERT SYSTEM System Architecture § 10.310 Federal alert gateway....

  4. 47 CFR 10.310 - Federal alert gateway. [Reserved

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... 47 Telecommunication 1 2011-10-01 2011-10-01 false Federal alert gateway. 10.310 Section 10.310 Telecommunication FEDERAL COMMUNICATIONS COMMISSION GENERAL COMMERCIAL MOBILE ALERT SYSTEM System Architecture § 10.310 Federal alert gateway....

  5. 47 CFR 10.310 - Federal alert gateway. [Reserved

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... 47 Telecommunication 1 2014-10-01 2014-10-01 false Federal alert gateway. 10.310 Section 10.310 Telecommunication FEDERAL COMMUNICATIONS COMMISSION GENERAL WIRELESS EMERGENCY ALERTS System Architecture § 10.310 Federal alert gateway....

  6. 47 CFR 10.310 - Federal alert gateway. [Reserved

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... 47 Telecommunication 1 2013-10-01 2013-10-01 false Federal alert gateway. 10.310 Section 10.310 Telecommunication FEDERAL COMMUNICATIONS COMMISSION GENERAL WIRELESS EMERGENCY ALERTS System Architecture § 10.310 Federal alert gateway....

  7. VO-compliant workflows and science gateways

    NASA Astrophysics Data System (ADS)

    Castelli, G.; Taffoni, G.; Sciacca, E.; Becciani, U.; Costa, A.; Krokos, M.; Pasian, F.; Vuerli, C.

    2015-06-01

    Workflow and science gateway technologies have been adopted by scientific communities as a valuable tool to carry out complex experiments. They offer the possibility to perform computations for data analysis and simulations, whereas hiding details of the complex infrastructures underneath. There are many workflow management systems covering a large variety of generic services coordinating execution of workflows. In this paper we describe our experiences in creating workflows oriented science gateways based on gUSE/WS-PGRADE technology and in particular we discuss the efforts devoted to develop a VO-compliant web environment.

  8. ORAL PRESENTATION:EPA'S ENVIRONMENTAL PHOTOGRAPHIC INTERPRETATION CENTER (EPIC)

    EPA Science Inventory

    This presentation provides an overview of the remote sensing technical support and research and development activities of the Environmental Photographic Interprettion Center (EPIC). It is the basis for a presentation given at the EPA's Office of Acquisition Management's Annual C...

  9. Students Speak With Gary Cox, EPIC Project Manager

    NASA Video Gallery

    From NASA’s International Space Station Mission Control Center Gary Cox EPIC Project Manager, participates in a Digital Learning Network (DLN) event with students at South Effingham Middle School...

  10. Operational experience from a large EPICS-based accelerator facility

    SciTech Connect

    Ciarlette, D.J.; Gerig, R.

    1995-12-31

    The Advanced Photon Source (APS) at Argonne National Laboratory is a third-generation x-ray light source which uses the Experimental Physics and Industrial Control System (EPICS) to operate its linear accelerator, positron accumulator ring, booster synchrotron, and storage ring equipment. EPICS has been used at the APS since the beginning of installation and commissioning. Currently, EPICS controls approximately 100 VME crates containing over 100,000 process variables. With this complexity, the APS has had to review some of the methods originally employed and make changes as necessary. In addition, due to commissioning and operational needs, higher-level operator software needed to be created. EPICS has been flexible enough to allow this.

  11. Open PV Project: Unlocking PV Installation Data (Brochure)

    SciTech Connect

    Not Available

    2012-04-01

    This brochure summarizes the Open PV Project, a collaborative effort of government, industry, and the public to compile a comprehensive database of PV installations in the United States. The brochure outlines the purpose and history of the project as well as the main capabilities and benefits of the online Open PV tool. The brochure also introduces how features of the tool are used, and it describes the sources and characteristics of Open PV's data and data collection processes.

  12. Experience with EPICS in a wide variety of applications

    SciTech Connect

    Kraimer, M.R.; Clausen, M.; Lupton, W.; Watson, C.

    1997-08-01

    Currently more than 70 organizations have obtained permission to use the Experimental Physics and Industrial Control System (EPICS), a set of software packages for building real-time control systems. In this paper representatives from four of these sites discuss the reasons their sites chose EPICS, provide a brief discussion of their control system development, and discuss additional control system tools obtained elsewhere or developed locally.

  13. EPA Remote Sensing Information Gateway

    NASA Astrophysics Data System (ADS)

    Paulsen, H. K.; Szykman, J. J.; Plessel, T.; Freeman, M.; Dimmick, F.

    2009-12-01

    The Remote Sensing Information Gateway was developed by the U.S. Environmental Protection Agency (EPA) to assist researchers in easily obtaining and combining a variety of environmental datasets related to air quality research. Current datasets available include, but are not limited to surface PM2.5 and O3 data, satellite derived aerosol optical depth , and 3-dimensional output from U.S. EPA's Models 3/Community Multi-scale Air Quality (CMAQ) modeling system. The presentation will include a demonstration that illustrates several scenarios of how researchers use the tool to help them visualize and obtain data for their work; with a particular focus on episode analysis related to biomass burning impacts on air quality. The presentation will provide an overview on how RSIG works and how the code has been—and can be—adapted for other projects. One example is the Virtual Estuary, which focuses on automating the retrieval and pre-processing of a variety of data needed for estuarine research. RSIG’s source codes are freely available to researchers with permission from the EPA principal investigator, Dr. Jim Szykman. RSIG is available to the community and can be accessed online at http://www.epa.gov/rsig. Once the JAVA policy file is configured on your computer you can run the RSIG applet on your computer and connect to the RSIG server to visualize and retrieve available data sets. The applet allows the user to specify the temporal/spatial areas of interest, and the types of data to retrieve. The applet then communicates with RSIG subsetter codes located on the data owners’ remote servers; the subsetter codes assemble and transfer via ordinary Internet protocols only the specified data to the researcher’s computer. This is much faster than the usual method of transferring large files via FTP and greatly reduces network traffic. The RSIG applet then visualizes the transferred data on a latitude-longitude map, automatically locating the data in the correct

  14. PV System Performance and Standards

    SciTech Connect

    Osterwald, C. R.

    2005-11-01

    This paper presents a brief overview of the status and accomplishments during fiscal year (FY) 2005 of the Photovoltaic (PV) System Performance and Standards Subtask, which is part of the PV Systems Engineering Project (a joint NREL-Sandia project).

  15. PV module degradation-analysis

    NASA Astrophysics Data System (ADS)

    Themelis, M. P.

    1982-06-01

    The energy potential of photovoltaic (PV) components in various test applications were evaluated. Visual and electrical degradation analyses were performed on 47 PV modules. Discoloration, cracking, scratches, and electrical degradation were detected.

  16. Aerosol Retrieval and Atmospheric Correction Algorithms for EPIC

    NASA Astrophysics Data System (ADS)

    Wang, Y.; Lyapustin, A.; Marshak, A.; Korkin, S.; Herman, J. R.

    2011-12-01

    EPIC is a multi-spectral imager onboard planned Deep Space Climate ObserVatoRy (DSCOVR) designed for observations of the full illuminated disk of the Earth with high temporal and coarse spatial resolution (10 km) from Lagrangian L1 point. During the course of the day, EPIC will view the same Earth surface area in the full range of solar and view zenith angles at equator with fixed scattering angle near the backscattering direction. This talk will describe a new aerosol retrieval/atmospheric correction algorithm developed for EPIC and tested with EPIC Simulator data. This algorithm uses the time series approach and consists of two stages: the first stage is designed to periodically re-initialize the surface spectral bidirectional reflectance (BRF) on stable low AOD days. Such days can be selected based on the same measured reflectance between the morning and afternoon reciprocal view geometries of EPIC. On the second stage, the algorithm will monitor the diurnal cycle of aerosol optical depth and fine mode fraction based on the known spectral surface BRF. Testing of the developed algorithm with simulated EPIC data over continental USA showed a good accuracy of AOD retrievals (10-20%) except over very bright surfaces.

  17. Real-Time performance measurements of EPICS IOCcore.

    SciTech Connect

    Xu, S.; Kraimer, M. R.; Accelerator Systems Division

    2005-01-01

    As the Experimental Physics and Industrial Control System (EPICS) is used in an increasing number of accelerator control systems, EPICS IOCcore is ported to a wider variety of OS platforms and thus the performance of EPICS IOCcore on different hardware and software platforms becomes more important. This paper provides real-time performance measurements of EPICS IOCcore on a VME hardware platform and on three different OS platforms: vxWorks, RTEMS, and Linux. EPICS Input/Output Controller core (IOCcore) software has been ported to several different operating systems (OSs) and many hardware platforms. This paper compares the EPICS IOCcore runtime performance on one hardware platform (MVME2100 PowerPC) and three popular Operating Systems: vxWorks, RTEMS, and Linux. For Linux the following versions were tested: Linux 2.4.2 hard hat 2.0, standard Linux 2.4.30, and Linux 2.6.13. For Linux 2.6.13, the kernel was built both preemptive and non-preemptive. Three real-time parameters are measured: interrupt, context switch, and total response latency. On Linux, more detailed interrupt latencies are measured: interrupt top half to bottom half, and interrupt bottom half to user space interrupt service routine. To implement the tests, several software components were developed. In order to port to other operating systems or hardware platforms only, one component has to be implemented.

  18. Aerosol Retrieval and Atmospheric Correction Algorithms for EPIC

    NASA Technical Reports Server (NTRS)

    Wang, Yujie; Lyapustin, Alexei; Marshak, Alexander; Korkin, Sergey; Herman, Jay

    2011-01-01

    EPIC is a multi-spectral imager onboard planned Deep Space Climate ObserVatoRy (DSCOVR) designed for observations of the full illuminated disk of the Earth with high temporal and coarse spatial resolution (10 km) from Lagrangian L1 point. During the course of the day, EPIC will view the same Earth surface area in the full range of solar and view zenith angles at equator with fixed scattering angle near the backscattering direction. This talk will describe a new aerosol retrieval/atmospheric correction algorithm developed for EPIC and tested with EPIC Simulator data. This algorithm uses the time series approach and consists of two stages: the first stage is designed to periodically re-initialize the surface spectral bidirectional reflectance (BRF) on stable low AOD days. Such days can be selected based on the same measured reflectance between the morning and afternoon reciprocal view geometries of EPIC. On the second stage, the algorithm will monitor the diurnal cycle of aerosol optical depth and fine mode fraction based on the known spectral surface BRF. Testing of the developed algorithm with simulated EPIC data over continental USA showed a good accuracy of AOD retrievals (10-20%) except over very bright surfaces.

  19. "Gateway" Districts Struggle to Serve Immigrant Parents

    ERIC Educational Resources Information Center

    Maxwell, Lesli A.

    2012-01-01

    As thousands of communities--especially in the South--became booming gateways for immigrant families during the 1990s and the early years of the new century, public schools struggled with the unfamiliar task of serving the large numbers of English-learners arriving in their classrooms. Instructional programs were built from scratch. Districts had…

  20. Gateway's Horizon: A Center of Excellence

    ERIC Educational Resources Information Center

    Herring, Jayne; Colony, Lee

    2007-01-01

    This article describes Gateway Technical College's Horizon Center for Transportation Technology, located in Kenosha, Wisconsin, which was the product of collaboration with business and industry, community support and a U.S. Department of Labor (DOL) grant. The center, which opened this fall, is a prime example of a sustainable community…

  1. Predicting Success in a Gateway Mathematics Course

    ERIC Educational Resources Information Center

    Morrison, Michael C.; Schmit, Shelly

    2010-01-01

    A logit model predicting student outcomes for a gateway course, Math for Liberal Arts, was successfully developed which fits the data well. Two variables, ACT math score and high school GPA, were found to be significant predictors of achieving a C or better in Math for Liberal Arts. A practical implication of the study suggests that with just two…

  2. TN State Profile. Tennessee: Gateway Examinations

    ERIC Educational Resources Information Center

    Center on Education Policy, 2010

    2010-01-01

    This paper provides information about Tennessee's Gateway Examinations. The purpose of the test is to: (1) Provide schools with student academic diagnostic information; (2) Determine prospective high school graduates' mastery of the state curriculum; (3) Encourage districts and schools to identify and serve students at risk of academic failure;…

  3. Gateways Intellectually Gifted Handbook. Report #501.

    ERIC Educational Resources Information Center

    Hersh, Leonard R.

    The document describes the Gateways program for intellectually gifted students of grades K-12 in Horseheads, New York. The introductory chapter presents the context in which the program developed, discussing program background and need. The next chapter focuses on identification of pupils with emphasis on the three stage process (nomination,…

  4. Review of "Gateways to the Principalship"

    ERIC Educational Resources Information Center

    Orr, Margaret Terry

    2012-01-01

    "Gateways to the Principalship: State Power to Improve the Quality of School Leaders" proposes state policies for improving principal effectiveness and student achievement. It uses policy examples from eight "lagging" and eight "leading" states as a means of advocating for a wide range of policy actions aimed at influencing principal preparation,…

  5. A Gateway Approach to Library System Networking.

    ERIC Educational Resources Information Center

    Anderson, David A.; Duggan, Michael T.

    1987-01-01

    Describes a technique for accessing a library system with limited interconnectivity by connecting the system to a gateway machine that is a host in the local area network and evaluates the performance of an existing prototype that has been implemented at the Los Alamos National Laboratory. (Author/CLB)

  6. Testing for PV Reliability (Presentation)

    SciTech Connect

    Kurtz, S.; Bansal, S.

    2014-09-01

    The DOE SUNSHOT workshop is seeking input from the community about PV reliability and how the DOE might address gaps in understanding. This presentation describes the types of testing that are needed for PV reliability and introduces a discussion to identify gaps in our understanding of PV reliability testing.

  7. SEDAC information gateway plan V(1)

    NASA Technical Reports Server (NTRS)

    Chen, Robert S. (Compiler)

    1995-01-01

    This annual update of the Information Gateway Plan incorporates changes recommended by the Socioeconomic Data and Applications Center (SEDAC) User Working Group (UWG) and reflects comments and suggestions from users, collaborators, and the Contracting Officer Technical Representative (COTR). The Information Gateway Plan is a concise and specific plan that outlines SEDAC activities and services in support of the earth and social sciences and other user communities. The SEDAC Information Gateway effort is a primary means by which the Earth Observing System Data and Information System (EOSDIS) can link meaningfully with a broad range of social science data sources and users in ways that lead to tangible benefits to the American people. The SEDAC Information Gateway provides interdisciplinary access to socioeconomic and physical science data and information resources held by SEDAC and numerous other institutions and networks around the world. The Plan describes the areas of research of earth scientists and socioeconomic scientists where interchange of data and information is most needed. It sets guidelines for the continued development of SEDAC's directory of social science datasets and establishes priorities for efforts to make data held by SEDAC or accessible through SEDAC available to the user community. The Plan also describes the means by which the SEDAC user community can access information products specified by the SEDAC Data and Applications Development Plan (DADP). Among other major activities, SEDAC will continue to enhance and operate a directory capability, interoperable with the Global Change Master Directory, that provides the socioeconomic community with information about earth science products and the earth science research community with information about socioeconomic data. The Information Gateway also serves as a unique and powerful access pathway for a wide range of users and potential users of socioeconomic and earth science data, including

  8. EPICS : Extensible record and device support.

    SciTech Connect

    Dalesio, L. R.; Kraimer, M. R.

    1997-11-18

    Although the design of extensible support was not intentionally object oriented, the design does have an object-oriented flavor. Here we discuss the good and bad aspects of using object-oriented ideas. Since the structures generated from a Record Description File contain only data and not methods, they are not similar to Java or C++ classes. Because methods are not present, a clear separation between static and run-time database access is possible. This is a good feature and should be kept. It also allows generation of C structures that can be used by either C or C++ code. The record and device support entry tables are almost like Java interfaces or pure abstract C++ classes. We can state that EPICS databases are defined via a Database Definition Language and an Abstract Interface Definition. The two main shortcomings of the existing implementation are (1) only two interfaces are defined RSETS and DSETS (actually a third called a driver entry table is also defined), and (2) the way hardware links are implemented makes it extremely difficult to support arbitrary bus types and additional hardware configuration information.

  9. PV Hourly Simulation Tool

    Energy Science and Technology Software Center (ESTSC)

    2010-12-31

    This software requires inputs of simple general building characteristics and usage information to calculate the energy and cost benefits of solar PV. This tool conducts and complex hourly simulation of solar PV based primarily on the area available on the rooftop. It uses a simplified efficiency calculation method and real panel characteristics. It includes a detailed rate structure to account for time-of-use rates, on-peak and off-peak pricing, and multiple rate seasons. This tool includes themore » option for advanced system design inputs if they are known. This tool calculates energy savings, demand reduction, cost savings, incentives and building life cycle costs including: simple payback, discounted payback, net-present value, and savings to investment ratio. In addition this tool also displays the environmental benefits of a project.« less

  10. PV Hourly Simulation Tool

    SciTech Connect

    Dean, Jesse; Metzger, Ian

    2010-12-31

    This software requires inputs of simple general building characteristics and usage information to calculate the energy and cost benefits of solar PV. This tool conducts and complex hourly simulation of solar PV based primarily on the area available on the rooftop. It uses a simplified efficiency calculation method and real panel characteristics. It includes a detailed rate structure to account for time-of-use rates, on-peak and off-peak pricing, and multiple rate seasons. This tool includes the option for advanced system design inputs if they are known. This tool calculates energy savings, demand reduction, cost savings, incentives and building life cycle costs including: simple payback, discounted payback, net-present value, and savings to investment ratio. In addition this tool also displays the environmental benefits of a project.

  11. A Robotic Communications Gateway for Ocean Observations

    NASA Astrophysics Data System (ADS)

    Orcutt, J. A.; Berger, J.; Laske, G.; Babcock, J.

    2015-12-01

    We describe a new technology that can provide real-time telemetry of sensor data from the ocean bottom. The breakthrough technology that makes this system possible is an autonomous surface vehicle called the Wave Glider developed by Liquid Robotics, Inc. of Sunnyvale, CA., which harvests wave and solar energy for motive and electrical power. The free-floating surface communications gateway uses a Liquid Robotics wave glider comprising a surfboard-sized float towed by a tethered, submerged glider, which converts wave motion into thrust. For navigation, the wave glider is equipped with a small computer, a GPS receiver, a rudder, solar panels and batteries, and an Iridium satellite modem. Acoustic communications connect the subsea instruments and the surface gateway while communications between the gateway and land are provided by the Iridium satellite constellation. Wave gliders have demonstrated trans-oceanic range and long-term station keeping capabilities. The topside acoustics communications package is mounted in a shallow tow body, which uses a WHOI micro modem and a Benthos low frequency, directional transducer. A matching bottom side modem and transducer are mounted on the ocean bottom package. Tests of the surface gateway in 4000 m of water demonstrated an acoustic efficiency of approximately 256 bits/J. For example, it has the ability to send four channels of compressed, one sample per second data from the ocean bottom to the gateway with an average power draw of approximately 0.36 W and a latency of about three minutes. This gateway is used to send near-real-time data from a broadband ocean bottom seismic observatory; we are presently designing and constructing a seafloor package with a two-year operational life. We have found that for frequencies f where f<10mHz, 35mHz < f < 120mHz and f>~3Hz, the vertical component, seafloor system noise characteristics are generally superior to similar observatories on land. Increasing the density of these stations over

  12. The EPIC Professional Learning Model: A Review of EPIC's Alignment with Leadership Development Research and Professional Learning National Standards. The Effective Practice Incentive Community (EPIC). Research Brief

    ERIC Educational Resources Information Center

    Sloan, Kay; Perreira-Leon, Maura

    2010-01-01

    With the creation of the Effective Practice Incentive Community (EPIC), New Leaders for New Schools hoped to accomplish two broad and ambitious goals. The first was to identify and reward leadership practices driving significant achievement gains in high-poverty, urban schools. The second was to learn from those practices and make them more widely…

  13. AERIAL PHOTO INTERPRETATION FOR SITE CHARACTERIZATION, ENVIRONMENTAL PHOTOGRAPHIC INTERPRETATION CENTER (EPIC)

    EPA Science Inventory

    The Environmental Photographic Interpretation Center (EPIC) is a field station of the Landscape Ecology Branch (LEB), Environmental Sciences Division - Las Vegas, Office of Research and Development EPIC provides remote sensing technical support to help the Agency achieve its mult...

  14. EPIC'S NEW REMOTE SENSING DATA AND INFORMATION TOOLS AVAILABLE FOR EPA CUSTOMERS

    EPA Science Inventory



    EPIC's New Remote Sensing Data and Information Tools Available for EPA Customers Donald Garofalo Environmental Photographic Interpretation Center (EPIC) Landscape Ecology Branch Environmental Sciences Division National Exposure Research Laboratory

    Several new too...

  15. DOE`s Pollution Prevention Information Clearinghouse (EPIC)

    SciTech Connect

    Otis, P.T.

    1994-05-01

    The US Department of Energy`s (DOE`s) Pollution Prevention Information Clearinghouse (EPIC) is a computer system intended for the exchange of pollution prevention information DOE-wide. EPIC is being developed as a distributed system that will allow access to other databases and applications. The first prototype of EPIC (Prototype I) was put on-line in January 1994. Prototype I contains information on EM-funded pollution prevention projects; relevant laws, regulations, guidance, and policy; facility and DOE contacts; and meetings and conferences. Prototype I also gives users access to the INEL Hazardous Solvent Substitution Data System (HSSDS) and to information contained on the US Environmental Protection Agency`s (EPNS) Pollution Prevention Infbrmation Exchange System (PIES) as a test of the distributed system concept. An initial user group of about 35 is testing and providing feedback on Prototype I. Prototype II, with a Graphical User Interface (GUI), is planned for the end of CY94. This paper describes the current state of EPIC in terms of architecture, user interface, and information content. Plans for Prototype II and the final system are then discussed. The EPIC development effort is being coordinated with EPA and US Department of Defense (DoD) efforts to develop or upgrade their pollution prevention information exchange systems.

  16. Gateway®-compatible plant transformation vectors.

    PubMed

    Smedley, Mark A; Harwood, Wendy A

    2015-01-01

    Studies in functional genomics and crop improvement programs often rely on the introduction and expression of transgenes in plants. There are two essential components required for in planta transgene expression, a plasmid vector on which the transgene sequence is carried and a delivery system capable of transferring the vector to the target cells. Agrobacterium-mediated plant transformation and the binary plasmid vector system is the preferred method of transgene delivery. The cloning technologies used for DNA manipulation underpin many of these studies. Increased demand for efficient high-throughput transformation systems is driving forward improvements in gene cloning techniques. This chapter gives an overview of Gateway(®)-compatible binary vectors for use in Agrobacterium-mediated transformation systems. It describes a fast, efficient, and robust cloning protocol for the production of an over-expression binary vector using Gateway(®) recombinational cloning. PMID:25300827

  17. BASSET: Scalable Gateway Finder in Large Graphs

    SciTech Connect

    Tong, H; Papadimitriou, S; Faloutsos, C; Yu, P S; Eliassi-Rad, T

    2010-11-03

    Given a social network, who is the best person to introduce you to, say, Chris Ferguson, the poker champion? Or, given a network of people and skills, who is the best person to help you learn about, say, wavelets? The goal is to find a small group of 'gateways': persons who are close enough to us, as well as close enough to the target (person, or skill) or, in other words, are crucial in connecting us to the target. The main contributions are the following: (a) we show how to formulate this problem precisely; (b) we show that it is sub-modular and thus it can be solved near-optimally; (c) we give fast, scalable algorithms to find such gateways. Experiments on real data sets validate the effectiveness and efficiency of the proposed methods, achieving up to 6,000,000x speedup.

  18. Space Station Freedom Gateway to the Future

    NASA Technical Reports Server (NTRS)

    1992-01-01

    The first inhabited outpost on the frontier of space will be a place to live, work, and discover. Experiments conducted on Freedom will advance scientific knowledge about our world, our environment, and ourselves. We will learn how to adapt to the space environment and to build and operate new spacecraft with destinations far beyond Earth, continuing the tradition of exploration that began with a journey to the Moon. What we learn from living and working on Freedom will strengthen our expertise in science and engineering, promote national research and development initiatives and inspire another generation of Americans to push forward and onward. On the eve of the 21st century, Space Station Freedom will be our gateway to the future. This material covers gateways to space, research, discovery, utilization, benefits, and NASA.

  19. Neutron Science TeraGrid Gateway

    NASA Astrophysics Data System (ADS)

    Lynch, Vickie; Chen, Meili; Cobb, John; Kohl, Jim; Miller, Steve; Speirs, David; Vazhkudai, Sudharshan

    2010-11-01

    The unique contributions of the Neutron Science TeraGrid Gateway (NSTG) are the connection of national user facility instrument data sources to the integrated cyberinfrastructure of the National Science FoundationTeraGrid and the development of a neutron science gateway that allows neutron scientists to use TeraGrid resources to analyze their data, including comparison of experiment with simulation. The NSTG is working in close collaboration with the Spallation Neutron Source (SNS) at Oak Ridge as their principal facility partner. The SNS is a next-generation neutron source. It has completed construction at a cost of 1.4 billion and is ramping up operations. The SNS will provide an order of magnitude greater flux than any previous facility in the world and will be available to all of the nation's scientists, independent of funding source, on a peer-reviewed merit basis. With this new capability, the neutron science community is facing orders of magnitude larger data sets and is at a critical point for data analysis and simulation. There is a recognized need for new ways to manage and analyze data to optimize both beam time and scientific output. The TeraGrid is providing new capabilities in the gateway for simulations using McStas and a fitting service on distributed TeraGrid resources to improved turnaround. NSTG staff are also exploring replicating experimental data in archival storage. As part of the SNS partnership, the NSTG provides access to gateway support, cyberinfrastructure outreach, community development, and user support for the neutron science community. This community includes not only SNS staff and users but extends to all the major worldwide neutron scattering centers.

  20. Neutron Science TeraGrid Gateway

    SciTech Connect

    Lynch, Vickie E; Chen, Meili; Cobb, John W; Kohl, James Arthur; Miller, Stephen D; Speirs, David A; Vazhkudai, Sudharshan S

    2010-01-01

    The unique contributions of the Neutron Science TeraGrid Gateway (NSTG) are the connection of national user facility instrument data sources to the integrated cyberinfrastructure of the National Science FoundationTeraGrid and the development of a neutron science gateway that allows neutron scientists to use TeraGrid resources to analyze their data, including comparison of experiment with simulation. The NSTG is working in close collaboration with the Spallation Neutron Source (SNS) at Oak Ridge as their principal facility partner. The SNS is a next-generation neutron source. It has completed construction at a cost of $1.4 billion and is ramping up operations. The SNS will provide an order of magnitude greater flux than any previous facility in the world and will be available to all of the nation's scientists, independent of funding source, on a peer-reviewed merit basis. With this new capability, the neutron science community is facing orders of magnitude larger data sets and is at a critical point for data analysis and simulation. There is a recognized need for new ways to manage and analyze data to optimize both beam time and scientific output. The TeraGrid is providing new capabilities in the gateway for simulations using McStas and a fitting service on distributed TeraGrid resources to improved turnaround. NSTG staff are also exploring replicating experimental data in archival storage. As part of the SNS partnership, the NSTG provides access to gateway support, cyberinfrastructure outreach, community development, and user support for the neutron science community. This community includes not only SNS staff and users but extends to all the major worldwide neutron scattering centers.

  1. SCORPION persistent surveillance system with universal gateway

    NASA Astrophysics Data System (ADS)

    Coster, Michael; Chambers, Jon; Winters, Michael; Belesi, Joe

    2008-04-01

    This paper addresses benefits derived from the universal gateway utilized in Northrop Grumman Systems Corporation's (NGSC) SCORPION, a persistent surveillance and target recognition system produced by the Xetron campus in Cincinnati, Ohio. SCORPION is currently deployed in Operations Iraqi Freedom (OIF) and Enduring Freedom (OEF). The SCORPION universal gateway is a flexible, field programmable system that provides integration of over forty Unattended Ground Sensor (UGS) types from a variety of manufacturers, multiple visible and thermal electro-optical (EO) imagers, and numerous long haul satellite and terrestrial communications links, including the Army Research Lab (ARL) Blue Radio. Xetron has been integrating best in class sensors with this universal gateway to provide encrypted data exfiltration and remote sensor command and control since 1998. SCORPION data can be distributed point to point, or to multiple Common Operational Picture (COP) systems, including Command and Control Personal Computer (C2PC), Common Data Interchange Format for the Situational Awareness Display (CDIF/SAD), Force XXI Battle Command Brigade and Below (FBCB2), Defense Common Ground Systems (DCGS), and Remote Automated Position Identification System (RAPIDS).

  2. The key technologies of the H.323 gateway

    NASA Astrophysics Data System (ADS)

    Bai, Yi-zhi; Huang, Yong-feng; Li, Xing

    2004-04-01

    Nowadays VoIP (Voice over IP) develops quickly. H.323 is the most popular and mature architecture for VoIP, in which Gateway is one of the most important components. In this paper, two main aspects of the Gateway are discussed. They are the processing of simultaneous initialization of multiple calls and the compatibility with other H.323 standard endpoints and different H.323 versions. At last, the test of our Gateway is shown and the result is discussed.

  3. Astronomy education resource gateway design based on the Virtual Observatory

    NASA Astrophysics Data System (ADS)

    Liu, Gao-Chao; Cui, Chen-Zhou; Zheng, Xiao-Ping; Zhao, Yong-Heng

    2004-06-01

    Beginning with the importance and current status of astronomy education, the paper sets forth the necessity and feasibility of building an astronomy education resource gateway based on the Virtual Observatory. Using technologies about metadata in the Virtual Observatory, a reasonable mechanism for building the gateway is discussed, including resource registry and discovery, metadata record creating, metadata database managing, resources querying, etc. Furthermore, an example is introduced on how to run and manage the gateway. Finally, the future of VO based education is prospected.

  4. Development of mpi_EPIC model for global agroecosystem modeling

    SciTech Connect

    Kang, Shujiang; Wang, Dali; Jeff A. Nichols; Schuchart, Joseph; Kline, Keith L.; Wei, Yaxing; Ricciuto, Daniel M.; Wullschleger, Stan D.; Post, Wilfred M.; Izaurralde, R. Cesar

    2014-12-31

    Models that address policy-maker concerns about multi-scale effects of food and bioenergy production systems are computationally demanding. We integrated the message passing interface algorithm into the process-based EPIC model to accelerate computation of ecosystem effects. Simulation performance was further enhanced by applying the Vampir framework. When this enhanced mpi_EPIC model was tested, total execution time for a global 30-year simulation of a switchgrass cropping system was shortened to less than 0.5 hours on a supercomputer. The results illustrate that mpi_EPIC using parallel design can balance simulation workloads and facilitate large-scale, high-resolution analysis of agricultural production systems, management alternatives and environmental effects.

  5. Development of mpi_EPIC model for global agroecosystem modeling

    DOE PAGESBeta

    Kang, Shujiang; Wang, Dali; Jeff A. Nichols; Schuchart, Joseph; Kline, Keith L.; Wei, Yaxing; Ricciuto, Daniel M.; Wullschleger, Stan D.; Post, Wilfred M.; Izaurralde, R. Cesar

    2014-12-31

    Models that address policy-maker concerns about multi-scale effects of food and bioenergy production systems are computationally demanding. We integrated the message passing interface algorithm into the process-based EPIC model to accelerate computation of ecosystem effects. Simulation performance was further enhanced by applying the Vampir framework. When this enhanced mpi_EPIC model was tested, total execution time for a global 30-year simulation of a switchgrass cropping system was shortened to less than 0.5 hours on a supercomputer. The results illustrate that mpi_EPIC using parallel design can balance simulation workloads and facilitate large-scale, high-resolution analysis of agricultural production systems, management alternatives and environmentalmore » effects.« less

  6. Science with EPICS, the E-ELT planet finder

    NASA Astrophysics Data System (ADS)

    Gratton, Raffaele; Kasper, Markus; Vérinaud, Christophe; Bonavita, Mariangela; Schmid, Hans M.

    2011-11-01

    EPICS is the proposed planet finder for the European Extremely Large Telescope. EPICS is a high contrast imager based on a high performing extreme adaptive optics system, a diffraction suppression module, and two scientific instruments: an Integral Field Spectrograph (IFS) for the near infrared (0.95-1.65 μm), and a differential polarization imager (E-POL). Both these instruments should allow imaging and characterization of planets shining in reflected light, possibly down to Earth-size. A few high interesting science cases are presented.

  7. EPICS: A control system software co-development success story

    SciTech Connect

    Knott, M.; Gurd, D.; Lewis, S.; Thuot, M.

    1993-11-01

    The Experimental Physics and Industrial Control Systems (EPICS) is the result of a software sharing and co-development effort of major importance now underway. The initial two participants, LANL and ANL, have now been joined by three other labs, and an earlier version of the software has been transferred to three commercial firms and is currently undergoing separate development. The reasons for EPICS`s success may be useful to enumerate and explain and the desire and prospects for its continued development are certainly worth examining.

  8. PV at the Pentagon

    SciTech Connect

    Bing, J.

    2000-02-01

    The US Department of Defense joins the battle against global warming with a photovoltaic installation at the Pentagon heating and refrigeration plant. Sitting in a line between the Pentagon and the Oval Office are four concentric arcs of iridescent silicon. In June 1999, the first half of this thirty kilowatt photovoltaic (PV) system was dedicated on the grounds of the heating and refrigeration plant that serves the Pentagon near Washington, DC. This first half of the system (the two center arcs) is the world's largest array composed solely of Ascension Technology's SunSine{reg{underscore}sign}300 AC modules. Each of these photovoltaic panels has its own DC to AC inverter mounted directly on its back side. The second half of the installation, brought on line in October 1999, includes a conventional DC array that powers a pair of newly developed Trace Technologies 10 kW inverters. The AC output of these two unique PV systems is combined at a central collection point and funneled into the electric grid that supplies power to the Pentagon. The project is a collaboration of the US Department of Defense (DoD) and the US Department of Energy (DOE), with cost-sharing support from Virginia Power, Johnson Controls, the Utility Photovoltaic Group (UPVG), and Applied Power Corporation. The systems were designed and installed by Ascension Technology, a division of Applied Power Corporation, with modules supplied by ASE Americas. This installation provides a unique real-world environment for researchers, utility engineers and power plant managers to test and compare the reliability, scalability, noise immunity and power quality of these two distinct approaches to PV energy production.

  9. PV water pumping: NEOS Corporation recent PV water pumping activities

    SciTech Connect

    Lane, C.

    1995-11-01

    NEOS Corporation has been very active in PV-powered water pumping, particularly with respect to electric utilities. Most of the recent activity has been through the Photovoltaic Services Network (PSN). The PSN is an independent, not-for-profit organization comprised of all types of electric utilities: rural electric coops, public power districts, investor-owned utilities, and power marketing agencies. The PSN`s mission is to work pro-actively to promote utility involvement in PV through education and training. PV information is distributed by the PSN in three primary forms: (1) consultation with PSN technical service representatives: (2) literature generated by the PSN; and (3) literature published by other organizations. The PSN can also provide assistance to members in developing PV customer service programs. The PSN`s product support activities include consolidation of information on existing packaged PV systems and facilitation of the development of new PV product packages that meet utility-defined specifications for cost performance, and reliability. The PSN`s initial product support efforts will be focused on commercially available packaged PV systems for a variety of off-grid applications. In parallel with this effort, if no products exist that meet the PSN`s functional specifications, the PSN will initiate the second phase of product development support process by encouraging the development of new packaged systems. Through these services and product support activities, the PSN anticipates engaging all segments for the PV industry, thus providing benefits to PV systems suppliers as well as local PV service contractors.This paper describes field testing of pv power systems for water pumping.

  10. Outdoor PV Degradation Comparison

    SciTech Connect

    Jordan, D. C.; Smith, R. M.; Osterwald, C. R.; Gelak, E.; Kurtz, S. R.

    2011-02-01

    As photovoltaic (PV) penetration of the power grid increases, it becomes vital to know how decreased power output; may affect cost over time. In order to predict power delivery, the decline or degradation rates must be determined; accurately. At the Performance and Energy Rating Testbed (PERT) at the Outdoor Test Facility (OTF) at the; National Renewable Energy Laboratory (NREL) more than 40 modules from more than 10 different manufacturers; were compared for their long-term outdoor stability. Because it can accommodate a large variety of modules in a; limited footprint the PERT system is ideally suited to compare modules side-by-side under the same conditions.

  11. Interband cascade (IC) photovoltaic (PV) architecture for PV devices

    DOEpatents

    Yang, Rui Q.; Tian, Zhaobing; Mishima, Tetsuya D.; Santos, Michael B.; Johnson, Matthew B.; Klem, John F.

    2015-10-20

    A photovoltaic (PV) device, comprising a PV interband cascade (IC) stage, wherein the IC PV stage comprises an absorption region with a band gap, the absorption region configured to absorb photons, an intraband transport region configured to act as a hole barrier, and an interband tunneling region configured to act as an electron barrier. An IC PV architecture for a photovoltaic device, the IC PV architecture comprising an absorption region, an intraband transport region coupled to the absorption region, and an interband tunneling region coupled to the intraband transport region and to the adjacent absorption region, wherein the absorption region, the intraband transport region, and the interband tunneling region are positioned such that electrons will flow from the absorption region to the intraband transport region to the interband tunneling region.

  12. Compilation of a standardised international folate database for EPIC.

    PubMed

    Nicolas, Geneviève; Witthöft, Cornelia M; Vignat, Jérôme; Knaze, Viktoria; Huybrechts, Inge; Roe, Mark; Finglas, Paul; Slimani, Nadia

    2016-02-15

    This paper describes the methodology applied for compiling an "international end-user" folate database. This work benefits from the unique dataset offered by the European Prospective Investigation into Cancer and Nutrition (EPIC) (N=520,000 subjects in 23 centres). Compilation was done in four steps: (1) identify folate-free foods then find folate values for (2) folate-rich foods common across EPIC countries, (3) the remaining "common" foods, and (4) "country-specific" foods. Compiled folate values were concurrently standardised in terms of unit, mode of expression and chemical analysis, using information in national food composition tables (FCT). 43-70% total folate values were documented as measured by microbiological assay. Foods reported in EPIC were either matched directly to FCT foods, treated as recipes or weighted averages. This work has produced the first standardised folate dataset in Europe, which was used to calculate folate intakes in EPIC; a prerequisite to study the relation between folate intake and diseases. PMID:26433299

  13. "El Norte," Deracination and Circularity: An Epic Gone Awry

    ERIC Educational Resources Information Center

    Brakel, Arthur

    2007-01-01

    Early journalistic reviews (e.g., Gold, Ebert, and Kael) of "El Norte" (1983), Gregory Nava's first major film, identify it as an epic. In "El Norte" the siblings Enrique and Rosa, two Guatemalan Amerindians, leave their native village on a quest to what for them is the mythical land in the North. Although "El Norte" corresponds to the general…

  14. Simulating field-scale soil organic carbon dynamics using EPIC

    Technology Transfer Automated Retrieval System (TEKTRAN)

    Simulation models integrate our understanding of soil organic C (SOC) dynamics and are useful tools for evaluating impacts of crop management on soil C sequestration, yet, they require local calibration. Our objectives were to calibrate the Environmental Policy Integrated Climate (EPIC) model, and e...

  15. The Epic Tradition in Science Fiction and Fantasy.

    ERIC Educational Resources Information Center

    Mahon, Robert Lee

    1987-01-01

    Claims that some of the finest works of contemporary science fiction and fantasy borrow heavily from the epic tradition. Proposes that science fiction and fantasy can avoid the disbelief problem by the simple expedient of removing the "here and now," and, thereby, the realistic diminishment of causes and heroes. (JD)

  16. Becoming Teachers' Little Epics: What Digital Storytelling Might Reveal

    ERIC Educational Resources Information Center

    Radford, Linda; Aitken, Avril

    2014-01-01

    This paper discusses pre-service teachers' use of multi-modal tools to produce three-minute films in light of critical moments in their teaching practice. Two cases are considered; each centers on a film, a "little epic" that was produced by a future teacher who attempts to work within an anti-racist framework for social justice.…

  17. The Epic of Sundiata: Using African Literature in the Classroom.

    ERIC Educational Resources Information Center

    Sullivan, Margaret Lo Piccolo

    1998-01-01

    Discusses the "Epic of Sundiata" which chronicles the rise of the Empire of Mali in the grasslands of northwestern Africa in the 13th century. This work is a compelling drama that bears comparison to such other hero tales as "The Iliad" and the Arthurian legend. Includes suggested teaching activities. (MJP)

  18. The Epic inside Us: Using Intuitive Play to Teach Beowulf

    ERIC Educational Resources Information Center

    Menzies, J. Beth Haase

    2004-01-01

    The element of play is underutilized in the secondary classroom in spite of the fact that play produces unique opportunities for meaningful learning. The ways in which the elements of epic poetry, Beowulf, and the Old English diction differed from the modern usage is discussed.

  19. The E.P.I.C. Journey Sanctioning Model

    ERIC Educational Resources Information Center

    Fueglein, Jennifer S.; Price, Kevin S.; Alicea-Rodriguez, Adriana; McKinney, Jan Wilson; Jimenez, Anne L.

    2012-01-01

    As universities look for more effective ways to address violations of behavioral standards, a proposed solution is to infuse intentional development into well-established conduct processes inherently focused on legal mandates and due process. The E.P.I.C. Journey Sanctioning Model was designed to refocus the outcomes of the conduct process to…

  20. High-performance parallel interface to synchronous optical network gateway

    DOEpatents

    St. John, Wallace B.; DuBois, David H.

    1996-01-01

    A system of sending and receiving gateways interconnects high speed data interfaces, e.g., HIPPI interfaces, through fiber optic links, e.g., a SONET network. An electronic stripe distributor distributes bytes of data from a first interface at the sending gateway onto parallel fiber optics of the fiber optic link to form transmitted data. An electronic stripe collector receives the transmitted data on the parallel fiber optics and reforms the data into a format effective for input to a second interface at the receiving gateway. Preferably, an error correcting syndrome is constructed at the sending gateway and sent with a data frame so that transmission errors can be detected and corrected in a real-time basis. Since the high speed data interface operates faster than any of the fiber optic links the transmission rate must be adapted to match the available number of fiber optic links so the sending and receiving gateways monitor the availability of fiber links and adjust the data throughput accordingly. In another aspect, the receiving gateway must have sufficient available buffer capacity to accept an incoming data frame. A credit-based flow control system provides for continuously updating the sending gateway on the available buffer capacity at the receiving gateway.

  1. High-performance parallel interface to synchronous optical network gateway

    DOEpatents

    St. John, W.B.; DuBois, D.H.

    1996-12-03

    Disclosed is a system of sending and receiving gateways interconnects high speed data interfaces, e.g., HIPPI interfaces, through fiber optic links, e.g., a SONET network. An electronic stripe distributor distributes bytes of data from a first interface at the sending gateway onto parallel fiber optics of the fiber optic link to form transmitted data. An electronic stripe collector receives the transmitted data on the parallel fiber optics and reforms the data into a format effective for input to a second interface at the receiving gateway. Preferably, an error correcting syndrome is constructed at the sending gateway and sent with a data frame so that transmission errors can be detected and corrected in a real-time basis. Since the high speed data interface operates faster than any of the fiber optic links the transmission rate must be adapted to match the available number of fiber optic links so the sending and receiving gateways monitor the availability of fiber links and adjust the data throughput accordingly. In another aspect, the receiving gateway must have sufficient available buffer capacity to accept an incoming data frame. A credit-based flow control system provides for continuously updating the sending gateway on the available buffer capacity at the receiving gateway. 7 figs.

  2. Science gateways for semantic-web-based life science applications.

    PubMed

    Ardizzone, Valeria; Bruno, Riccardo; Calanducci, Antonio; Carrubba, Carla; Fargetta, Marco; Ingrà, Elisa; Inserra, Giuseppina; La Rocca, Giuseppe; Monforte, Salvatore; Pistagna, Fabrizio; Ricceri, Rita; Rotondo, Riccardo; Scardaci, Diego; Barbera, Roberto

    2012-01-01

    In this paper we present the architecture of a framework for building Science Gateways supporting official standards both for user authentication and authorization and for middleware-independent job and data management. Two use cases of the customization of the Science Gateway framework for Semantic-Web-based life science applications are also described. PMID:22942003

  3. 47 CFR 10.320 - Provider alert gateway requirements.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 47 Telecommunication 1 2010-10-01 2010-10-01 false Provider alert gateway requirements. 10.320 Section 10.320 Telecommunication FEDERAL COMMUNICATIONS COMMISSION GENERAL COMMERCIAL MOBILE ALERT SYSTEM System Architecture § 10.320 Provider alert gateway requirements. This section specifies the...

  4. 36 CFR 7.29 - Gateway National Recreation Area.

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 36 Parks, Forests, and Public Property 1 2010-07-01 2010-07-01 false Gateway National Recreation Area. 7.29 Section 7.29 Parks, Forests, and Public Property NATIONAL PARK SERVICE, DEPARTMENT OF THE INTERIOR SPECIAL REGULATIONS, AREAS OF THE NATIONAL PARK SYSTEM § 7.29 Gateway National Recreation Area. (a) Operation of motor vehicles....

  5. 36 CFR 7.29 - Gateway National Recreation Area.

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 36 Parks, Forests, and Public Property 1 2012-07-01 2012-07-01 false Gateway National Recreation Area. 7.29 Section 7.29 Parks, Forests, and Public Property NATIONAL PARK SERVICE, DEPARTMENT OF THE INTERIOR SPECIAL REGULATIONS, AREAS OF THE NATIONAL PARK SYSTEM § 7.29 Gateway National Recreation Area. (a) Operation of motor vehicles....

  6. SS focused technology: Gateways and NOS's

    NASA Technical Reports Server (NTRS)

    Hartenstein, R.

    1985-01-01

    The extensions and enhancements of the fiber optic data bus technology supported by the Space Station Focused Technology Program are discussed. This includes the operating software for the network called the Network Operating System (NOS); gateways and bridges for multiple network topologies; and very large scale topology implimentations to shrink the size and power of the Bus Interface Unit (BIU) down to more manageable dimensions. CMOS is being investigated for the lower speed (parallel) logic. Gallium arsendide is being studied for the high speed (serial) logic.

  7. Integrated IP telephony gateway and its stochastic petri net model

    NASA Astrophysics Data System (ADS)

    Huang, Yongfeng; Li, Xing

    2001-10-01

    With rapid development of computer network and a wide application of Internet, IP telephony has been realized. Currently, one of the most important research areas of IP telephony system is to develop the IP telephony gateway. In this paper, a new idea of design on an Integrated IP Telephony Gateway is proposed, and the hardware of Integrated IP Telephony is discussed in detail. The software architecture of the Integrated IP telephone gateway is studied, and this paper focus on the voice compression module and SPOX schedule module. In addition, Stochastic Petri Net Model of an Integrated IP Telephony Gateway is set up, and its performance analyzed through the Stochastic Petri Net model. Array of Petri Net Model is computed, and educes the mathematical relationship of CPU efficiency and structure parameters of the IP telephony gateway.

  8. An Evaluation of EPIC's Analysis of School Practice & Knowledge System. The Effective Practice Incentive Community (EPIC). Research Brief

    ERIC Educational Resources Information Center

    Sloan, Kay; Pereira-Leon, Maura; Honeyford, Michelle

    2012-01-01

    Established in 2006 by New Leaders for New Schools[TM], the Effective Practice Incentive Community (EPIC) initiative rewards high-need urban schools showing significant gains in student achievement. In exchange, schools agree to share the practices helping to drive those gains, which they do through an in-depth study of practice, aided by the EPIC…

  9. Gateway: An earth orbiting transportation node

    NASA Technical Reports Server (NTRS)

    1988-01-01

    University of Texas Mission Design (UTMD) has outlined the components that a space based transportation facility must include in order to support the first decade of Lunar base buildup. After studying anticipated traffic flow to and from the hub, and taking into account crew manhour considerations, propellant storage, orbital transfer vehicle maintenance requirements, and orbital mechanics, UTMD arrived at a design for the facility. The amount of activity directly related to supporting Lunar base traffic is too high to allow the transportation hub to be part of the NASA Space Station. Instead, a separate structure should be constructed and dedicated to handling all transportation-related duties. UTMD found that the structure (named Gateway) would need a permanent crew of four to perform maintenance tasks on the orbital transfer and orbital maneuvering vehicles and to transfer payload from launch vehicles to the orbital transfer vehicles. In addition, quarters for 4 more persons should be allocated for temporary accommodation of Lunar base crew passing through Gateway. UTMD was careful to recommend an expendable structure that can adapt to meet the growing needs of the American space program.

  10. High-Performance Satellite/Terrestrial-Network Gateway

    NASA Technical Reports Server (NTRS)

    Beering, David R.

    2005-01-01

    A gateway has been developed to enable digital communication between (1) the high-rate receiving equipment at NASA's White Sands complex and (2) a standard terrestrial digital communication network at data rates up to 622 Mb/s. The design of this gateway can also be adapted for use in commercial Earth/satellite and digital communication networks, and in terrestrial digital communication networks that include wireless subnetworks. Gateway as used here signifies an electronic circuit that serves as an interface between two electronic communication networks so that a computer (or other terminal) on one network can communicate with a terminal on the other network. The connection between this gateway and the high-rate receiving equipment is made via a synchronous serial data interface at the emitter-coupled-logic (ECL) level. The connection between this gateway and a standard asynchronous transfer mode (ATM) terrestrial communication network is made via a standard user network interface with a synchronous optical network (SONET) connector. The gateway contains circuitry that performs the conversion between the ECL and SONET interfaces. The data rate of the SONET interface can be either 155.52 or 622.08 Mb/s. The gateway derives its clock signal from a satellite modem in the high-rate receiving equipment and, hence, is agile in the sense that it adapts to the data rate of the serial interface.

  11. Development of ISO connection-oriented/correctionless gateways

    NASA Technical Reports Server (NTRS)

    Landweber, Lawrence H.

    1991-01-01

    The project had two goals, establishment of a gateway between French and U.S. academic networks and studies of issues related to the development of ISO connection-oriented/connectionless (CO/CL) gateways. The first component involved installation of a 56K bps line between Princeton Univ. and INRIA in France. The end-points of these lines were connected by Vitalink link level bridges. The Princeton end was then connected to the NSFNET via the John Von Neumann Supercomputer Center. The French end was connected to Transpac, the French X.25 public data network and to the French IP research internet. U.S. users may communicate with users of the French internet by e-mail and may access computational and data resources in France by use of remote login and file transfer. The connection to Transpac enables U.S. users to access the SIMBAD astronomical database outside of Paris. Access to this database from the U.S. can be via TCP/IP or DECNET (via a DECNET to TCP/IP gateway) protocols utilizing a TCP/IP to X.25 gateway developed and operated by INRIA. The second component of the project involved experiments aimed at understanding the issues involved is ISO CO/CL gateways. An experimental gateway was developed at Wisconsin and a preliminary report was prepared. Because of the need to devote most resources to the first component of the project, work in this area did not go beyond development of a prototype gateway.

  12. EPICS : input / output controller (IOC) application developer's guide. EPICS release 3.12 specific documentation.[Experimental Physics and Industrial Control System

    SciTech Connect

    Kraimer, M. R.

    2002-01-30

    This document describes the core software that resides in an Input/Output Controller (IOC), one of the major components of EPICS. EPICS consists of a set of software components and tools that Application Developers use to create a control system. The basic components are: OPI--Operator Interface. This is a UNIX based workstation which can run various EPICS tools; IOC--Input/Output Controller. This is a VME/VXI based chassis containing a processor, various I/O modules and VME modules that provide access to other I/O buses such as GPIB; and LAN--Local Area Network. This is the communication network which allows the IOCs and OPIs to communicate. EPICS provides a software component, Channel Access, which provides network transparent communication between a Channel Access client and an arbitrary number of Channel Access servers. This report is intended for anyone developing EPICS IOC databases and/or new record/device/driver support.

  13. Expression, purification, and characterization of EpiC, an enzyme involved in the biosynthesis of the lantibiotic epidermin, and sequence analysis of Staphylococcus epidermidis epiC mutants.

    PubMed Central

    Kupke, T; Gotz, F

    1996-01-01

    The plasmid-encoded epidermin biosynthetic gene epiC of Staphylococcus epidermidis Tü3298 was expressed in Escherichia coli by using the T7 RNA polymerase-promoter system, and the gene product EpiC was identified by Western blotting (immunoblotting) with an anti-EpiC-peptide antiserum. EpiC was a hydrophobic but soluble protein. EpiC was purified by hydrophobic-interaction chromatography. The determined amino-terminal amino acid sequence was M I N I N N I .... The electrophoretic migration behavior of EpiC depended on the oxidation state of the enzyme, indicating the formation of an intramolecular disulfide bridge between C-274 and C-321. The cysteine residues in the motifs WC-274YG and C-321HG of EpiC are conserved in all lantibiotic enzymes of the C type (so-called LanC proteins) and in the CylM protein. Mutated epiC genes from S. epidermidis epiC mutants were cloned and expressed in E. coli. Sequence analysis revealed that the mutations occurred in the two motifs -S-X-X-X-G-X-X-G- and -N-X-G-X-A-H-G-X-X-G-, which are conserved in all LanC proteins. For the investigation of EpiC-EpiA interactions, precursor peptide EpiA was coupled to N-hydroxysuccinimide-activated Sepharose High Performance Material (HiTrap). Under reducing conditions, EpiC was retarded on the EpiA-HiTrap column. In the incubation experiments, EpiC did not react with EpiA, with proepidermin, or with oxidative decarboxylated peptides. PMID:8631710

  14. Mapping, monitoring, and modeling Western Gateway Community landscape dynamics

    USGS Publications Warehouse

    Hester, David J.

    2013-01-01

    Federal public lands in the western United States are becoming increasingly surrounded by Gateway Communities. These communities are undergoing landscape change due to population growth, economic growth, and the resulting land-use development. Socioeconomic, demographic, and land-use changes in Gateway Communities are often perceived as threats to Federal land resources, natural amenities, cultural resources, and recreational opportunities. However, land-surface disturbances on Federal public lands, such as conventional and alternative energy development (which impact surrounding Gateway Communities), are also environmental and societal issues that Federal land and adjacent regional community planners need to consider in their long-range land-use planning.

  15. areaDetector: Software for 2-D Detectors in EPICS

    SciTech Connect

    Rivers, M.

    2011-09-23

    areaDetector is a new EPICS module designed to support 2-D detectors. It is modular C++ code that greatly simplifies the task of writing support for a new detector. It also supports plugins, which receive detector data from the driver and process it in some way. Existing plugins perform Region-Of-Interest extraction and analysis, file saving (in netCDF, HDF, TIFF and JPEG formats), color conversion, and export to EPICS records for image display in clients like ImageJ and IDL. Drivers have now been written for many of the detectors commonly used at synchrotron beamlines, including CCDs, pixel array and amorphous silicon detectors, and online image plates.

  16. areaDetector: Software for 2-D Detectors in EPICS

    SciTech Connect

    Rivers, Mark L.

    2010-06-23

    areaDetector is a new EPICS module designed to support 2-D detectors. It is modular C++ code that greatly simplifies the task of writing support for a new detector. It also supports plugins, which receive detector data from the driver and process it in some way. Existing plugins perform Region-Of-Interest extraction and analysis, file saving (in netCDF, HDF, TIFF and JPEG formats), color conversion, and export to EPICS records for image display in clients like ImageJ and IDL. Drivers have now been written for many of the detectors commonly used at synchrotron beamlines, including CCDs, pixel array and amorphous silicon detectors, and online image plates.

  17. PV module mounting method and mounting assembly

    DOEpatents

    Lenox, Carl J.S.; Johnson, Kurt M.

    2013-04-23

    A method for mounting PV modules to a deck includes selecting PV module layout pattern so that adjacent PV module edges are spaced apart. PV mounting and support assemblies are secured to the deck according to the layout pattern using fasteners extending into the deck. The PV modules are placed on the PV mounting and support assemblies. Retaining elements are located over and secured against the upper peripheral edge surfaces of the PV modules so to secure them to the deck with the peripheral edges of the PV modules spaced apart from the deck. In some examples a PV module mounting assembly, for use on a shingled deck, comprises flashing, a base mountable on the flashing, a deck-penetrating fastener engageable with the base and securable to the deck so to secure the flashing and the base to the shingled deck, and PV module mounting hardware securable to the base.

  18. Pressure-equalizing PV assembly and method

    DOEpatents

    Dinwoodie, Thomas L.

    2004-10-26

    Each PV assembly of an array of PV assemblies comprises a base, a PV module and a support assembly securing the PV module to a position overlying the upper surface of the base. Vents are formed through the base. A pressure equalization path extends from the outer surface of the PV module, past the PV module, to and through at least one of the vents, and to the lower surface of the base to help reduce wind uplift forces on the PV assembly. The PV assemblies may be interengaged, such as by interengaging the bases of adjacent PV assemblies. The base may include a main portion and a cover and the bases of adjacent PV assemblies may be interengaged by securing the covers of adjacent bases together.

  19. PSCAD Modules Representing PV Generator

    SciTech Connect

    Muljadi, E.; Singh, M.; Gevorgian, V.

    2013-08-01

    Photovoltaic power plants (PVPs) have been growing in size, and the installation time is very short. With the cost of photovoltaic (PV) panels dropping in recent years, it can be predicted that in the next 10 years the contribution of PVPs to the total number of renewable energy power plants will grow significantly. In this project, the National Renewable Energy Laboratory (NREL) developed a dynamic modeling of the modules to be used as building blocks to develop simulation models of single PV arrays, expanded to include Maximum Power Point Tracker (MPPT), expanded to include PV inverter, or expanded to cover an entire PVP. The focus of the investigation and complexity of the simulation determines the components that must be included in the simulation. The development of the PV inverter was covered in detail, including the control diagrams. Both the current-regulated voltage source inverter and the current-regulated current source inverter were developed in PSCAD. Various operations of the PV inverters were simulated under normal and abnormal conditions. Symmetrical and unsymmetrical faults were simulated, presented, and discussed. Both the three-phase analysis and the symmetrical component analysis were included to clarify the understanding of unsymmetrical faults. The dynamic model validation was based on the testing data provided by SCE. Testing was conducted at SCE with the focus on the grid interface behavior of the PV inverter under different faults and disturbances. The dynamic model validation covers both the symmetrical and unsymmetrical faults.

  20. New therapeutic approaches in PV

    PubMed Central

    Falchi, Lorenzo; Newberry, Kate J.; Verstovsek, Srdan

    2015-01-01

    Polycytemia vera (PV) is one of the three Philadelphia-negative myeloproliferative neoplasms. Clinically, PV is an indolent disease but its course can be complicated by arterial and venous vascular accidents, evolution to myelofibrosis or leukemic transformation. Treatment of PV is, therefore, aimed at preventing such acute complications. The cornerstone of therapy of low-risk patients remains strict control of cardiovascular risk factors, the use of phlebotomy and low dose aspirin. Higher risk patients should also receive cytoreductive treatments. Hydroxyurea and interferon-α represent standard first-line options for newly diagnosed high-risk PV patients. Recommendations for patients who fail these therapies are less clearly defined. The discovery of a mutation in the Janus kinase 2 gene (V617F) in almost all cases of PV has prompted the development of molecularly targeted agents for the treatment of these patients. In this review we will discuss key clinical aspects, the current therapeutic armamentarium and data on the use of novel agents in patients with PV. PMID:26297275

  1. EPICS SCA CLIENTS ON THE .NET X64 PLATFORM

    SciTech Connect

    Timossi, Chris; Nishimura, Hiroshi

    2006-10-19

    We have developed a .NET assembly, which we call SCA.NET,which we have been using for building EPICS based control roomapplications at the Advanced Light Source (ALS). In this paper we reporton our experiences building a 64-bit version of SCA.NET and theunderlying channel access libraries for Windows XP x64 (using a dual coreAMD Athlon CPU). We also report on our progress in building newaccelerator control applications for this environment.

  2. Simulating Field-Scale Soil Organic Carbon Dynamics Using EPIC

    SciTech Connect

    Causarano, Hector J.; Shaw, Joey N.; Franzluebbers, A. J.; reeves, D. W.; Raper, Randy L.; Balkcom, Kipling S.; Norfleet, M. L.; Izaurralde, R Cesar

    2007-07-01

    Simulation models integrate our knowledge of soil organic C (SOC) dynamics and are useful tools for evaluating impacts of crop management on soil C sequestration; yet, they require local calibration. Our objectives were to calibrate the Environmental Policy Integrated Climate (EPIC) model, and evaluate its performance for simulating SOC fractions as affected by soil landscape and management. An automated parameter optimization procedure was used to calibrate the model for a site-specific experiment in the Coastal Plain of central Alabama. The ability of EPIC to predict corn (Zea mays L.) and cotton (Gossypium hirsutum L.) yields and SOC dynamics on different soil landscape positions (summit, sideslope and drainageway) during the initial period of conservation tillage adoption (5 years) was evaluated using regression and mean squared deviations. Simulated yield explained 88% of measured yield variation, with greatest disagreement on the sideslope position and highest agreement in the drainageway. Simulations explained approximately 1, 34 and 40% of the total variation in microbial biomass C (MBC), particulate organic C (POC) and total organic C (TOC), respectively. Lowest errors on TOC simulations (0-20 cm) were found on the sideslope and summit. We conclude that the automated parameterization was generally successful, although further work is needed to refine the MBC and POC fractions, and to improve EPIC predictions of SOC dynamics with depth. Overall, EPIC was sensitive to spatial differences in C fractions that resulted from differing soil landscape positions. The model needs additional refinement for accurate simulations of field-scale SOC dynamics affected by short-term management decisions.

  3. Sedimentary response to ocean gateway circulation changes

    NASA Astrophysics Data System (ADS)

    Heinze, Christoph; Crowley, Thomas J.

    1997-12-01

    Previous modeling studies suggested that changes in ocean gateways may have exerted a dramatic influence on the ocean circulation. In this pilot study we extend those results to examining the potential ramifications of circulation changes on the sedimentary record. A version of the Hamburg carbon cycle/sediment model is used in these sensitivity experiments. Results indicate that internal reorganization of the ocean circulation can potentially cause very large regional changes in lysocline depth (1500-3000 m) and opal deposition. These shifts are sometimes comparable in magnitude to those imposed by changes in external forcing (e.g., climate, sea level, and weathering). Comparisons of the model response with the geologic record indicate some significant levels of first-order agreement. This exercise suggests that opportunities now exist for physically based modeling of past sediment responses to circulation and climate changes.

  4. Accessibility: global gateway to health literacy.

    PubMed

    Perlow, Ellen

    2010-01-01

    Health literacy, cited as essential to achieving Healthy People 2010's goals to "increase quality and years of healthy life" and to "eliminate health disparities," is defined by Healthy People as "the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions." Accessibility, by definition, the aforementioned "capacity to obtain," thus is health literacy's primary prerequisite. Accessibility's designation as the global gateway to health literacy is predicated also on life's realities: global aging and climate change, war and terrorism, and life-extending medical and technological advances. People with diverse access needs are health professionals' raison d'être. However, accessibility, consummately cross-cultural and universal, is virtually absent as a topic of health promotion and practice research and scholarly discussion of health literacy and equity. A call to action to place accessibility in its rightful premier position on the profession's agenda is issued. PMID:18955546

  5. Cloud Detection with the Earth Polychromatic Imaging Camera (EPIC)

    NASA Technical Reports Server (NTRS)

    Meyer, Kerry; Marshak, Alexander; Lyapustin, Alexei; Torres, Omar; Wang, Yugie

    2011-01-01

    The Earth Polychromatic Imaging Camera (EPIC) on board the Deep Space Climate Observatory (DSCOVR) would provide a unique opportunity for Earth and atmospheric research due not only to its Lagrange point sun-synchronous orbit, but also to the potential for synergistic use of spectral channels in both the UV and visible spectrum. As a prerequisite for most applications, the ability to detect the presence of clouds in a given field of view, known as cloud masking, is of utmost importance. It serves to determine both the potential for cloud contamination in clear-sky applications (e.g., land surface products and aerosol retrievals) and clear-sky contamination in cloud applications (e.g., cloud height and property retrievals). To this end, a preliminary cloud mask algorithm has been developed for EPIC that applies thresholds to reflected UV and visible radiances, as well as to reflected radiance ratios. This algorithm has been tested with simulated EPIC radiances over both land and ocean scenes, with satisfactory results. These test results, as well as algorithm sensitivity to potential instrument uncertainties, will be presented.

  6. E-Cigarettes a Gateway to Smoking for Teens

    MedlinePlus

    ... page: https://medlineplus.gov/news/fullstory_159340.html E-Cigarettes a Gateway to Smoking for Teens: Study ... who had never smoked, but who had used e-cigarettes, were substantially more likely to begin smoking ...

  7. GATEWAY Demonstrations: Exploring SSL Product Performance in the Real World

    SciTech Connect

    2013-10-01

    Fact sheet that outlines DOE's GATEWAY technology demonstration program, which evaluates high-performance SSL products for general illumination in a variety of real-world exterior and interior applications.

  8. High-performance parallel interface to synchronous optical network gateway

    DOEpatents

    St. John, Wallace B.; DuBois, David H.

    1998-08-11

    A digital system provides sending and receiving gateways for HIPPI interfaces. Electronic logic circuitry formats data signals and overhead signals in a data frame that is suitable for transmission over a connecting fiber optic link. Multiplexers route the data and overhead signals to a framer module. The framer module allocates the data and overhead signals to a plurality of 9-byte words that are arranged in a selected protocol. The formatted words are stored in a storage register for output through the gateway.

  9. An Authentication Gateway for Integrated Grid and Cloud Access

    NASA Astrophysics Data System (ADS)

    Ciaschini, V.; Salomoni, D.

    2011-12-01

    The WNoDeS architecture, providing distributed, integrated access to both Cloud and Grid resources through virtualization technologies, makes use of an Authentication Gateway to support diverse authentication mechanisms. Three main use cases are foreseen, covering access via X.509 digital certificates, federated services like Shibboleth or Kerberos, and credit-based access. In this paper, we describe the structure of the WNoDeS authentication gateway.

  10. Low concentrator PV optics optimization

    NASA Astrophysics Data System (ADS)

    Sharp, Leonard; Chang, Ben

    2008-08-01

    Purpose: Cost reduction is a major focus of the solar industry. Thin film technologies and concentration systems are viable ways to reducing cost, with unique strengths and weakness for both. Most of the concentrating PV work focuses on high concentration systems for reducing energy cost. Meanwhile, many believe that low concentrators provide significant cost reduction potential while addressing the mainstream PV market with a product that acts as a flat panel replacement. This paper analyzes the relative benefit of asymmetric vs. symmetric optics for low-concentrators in light of specific PV applications. Approach: Symmetric and asymmetric concentrating PV module performance is evaluated using computer simulation to determine potential value across various geographic locations and applications. The selected optic design is modeled against standard cSi flat panels and thin film to determine application fit, system level energy density and economic value. Results: While symmetric designs may seem ideal, asymmetric designs have an advantage in energy density. Both designs are assessed for aperture, optimum concentration ratio, and ideal system array configuration. Analysis of performance across climate specific effects (diffuse, direct and circumsolar) and location specific effects (sunpath) are also presented. The energy density and energy production of low concentrators provide a compelling value proposition. More significantly, the choice of optics for a low concentrating design can affect real world performance. With the goal of maximizing energy density and return on investment, this paper presents the advantages of asymmetric optic concentration and illustrates the value of this design within specific PV applications.

  11. Lightweight flexible rooftop PV module

    SciTech Connect

    Izu, M.; Ovshinsky, H.C.; Whelan, K.

    1994-12-31

    Energy Conversion Devices, Inc. (ECD) and United Solar Systems Corp. (United Solar) are developing lightweight, flexible photovoltaic modules that can replace conventional roofing materials and be economically and aesthetically integrated into residential and commercial buildings. The modules will be fabricated from high-efficiency multi-junction a-Si alloy solar cells developed by ECD and United Solar. These cells are produced on thin, flexible, stainless steel substrates. Two types of products 1 ft by 10 ft overlapping PV shingles and 1.3 ft by 20 ft PV roof panels are being developed by United Solar and ECD, respectively. United Solar`s shingle type design uses a roof mounting procedures similar to those used with conventional asphalt shingles, while ECD`s PV panel uses mounting procedures conforming to metal roof systems. Thus, they can be installed on roof sheathings, replacing ordinary shingles or metal roofing panels, on a standard wood roof construction.

  12. Comparison of Pyranometers vs. PV Reference Cells for Evaluation of PV Array Performance

    SciTech Connect

    Dunn, L.; Gostein, M.; Emery, K.

    2012-09-01

    As the photovoltaics (PV) industry has grown, the need for accurately monitoring the solar resource of PV power plants has increased. Historically, the PV industry has relied on thermopile pyranometers for irradiance measurements, and a large body of historical irradiance data taken with pyranometers exists. However, interest in PV reference devices is increasing. In this paper, we discuss why PV reference devices are better suited for PV applications, and estimate the typical uncertainties in irradiance measurements made with both pyranometers and PV reference devices. We assert that the quantity of interest in monitoring a PV power plant is the equivalent irradiance under the IEC 60904-3 reference solar spectrum that would produce the same electrical response in the PV array as the incident solar radiation. For PV-plant monitoring applications, we find the uncertainties in irradiance measurements of this type to be on the order of +/-5% for thermopile pyranometers and +/-2.4% for PV reference devices.

  13. Correspondence and Contradiction in Ancient Greek Society and Education: Homer's Epic Poetry and Plato's Early Dialogues.

    ERIC Educational Resources Information Center

    Sichel, Betty A.

    1983-01-01

    Homer's epic poetry illustrates correspondence between society's needs and the values stressed in education, while Socrates' thought uncovers contradictions between social and educational values and seeks a new form of correspondence. Examples from the Epics and Plato's early dialogues trace changing educational attitudes among the Classical…

  14. An Evaluation of OCLC's EPIC as a Resource for Subject Access to Videos.

    ERIC Educational Resources Information Center

    Palmer, Joseph W.

    1992-01-01

    An examination of OCLC's EPIC service and standard video reference tools revealed that EPIC was more comprehensive in finding video titles on the popular or specialized topics of bonsai, genealogy, karate, and holography, because of its keyword searching ability on the massive OCLC database. (11 references) (EA)

  15. Evaluating EPIC-based Harvest Index Approach for Yield Prediction and Response to Soil Water

    Technology Transfer Automated Retrieval System (TEKTRAN)

    The EPIC-based plant growth model has been used in many national modeling efforts such as WEPP, WEPPS, SWAT, and GPFARM. Many approaches are used in simulation models to predict final crop harvestable yield. The EPIC-based plant growth model uses the harvest index (HI, defined here as the ratio of h...

  16. Teaching about Indian Culture through Its Epic Literature: "The Mahabharata" and "the Ramayana."

    ERIC Educational Resources Information Center

    Grant, Patrick S.

    Two epic poems from India, "The Mahabharata" and "The Ramayana" have endured for more than 2,000 years as important parts of Indian culture, and the study of these epics can yield insights into Indian life and religion. This paper contains a list of the major characters and an explanation of the major themes in both books. The themes include good…

  17. EPIC Simulations of Crop Yields and Soil Organic Carbon in Iowa

    Technology Transfer Automated Retrieval System (TEKTRAN)

    Depending on management, soil organic carbon is source or sink of atmospheric carbon dioxide. The Environmental Policy Integrated Climate (EPIC) model is a useful tool for predicting impacts of soil management on crop yields and soil organic carbon. We used EPIC-Century to simulate changes in soil o...

  18. Science Gateways, Scientific Workflows and Open Community Software

    NASA Astrophysics Data System (ADS)

    Pierce, M. E.; Marru, S.

    2014-12-01

    Science gateways and scientific workflows occupy different ends of the spectrum of user-focused cyberinfrastructure. Gateways, sometimes called science portals, provide a way for enabling large numbers of users to take advantage of advanced computing resources (supercomputers, advanced storage systems, science clouds) by providing Web and desktop interfaces and supporting services. Scientific workflows, at the other end of the spectrum, support advanced usage of cyberinfrastructure that enable "power users" to undertake computational experiments that are not easily done through the usual mechanisms (managing simulations across multiple sites, for example). Despite these different target communities, gateways and workflows share many similarities and can potentially be accommodated by the same software system. For example, pipelines to process InSAR imagery sets or to datamine GPS time series data are workflows. The results and the ability to make downstream products may be made available through a gateway, and power users may want to provide their own custom pipelines. In this abstract, we discuss our efforts to build an open source software system, Apache Airavata, that can accommodate both gateway and workflow use cases. Our approach is general, and we have applied the software to problems in a number of scientific domains. In this talk, we discuss our applications to usage scenarios specific to earth science, focusing on earthquake physics examples drawn from the QuakSim.org and GeoGateway.org efforts. We also examine the role of the Apache Software Foundation's open community model as a way to build up common commmunity codes that do not depend upon a single "owner" to sustain. Pushing beyond open source software, we also see the need to provide gateways and workflow systems as cloud services. These services centralize operations, provide well-defined programming interfaces, scale elastically, and have global-scale fault tolerance. We discuss our work providing

  19. EAARL topography: Gateway National Recreation Area

    USGS Publications Warehouse

    Brock, John C.; Wright, C. Wayne; Patterson, Matt; Nayegandhi, Amar; Patterson, Judd

    2007-01-01

    This Web site contains Lidar-derived topography (bare earth) maps and GIS files for the Sandy Hook Unit within Gateway National Recreation Area in New Jersey. These Lidar-derived topography maps were produced as a collaborative effort between the U.S. Geological Survey (USGS) Coastal and Marine Geology Program, FISC St. Petersburg, the National Park Service (NPS) South Florida/Caribbean Network Inventory and Monitoring Program, and the National Aeronautics and Space Administration (NASA) Wallops Flight Facility. One objective of this research is to create techniques to survey coral reefs and barrier islands for the purposes of geomorphic change studies, habitat mapping, ecological monitoring, change detection, and event assessment. As part of this project, data from an innovative instrument under development at the NASA Wallops Flight Facility, the NASA Experimental Airborne Advanced Research Lidar (EAARL) are being used. This sensor has the potential to make significant contributions in this realm for measuring subaerial and submarine topography wthin cross-environment surveys. High spectral resolution, water-column correction, and low costs were found to be key factors in providing accurate and affordable imagery to costal resource managers.

  20. Gateways to clinical trials. December 2008.

    PubMed

    Tomillero, A; Moral, M A

    2008-12-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: AAV1/SERCA2a; Abatacept, ABT-263, Adalimumab, Aflibercept, Afobazole, Aliskiren fumarate, Anakinra, Atazanavir/ritonavir, Aviscumine, Axitinib, Azacitidine; Bevacizumab, Biphasic insulin aspart, Bortezomib, Briobacept; Carmoterol hydrochloride, CCX-282, Ceftobiprole medocaril, Certolizumab pegol, Cetuximab; Darifenacin hydrobromide, Dasatinib, Denosumab, Doripenem, Duloxetine hydrochloride; E-7080, Epratuzumab, Erlotinib hydrochloride, Everolimus, Exenatide, Ezetimibe/simvastatin; Gefitinib, Golimumab; gamma-Hydroxybutyrate sodium; Imatinib mesylate, Insulin detemir, Insulin glulisine, IVX-0142; Laquinimod sodium, Linezolid, Lopinavir/ritonavir; Ocrelizumab, Omalizumab; Parecoxib sodium, Pemetrexed disodium, Pregabalin; Rosuvastatin calcium, Rotigotine; Sorafenib, Sugammadex sodium; Tapentadol hydrochloride, Tenofovir disoproxil fumarate/emtricitabine, Tocilizumab; Ularitide, Ustekinumab; Valsartan/amlodipine besylate, Varenicline tartrate, Vatalanib succinate, Vildagliptin, Vorinostat. PMID:19271026

  1. Gateways to clinical trials. March 2003.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2003-03-01

    Gateways to clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and devlopment protal, http://integrity.prous.com. This issue focuses on the following selection of drugs: AAV-CF, adalimumab, ademetionine, afeletecan hydrochloride, agomelatine, alemtuzumab, almotriptan, amdoxovir, aplidine, aranose, arsenic sulfide, atazanavir, atlizumab; Bimatoprost, BMS-181176, BMS-188667, bortezomib, bryostatin 1; Combretastatin A-4 phosphate; Darbepoetin alfa, darusentan, deferasirox, desloratadine, DTaP-HBV-IPV/Hib-vaccine, DTI-0009; Eculizumab, edodekin alfa, emtricitabine, enfuvirtide, epoetin, esomeprazole magnesium etoricoxib; Fampridine, fenretinide, FR-146687; Galiximab, gamma-Hydroxybutyrate sodium, ganirelix acetate, gefitinib, Gemtuzumab ozogamicin, gimatecan; HEA125xOKT3, hIL-13-PE38QQR, HSV-2 theracine, Hu14.18-IL-2, human gammaglobulin; Idraparinux sodium, imatinib mesylate, IMiD3, insulin detemir, interleukin-4, irofulven, ISAtx-247; JT-1001; Levetiracetam, levosimendan, liposomal doxorubicin, liposomal vincristine sulfate, lixivaptan, lopinavir, lumiracoxib; Maxacalcitol, melatonin, midostaurin, MLN-518; Neridronic acid, nesiritide, nitronaproxen; Oblimersen sodium, oregovomab; PEG-filgrastim polyglutamate paclitaxel, prasterone, pregabalin; Rosuvastatin calcium, rotigotine hydrochloride; SGN-30; T-1249, tenofovir disoproxil fumarate, teriparatide, tiotropium bromide, tipranavir, TMC-114, trabectedin, transdermal selegiline; UK-427857; Valdecoxib, valganciclovir hydrochloride, vardenafil, vatalanib succinate, vincristine sulfate TCS; Zofenopril calcium. PMID:12731460

  2. The "epic" challenge of optimizing antimicrobial stewardship: the role of electronic medical records and technology.

    PubMed

    Kullar, Ravina; Goff, Debra A; Schulz, Lucas T; Fox, Barry C; Rose, Warren E

    2013-10-01

    Antimicrobial stewardship programs (ASPs) are established means for institutions to improve patient outcomes while reducing the emergence of resistant bacteria. With the increased adoption and evolution of electronic medical records (EMRs), there is a need to assimilate the tools of ASPs into EMRs, using decision support and feedback. Third-party software vendors provide the mainstay for integration of individual institutional EMR and ASP efforts. Epic is the leading implementer of EMR technology in the United States. A collaboration of physicians and pharmacists are working closely with Epic to provide a more comprehensive platform of ASP tools that may be institutionally individualized. We review the historical relationship between ASPs and the EMR, cite examples of Epic stewardship tools from 3 academic medical centers' ASPs, discuss limitations of these Epic tools, and conclude with the current process in evolution to integrate ASP tools and decision support capacities directly into Epic's EMR. PMID:23667260

  3. EPICS Input Output Controller (IOC) Record Reference Manual

    SciTech Connect

    Anderson, J.B.; Kraimer, M.R.

    1994-12-01

    This manual describes all supported EPICS record types. The first chapter gives introduction and describes the field summary table. The second chapter describes the fields in database common, i.e. the fields that are present in every record type. The third chapter describes the input and output field that are common to many record types and have the same usage wherever they are used. Following the third chapter is a separate chapter for each record type containing a description of all the fields for that record type except those in database common.

  4. Perfusion Electronic Record Documentation Using Epic Systems Software

    PubMed Central

    Steffens, Thomas G.; Gunser, John M.; Saviello, George M.

    2015-01-01

    Abstract: This paper describes the design and use of Epic Systems software for documentation of perfusion activities as part of the patient electronic medical record. The University of Wisconsin Hospital and Clinics adapted the Anesthesia software module and developed an integrated perfusion/anesthesia record for the documentation of cardiac and non-cardiac surgical procedures. This project involved multiple committees, approvals, and training to successfully implement. This article will describe our documentation options, concepts, design, challenges, training, and implementation during our initial experience. PMID:26834288

  5. EPIC: an Error Propagation/Inquiry Code. [EPIC estimates the variance of a materials balance closed about a materials balance area in a processing plant

    SciTech Connect

    Baker, A.L.

    1985-01-01

    The use of a computer program EPIC (Error Propagation/Inquiry Code) will be discussed. EPIC calculates the variance of a materials balance closed about a materials balance area (MBA) in a processing plant operated under steady-state conditions. It was designed for use in evaluating the significance of inventory differences in the Department of Energy (DOE) nuclear plants. EPIC rapidly estimates the variance of a materials balance using average plant operating data. The intent is to learn as much as possible about problem areas in a process with simple straightforward calculations assuming a process is running in a steady-state mode. EPIC is designed to be used by plant personnel or others with little computer background. However, the user should be knowledgeable about measurement errors in the system being evaluated and have a limited knowledge of how error terms are combined in error propagation analyses. EPIC contains six variance equations; the appropriate equation is used to calculate the variance at each measurement point. After all of these variances are calculated, the total variance for the MBA is calculated using a simple algebraic sum of variances. The EPIC code runs on any computer that accepts a standard form of the BASIC language. 2 refs., 1 fig., 6 tabs.

  6. 77 FR 47621 - Appalachian Gateway Project; Notice of Availability of Draft General Conformity Analysis

    Federal Register 2010, 2011, 2012, 2013, 2014

    2012-08-09

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Appalachian Gateway Project; Notice of Availability of Draft General... prepared this draft General Conformity Determination (GCD) for the Appalachian Gateway Project (Project)...

  7. The EPIC-MOS Particle-Induced Background Spectra

    NASA Technical Reports Server (NTRS)

    Kuntz, K. D.; Sowden, S. L.

    2007-01-01

    In order to analyse diffuse emission that fills the field of view, one must accurately characterize the instrumental backgrounds. For the XMM-Newton EPIC instrument these backgrounds include a temporally variable "quiescent" component. as well as the strongly variable soft proton contamination. We have characterized the spectral and spatial response of the EPIC detectors to these background components and have developed tools to remove these backgrounds from observations. The "quiescent" component was characterized using a combination of the filter-wheel-closed data and a database of unexposed-region data. The soft proton contamination was characterized by differencing images and spectra taken during flared and flare-free intervals. After application of our modeled backgrounds, the differences between independent observations of the same region of "blank sky" are consistent with the statistical uncertainties except when there is clear spectral evidence of solar wind charge exchange emission. Using a large sample of blank sky data, we show that strong magnetospheric SWCX emission requires elevated solar wind fluxes; observations through the densest part of the magnetosheath are not necessarily strongly contaminated with SWCX emission.

  8. Characteristics of the Eclipsing Triple System EPIC 202062176

    NASA Astrophysics Data System (ADS)

    Lester, Kathryn Victoria; Gies, Douglas R.; Guo, Zhao

    2016-01-01

    Time series photometry from the Kepler K2 mission has led to the discovery of a number of particularly interesting eclipsing binary systems. One of these is EPIC 202062176, a young, eccentric binary found in the star forming region NGC 2175. Our analysis of the light curve from K2 Campaign 0 and spectra from the CHIRON spectrograph and CTIO's 1.5m telescope indicates that EPIC 202062176 is actually a triple system composed of a hot B-type star and a distant pair of less massive stars. We determined the pulsation frequency of the hot star with Period04, removed this signal from the light curve, and then modeled the eclipses of the companion binary with the Eclipsing Light Curve (ELC) program. We estimated the effective temperature and flux contribution for the hot star by comparison with TLUSTY model spectra, and we completed a radial velocity analysis of the hot star using cross-correlation methods. We present the characteristics of the triple system, including the stellar parameters of the primary B0V star and the orbital elements of the companion eclipsing binary system.

  9. JBluIce-EPICS control system for macromolecular crystallography.

    SciTech Connect

    Stepanov, S.; Makarov, O.; Hilgart, M.; Pothineni, S.; Urakhchin, A.; Devarapalli, S.; Yoder, D.; Becker, M.; Ogata, C.; Sanishvili, R.; Nagarajan, V.; Smith, J. L.; Fischetti, R. F.

    2011-01-01

    The trio of macromolecular crystallography beamlines constructed by the General Medicine and Cancer Institutes Collaborative Access Team (GM/CA-CAT) in Sector 23 of the Advanced Photon Source (APS) have been in growing demand owing to their outstanding beam quality and capacity to measure data from crystals of only a few micrometres in size. To take full advantage of the state-of-the-art mechanical and optical design of these beamlines, a significant effort has been devoted to designing fast, convenient, intuitive and robust beamline controls that could easily accommodate new beamline developments. The GM/CA-CAT beamline controls are based on the power of EPICS for distributed hardware control, the rich Java graphical user interface of Eclipse RCP and the task-oriented philosophy as well as the look and feel of the successful SSRL BluIce graphical user interface for crystallography. These beamline controls feature a minimum number of software layers, the wide use of plug-ins that can be written in any language and unified motion controls that allow on-the-fly scanning and optimization of any beamline component. This paper describes the ways in which BluIce was combined with EPICS and converted into the Java-based JBluIce, discusses the solutions aimed at streamlining and speeding up operations and gives an overview of the tools that are provided by this new open-source control system for facilitating crystallographic experiments, especially in the field of microcrystallography.

  10. Data acquisition system for KOMAC beam monitoring using EPICS middleware

    NASA Astrophysics Data System (ADS)

    Song, Young-Gi

    2015-10-01

    The beam diagnostics instrument used to measure the beam properties is one of the important devices for the 100-MeV proton linear accelerator of the KOrea Multi-purpose Accelerator Complex (KOMAC). A data acquisition system (DAQ) is required to collect the output beam signals conditioned in the analog front-end circuitry of a beam loss monitor (BLM) and a beam position monitor (BPM). The electrical beam signal must be digitized, and the sampling has to be synchronized to a global timing system that produces a pulse signal for the pulsed beam operation. The digitized data must be accessible by the experimental physics and industrial control system (EPICS)-based control system, which manages all accelerator control. An input output controller (IOC), which runs Linux on a central process unit (CPU) module with a peripheral component interconnect (PCI) express-based Analog-to-digital converter (ADC) card, has been adopted to satisfy the requirements. An associated Linux driver and EPICS device support module have also been developed. The IOC meets the requirements, and the development and maintenance of software for the IOC is very efficient. In this paper, the details of the DAQ system for the BLM and the BPM with the introduction of the KOMAC beam-diagnostics devices, along with the performance, are described.